# TABLE OF CONTENTS

## Fire and EMS Protocols

### EMS Protocols, Policies, Formulary, and Procedures

**Introduction**
- Foreword ........................................................................... i
- Guidelines for Use .............................................................. ii

### Standard Operating Guidelines (EMS)
- Medical Communications ................................................ 1
- Transfer of Care Policy ....................................................... 2
- Consent / Refusal of Care Policy ........................................ 5
- Air Transport Utilization .................................................... 9

### General Patient Management
- Medical Control ................................................................. 11
- General Assessment and Universal Care ............................. 12
- Airway Management and Oxygen Therapy ...................... 23
- Clinical Priorities (Adult - Ped.) ........................................ 27
- Hospital Capabilities Chart ............................................... 29

### Treatment Protocols - Cardiac Emergencies
- Asystole / Pulseless Electrical Activity (PEA) (Adult - Ped.) .... 31
- Ventricular Fibrillation / Pulseless V-Tachycardia (Adult - Ped.) ... 34
- Return of Spontaneous Circulation (ROSC) (Adult - Ped.) ........ 37
- Wide Complex Tachycardia / V-Tach w/ a Pulse (Adult - Ped.) .... 39
- Narrow Complex Tachycardia (Adult - Ped.) ....................... 43
- Bradycardia (Adult - Ped.) .............................................. 46
- Acute Coronary Syndrome (ACS) / Chest Pain (Adult) ............ 49
- Acute Pulmonary Edema (CHF) (Adult - Ped.) ...................... 53

### Treatment Protocols - Respiratory Emergencies
- Airway Obstruction (Adult - Ped.) ....................................... 55
- Bronchospasm Asthma / COPD (Adult - Ped.) ..................... 56
- Croup / Upper Airway Compromise (Pediatric) .................... 60
- Respiratory Failure / Arrest (Adult - Ped.) ......................... 61

### Treatment Protocols - Medical Emergencies
- Abdominal Pain (Non-traumatic) (Adult - Ped.) .................. 63
- Altered Mental Status / Syncope / Unconscious (Adult - Ped.) .. 65
- Anaphylaxis / Allergic Reaction (Adult - Ped.) .................... 69
- Dystonic Reaction (Adult) .................................................. 72
- CVA / Brain Attack ........................................................... 74
- Hypertensive Crisis ........................................................... 77
- Hypoperfusion (Non-Traumatic) Sepsis (Adult - Ped.) .......... 78
- Pain Management (Adult - Ped.) ....................................... 79
- Adrenal Insufficiency (Adult - Ped.) ................................... 82
- Seizures (Adult - Ped.) ..................................................... 85
# TABLE OF CONTENTS

## Treatment Protocols – Environmental Emergencies
- Hyperthermia (Adult - Ped.) ................................................................. 89
- Hypothermia (Adult - Ped.) ............................................................... 91
- Drowning / Near Drowning (Adult –Ped.) ........................................ 93

## Treatment Protocols – Toxicology Emergencies
- Overdose / Poisoning (Adult - Ped.) .................................................. 95
- Excited Delirium (Adult - Ped.) ........................................................ 98
- Envenomations / Bites / Stings (Adult - Ped.) ..................................... 101
- Carbon Monoxide (CO) Exposure (Adult - Ped.) .............................. 103
- Smoke Inhalation (Cyanide Exposure) (Adult - Ped.) ....................... 105

## Treatment Protocols – OB/GYN Emergencies
- Management of Uncomplicated Delivery ....................................... 109
- Pre-Eclampsia / Eclampsia ................................................................. 110
- Prolapsed Cord ................................................................................. 112
- Limb Presentation ............................................................................ 113
- Breech Presentation ......................................................................... 114
- Uterine Inversion ............................................................................ 115
- Management of Vaginal Hemorrhage ............................................ 116
- Newborn Resuscitation .................................................................. 117

## Treatment Protocols – Trauma Emergencies
- Amputations (Adult - Ped.) ................................................................. 119
- Burns – Thermal / Chemical (Adult - Ped.) ....................................... 122
- Burns – Electrocution / Lightning Injuries (Adult - Ped.) .............. 126
- Crush Injuries / Compartment Syndrome (Adult - Ped.) ............... 127
- Eye Injuries (Adult - Ped.) ................................................................. 131
- Single / Multiple System Trauma (Adult - Ped.) ............................. 132
- Traumatic Cardiac Arrest (Adult - Ped.) .......................................... 134
- Trauma in Pregnancy ........................................................................ 136
- Traumatic Brain Injuries (TBI) (Adult - Ped.) .................................. 138
- Selective Spinal Immobilization (Adult - Ped.) ............................... 140
- Field Trauma Triage Algorithm (Adult - Ped.) ............................... 142

## Special Care Protocols
- Behavioral / Psychological Emergencies (Adult - Ped.) ............... 143
- Termination of Resuscitation .......................................................... 145
- Presumed Dead on Arrival (PDOA) (Adult - Ped.) ....................... 147
- Do Not Resuscitate (DNR) / Comfort of Care ............................... 149
- Children with Special Healthcare Needs ....................................... 152
- Suspected Child / Elderly Abuse ..................................................... 155
- Personal Protective Equipment (PPE) / Exposure Control ............ 157

---

**Effective Date:** April 15, 2015  
**Version:** 2.1  
**Revision Date:** March 31, 2015
TABLE OF CONTENTS

Major Incident Operations

- Mass Casualty Incidents/ START and JumpSTART Triage ............................................. 159
- Incident Rehabilitation .................................................................................................. 163
- WMD Emergencies ....................................................................................................... 167
  - Nerve Agent / Organophosphate Poisoning ............................................................. 167
  - Biological .................................................................................................................... 174
  - Radiological ............................................................................................................... 174
- Pandemic Influenza ...................................................................................................... 176

Medical Procedures

Airway Management

- Continuous Quantitative Waveform Capnography (ETCO₂) ............................................. 177
- Carbon Monoxide (CO) Oximeter (ALS - BLS) .............................................................. 179
- Continuous Positive Airway Pressure (CPAP) (ALS - BLS) ........................................ 180
- Needle Cricothyroidotomy (Quicktrach) (ALS) ............................................................. 181
- Medication Facilitated Intubation (ALS) ......................................................................... 182
- King LT-D™ Airway Device (ALS - BLS) ..................................................................... 184
- Meconium Suctioning (ALS) .......................................................................................... 186
- Nasotracheal Intubation (ALS) ...................................................................................... 187
- Needle Thoracostomy (ALS) ......................................................................................... 189
- Orotracheal Intubation (ALS) ........................................................................................ 190
- Endotracheal Tube Introducer (Bougie) (ALS) .............................................................. 191
- Pulse Oximetry (ALS - BLS) .......................................................................................... 193
- Stoma Airway Maintenance (ALS - BLS) ....................................................................... 194

Cardiac Management

- Defibrillation - Automated (AED) (ALS - BLS) ............................................................... 197
- Defibrillation - Manual (ALS) ....................................................................................... 198
- Defibrillation - Double Sequential Defibrillation (ALS) ............................................. 199
- Lucas 2™ Compression Device (ALS - BLS) ................................................................. 200
- EKG - 12 lead (ALS - BLS) ............................................................................................ 202
- Synchronized Cardioversion (ALS) ................................................................................ 204
- Transcutaneous Cardiac Pacing (ALS) ........................................................................... 205
- Pit Crew CPR (ALS - BLS) ............................................................................................ 206
- Impedance Threshold Device (ResQPOD™) (ALS - BLS) ............................................. 209

Venous Access Management

- Blood Glucose Analysis (ALS - BLS) ............................................................................. 211
- Venous Access - Existing Catheters (ALS) ................................................................. 212
- Venous Access - External Jugular (ALS - AEMT) ....................................................... 213
- Venous Access - EZ-IO™ (ALS - AEMT) ................................................................. 214
- Venous Access - Intraosseous (Jamshidi) (ALS) ......................................................... 216
TABLE OF CONTENTS

EMS Procedures
Broselow™ Pediatric Emergency Tape (ALS - BLS) ...................... 217
Spinal Immobilization (ALS - BLS) ..................................... 218
Helmet Removal (ALS - BLS) ............................................. 219
Physical Restraint (ALS - BLS) ........................................... 221
Tourniquet Use (ALS - BLS) ............................................. 223
Morgan Lens (ALS - BLS) .................................................. 224

Medication Administration
Endotracheal Drug Administration (ALS) ................................ 225
Intranasal Medication Administration (ALS - BLS) ..................... 226
Medication Administration - IV/IO/IM/SQ/Nebulized (ALS - BLS) .... 227

Medication Formulary
Approved Medication List .................................................. 229
Acetylsalicylic Acid (Aspirin) ............................................. 230
Adenosine (Adenocard) ..................................................... 231
Albuterol Sulfate (Proventil) .............................................. 232
Amiodarone (Cordarone) .................................................. 234
Atropine Sulfate .............................................................. 236
Calcium Chloride 10% ....................................................... 238
Dextrose 50%, 25%, 10% .................................................... 239
Diazepam (Valium) (Controlled Medication) (WMD) ................. 240
Diltiazem (Cardizem) ......................................................... 241
Diphenhydramine HCL (Benadryl) ..................................... 243
Dopamine (Intropin) .......................................................... 244
Enalaprilat (Vasotec) ....................................................... 245
Epinephrine HCL 1:1,000 / 1:10,000 (Adrenalin) ...................... 246
Etomidate (Amidate) ......................................................... 248
Fentanyl (Sublimaze) (Controlled Medication) ......................... 249
Furosemide (Lasix) ............................................................ 250
Glucagon HCL ................................................................. 251
Glucose (Oral) .................................................................... 253
Haloperidol (Haldol) .......................................................... 254
Hydrocortisone (Solu-Cortef) .......................................... 255
Hydroxocobalamin (Cyanokit) ........................................... 256
Ipratropium Bromide (Atrovent) ........................................ 257
Ketamine (Ketalar) (Controlled Medication) ......................... 258
Labetalol (Normodyne) ..................................................... 259
Lidocaine HCL (Xylocaine) .............................................. 260
Magnesium Sulfate ........................................................... 262
Methylprednisolone Sodium Succinate (Solu-Medrol) ............. 264
Midazolam HCL (Versed) (Controlled Medication) ................. 265
Morphine Sulfate (Controlled Medication) ............................ 267
Naloxone HCL (Narcan) ..................................................... 269
Nitroglycerin (Nitrostat) ................................................................. 270
Ondansetron (Zofran) ................................................................. 272
Oxygen ...................................................................................... 273
Pralidoxime Chloride / 2-Pam CL (WMD) .................................... 274
Prednisone .................................................................................. 275
Prochlorperazine (Compazine) .................................................... 276
Racemic Epinephrine .................................................................... 277
Sodium Bicarbonate .................................................................... 278
Sodium Chloride 0.9% .................................................................. 279
Tetracaine Hydrochloride ............................................................. 280
Tranexamic Acid (TXA, Cyklokapron) ........................................... 281

Appendix
Abdominal Pain Differential ......................................................... 282
Chest Pain Differential ................................................................. 283
Glasgow Coma Score Chart ......................................................... 285
Dopamine Infusion Chart ............................................................. 286
Epinephrine Infusion Chart ......................................................... 287
Normal Vital Signs Chart ............................................................. 288
APGAR Scoring Chart ................................................................. 289
ET, Suction and, Orogastric Tube Size Chart ............................... 290
Burn Assessment Chart ............................................................. 291
Infectious Diseases ..................................................................... 292
Abbreviations (approved for use) ............................................... 294
Pediatric Cyanokit Dose Card ...................................................... 297
These protocols were developed under the direct auspices of the Medical Director for the District of Columbia Fire and Emergency Medical Services Department (DCFEMS). The clinical pathways are consistent with current medical practice and adhere to treatment regimens established by professional organizations such as the National Association of EMS Physicians. The sources of the manual represent the consolidation of medical procedures and emergency pre-hospital guidelines and publications that are nationally and regionally accepted as the standard of practice.

The District of Columbia Department of Health (DOH) and the United States Department of Transportation (USDOT) have established a standardized Scope of Practice for each level of EMS field provider. DCFEMS providers meet or exceed National Registry of EMT’s and DOH standards. This Pre-Hospital Patient Care Manual establishes the standardized medical direction for patient care that should be provided by all Emergency Medical Services providers under the authority of the DCFEMS Medical Director.

The following policies, procedures, and pathways are to be used as directives for the delivery of emergency medical care. These medical directives are the established standards of authorized practice and care for the providers of this Department. If a provider has questions about any procedure or standard of care, they are instructed to consult with a Medical Control physician for orders.

Treatment protocols are orders that guide actions that an emergency medical service provider (EMS) is expected to take. Treatment protocols should be followed unless the protocol requires such contact with a Medical Control physician. It is imperative that providers establish contact with Medical Control for confirmation of medical care and further medical direction in situations that are not covered in treatment protocols.

Our commitment is to provide the best possible care and service to the citizens, public and private sector employees, and visitors of the Nation’s Capital.
District of Columbia
Fire and EMS Protocols
EMS Protocols, Policies, Formulary, and Procedures

General Overview

The purpose of this protocol manual is to provide EMS providers with directives and guidelines in the pre-hospital treatment of the majority of patients. Providers are also expected to rely on knowledge gained from training, consultation with Medical Control, and experience when encountering situations not covered in these protocols. Providers should always do what is right for the patient as long as it is within your scope of practice.

This manual is divided into four main sections:

(1) Policies related to the delivery of EMS care;
(2) Medical Directives (protocols);
(3) Medical Procedures; and
(4) The Medication Formulary

Policies Related to the Delivery of EMS Care

The manual contains numerous DCFEMS policies that serve as Standard Operating Guidelines (SOGs) for the delivery of EMS by the Department’s members. Providers are expected to familiarize themselves with these policies. If, while operating in the scene a provider becomes unsure of what action to take, then the member should make contact with a Battalion EMS Supervisor or have a supervisor dispatched to the scene. Failure to adhere to these policies or SOGs will be considered an operational variance and will be investigated.

Medical Directives (Protocol) Section

The treatment protocol section provides direction for the pre-hospital treatment of the majority of patients. Interventions are based upon certification levels and skill sets. The headings separating and designating interventions based on skill sets are illustrated below:

<table>
<thead>
<tr>
<th>Interpreting Headings in Treatment Protocol Sections</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL PROVIDER LEVELS (For BLS and ALS Providers)</td>
</tr>
<tr>
<td>ADVANCED LIFE SUPPORT PROVIDERS (For ALS Providers)</td>
</tr>
<tr>
<td>MEDICAL CONTROL OPTIONS (On Line Medical Control order only)</td>
</tr>
</tbody>
</table>

The treatments and procedures are outlined in chronological order. Although every patient contact and situation is different, the order of the steps should be adhered to as close as possible. It is understood that several providers may be providing care to a patient and interventions may be implemented simultaneously or at near simultaneous times or reordered based on situational needs.
This is acceptable as long as the interventions are executed in timely manner and do not negate or skip over any of the primary assessment and essential treatment requirements.

**Medical Procedures Section**

The medical procedures section lists the indications and contraindications that are to be utilized by the medical provider. They also describe the procedure and any special notes for the majority of skills used by field providers. Skills within each subcategory include a heading that indicates the provider level that is allowed to utilize the skill. Procedures in this manual are consistent with established national standards. New, non-traditional procedures or off-label use of medications will be the subject of intensive training via programs directly supervised by the Medical Director or his/her designee.

Certain procedures and medications will be delegated practice for “Credentialed Providers” as designated by the Medical Director. Providers with this designation will be required to recertify and show competency in the skill set. This recertification will be on a basis as determined by the Medical Director. The medical Director may withdraw this endorsement and credential at his/her discretion.

**Medication Formulary**

The medication formulary lists indications, dosages, contraindications, side effects, and special notes for all medications that EMS providers are authorized to administer. Providers will use these medications as indicated in the formulary and the specific protocol. It is understood that EMS providers can administer a patient’s prescribed medication. Many of the contraindications listed for specific drugs are relative to the patient’s condition. Providers are directed to contact Medical Control if there are concerns regarding a listed contraindication.

Providers must contact **Medical Control** to administer other prescribed rescue medications not specifically mentioned in the District of Columbia Fire and EMS Medical Protocols or formulary (i.e. Diastat rectal diazepam or Solucortef). The rescue medication must be provided by the patient or caregiver and the label must have the patient’s name and the amount of medication to be given. The mechanism of delivery must be within the provider’s scope of practice.

In certain therapies multiple medications can be used to produce similar therapeutic effects. In those instances where the Medical Director has authorized the use of more than one medication, the following graphic will be used to designate when alternate medication choices are authorized.
The order of the listing in the protocol does not dictate a favoring of one medication over the other. The provider should utilize whichever medication is immediately available from the DCFEMS medical supply services at property.

This measure has been instituted to introduce flexibility if supply chains are disrupted due to manufacturing shortages or an inability to procure one of the medications.

Emergency Medical Services for Children (EMSC) Bear

The EMC Bear symbolizes when Pediatric Care is warranted and Medical Control is required.
Medical communications is a vital component of pre-hospital care. Information reported should be concise and provide an accurate description of the patient’s condition as well as treatment rendered. Therefore, a complete patient assessment and set of vital signs should be completed prior to contacting Medical Control or a receiving facility. Regardless of the destination, early and timely notification of Medical Control or the receiving hospital is essential for prompt care to be delivered by all involved.

1. Medical communications with Medical Control or a receiving facility should be conducted for every Priority 1 patient.

2. Contact Medical Control as soon as feasible in accordance with protocols for medication or treatment modality orders. For seriously injured or critically ill patients notification to the receiving facility is required. It is preferred that this be accomplished by the transport unit, however, notification through the Office of Unified Communications is acceptable.

3. When communicating with Medical Control or a receiving facility, a verbal report should include these essential elements:
   - Identify unit, level of provider and name
   - Destination hospital and ETA
   - Patient’s age, sex
   - Mental status
   - Patient’s chief complaint
   - Brief pertinent history of the present illness
   - Baseline vital signs to include EKG, glucose, or other pertinent assessments
   - Pertinent findings of the physical exam
   - Past medical history, current meds and allergies
   - Treatment rendered in the field
   - Patient response to emergency care given
   - Orders requested, repeat granted orders back to physician
   - If Medical Control is obtained, document the physician’s name

4. Advise receiving facility of change occurring in patient’s condition en route to the medical facility.

5. When transmitting patient information, **DO NOT** include personal or sensitive information (e.g. name, social security number, address, race, etc.).
Responsibility for patient care in the pre-hospital setting may be transferred between pre-hospital personnel according to established procedures. These procedures are applicable for turnover responsibility to or from EMS providers or to hospital staff.

I. ALS Provider Transfer of Care to and equal or higher level provider

1. Non-transport ALS provider to transporting ALS provider
   - When first on-scene, the non-transporting ALS provider should transfer patient care authority upon arrival of the transporting ALS provider.
   - When the transferring ALS provider has initiated ALS care and the transfer of care might negatively affect patient care, the non-transporting ALS provider should maintain patient care authority during transport.
   - The transferring ALS provider should provide the transporting ALS provider a full patient report to include vital signs and physical assessment if applicable.

II. ALS Provider Transfer of Care to a BLS provider

1. Once a patient has received medications administered by any level of DCFEMS provider, the patient is categorically considered an ALS level patient. BLS providers are directed to transport the patient to the hospital if the estimated time of arrival of an ALS resource is greater than the transport time to the closest appropriate hospital. If an ALS resource arrives on the scene, the ALS provider shall assume patient care responsibilities and accompany the patient to the hospital.

2. No patient will be turned over to BLS care once ALS interventions (Medications, Airway) have been initiated. An exception to this rule can be made in a Mass Casualty or disaster scenario.

3. Patients must be stable with complaints that would be cared for at the BLS level. Prior to transferring care to the BLS provider, the examining paramedic will reasonably determine that there are no anticipated changes in the patient's present condition that would deem the patient unstable.

4. Transfer of care can take place if:
   - The patient has a patent airway, maintained without assistance or adjuncts.
   - The patient is hemodynamically stable. Vital signs should be steady and commensurate with the patient's condition.
The patient is at his or her baseline mental status and not impaired as a result of medications or drug ingestion.

- No mechanism or injury warrants a trauma alert or activation.
- No cardiac, respiratory, or neurological complaints that warrant ALS intervention exist.
- The ALS provider provides the BLS provider with a full patient report to include vital signs and physical assessment.
- The EMT who will be in attendance is comfortable with the patient's condition and will assume care.

III. Transfer of Care at the Medical Facility

1. Upon arriving at a receiving facility, EMS providers will not initiate new medical care once they cross the threshold of the facility. Examples include, spiking new IV bags, starting O₂, immobilization, and restraint application.

2. EMS providers will continue any and all pre-hospital care initiated during the transport until the patient has been triaged or until the time-limit detailed below is reached, whichever occurs first. Examples include pre-hospital O₂; maintaining IV's begun in the field until they run out, and maintaining of splints applied in the field.

3. Hospitals will designate personnel to assess patients brought by EMS transport units with the goal of transferring care and releasing the unit within 10 minutes of the patient’s arrival to the Emergency Department (ED). Transfer of care includes movement of the patient to the hospital-owned equipment, i.e. bed, stretcher, waiting room etc.

4. Transfer of care will be documented on the patient care report (PCR). The triaging personnel will be expected to sign the time stamped receipt of delivery of the patient at the time transfer of care takes place.

5. In the event that transfer of care is delayed for longer than 20 minutes, the EMS provider will contact the EMS Liaison Officer (ELO), who will in-turn contact the authorized hospital point of contact and attempt to resolve the delay in patient transfer until release.

6. If the EMS provider is still unable to obtain a signature, this fact will be documented by the EMS provider in lieu of the signature itself, and the ELO will inform the authorized hospital personnel that the process outlined in paragraph 7 below will be followed.
7. Patients that have been assessed by hospital personnel and are placed in a stable category will be escorted to the waiting room intake by EMS personnel and presented to the hospital's ambulatory patient intake personnel. The EMS crew will then go back in service.
I. Purpose:

To establish guidelines for the management and documentation of situations where patients refuse treatment or transportation, or insist on transportation to a destination other than that recommended by the EMS provider.

The Definition of a Patient for purposes of this policy shall be:

- Obtaining a history or interview of a client
  AND/OR
- Physical exam, vital signs, assessment, or mental status examination that leads to clinical decision making actions such as treatment, transport, refusal or referral to another agency/service provider.

II. Guidelines:

1. Obtain Consent
   A. Informed Consent – when a competent patient or guardian is informed of the potential benefits and risks of a process or procedure, alternatives to that procedure, and the possible consequences related to each.
   B. Expressed Consent – written or verbal request to be evaluated and treated.
   C. Implied Consent – when a patient is unable to express consent because of altered mental status or severe distress.

2. Patient Assessment
   A. Providers should attempt to obtain a history and perform a physical assessment in as much detail as is permitted by the patient.
   B. Conduct Three Assessments: Providers should attempt to assess the following three major areas prior to permitting a patient to refuse care and/or transportation:
     - Legal Capacity to Refuse Care
       o Ensure that the patient is at least 18 years of age in order to refuse care.
       o If the patient is a minor, he or she may refuse care if he or she is emancipated (over age 16) by declaration of the court, or is married.
Any minor of any age may consent or refuse care for health services for prevention, diagnosis or treatment of the following conditions:

1. Pregnancy or its lawful termination
2. Substance Abuse to include drug and alcohol abuse
3. Mental or Emotional Condition
4. Sexually transmitted disease

Patients subject to a court decree of incapacity are not legally competent to refuse care.

- **Mental Capacity to Refuse Care**
  - Ensure that patient is oriented to person, place, time and purpose.
  - Establish that patient is not a danger to himself or others.
  - Ensure that patient is capable of understanding the risks of refusing care or transportation and any proposed alternatives.

- **Medical or situational capacity**
  - Ensure that patient is suffering from no acute medical conditions that might impair his or her ability to make an informed decision to refuse care or transportation.
  - Check to be sure that patient is exhibiting no other signs or symptoms of potential mental incapacity, including drug or alcohol intoxication, unsteady gait, slurred speech, post ictal period after seizure, cognitive deficits after hypoglycemia or drug intoxication, etc.
  - If possible, rule out conditions such as hypovolemia, hypoxia, head trauma, metabolic emergencies (e.g., diabetic shock); hypothermia, hyperthermia, etc.
  - Attempt to determine if patient lost consciousness for any period of time.

### III. Who May Refuse Care

1. The Patient:
   
   A. If patient has legal, mental, medical and situational capacity to understand the risks and alternatives to treatment and transportation, the patient has a right to refuse care. Obtain refusal signature.

   B. Implied consent -- if patient is unconscious lacks capacity and/or is seriously injured or in need of further medical attention, treat and transport patient despite patient’s inability to consent or the unavailability of another party to provide consent.
2. Parent:
   A. A custodial parent (i.e., a parent with a legal right to custody of a minor child) may refuse care on behalf of a minor child. Obtain refusal signature from parent.
   B. A parent of a patient who is 18 years of age or older may not refuse care on behalf of his or her child (unless the parent also happens to be a legal guardian – see below).
   C. A minor (i.e., under 18 years of age) may refuse care for his or her child. Obtain refusal signature from the minor parent.

3. Guardian:
   A. A legal guardian is one who is appointed by a court to act as “guardian of the person” of an individual who has been found by a court to be incapacitated.
   B. Legal guardian may also be appointed in lieu of parents for a minor. If a person indicates they are a legal guardian to the patient, attempt to obtain documentation of this fact (court order, etc.). If no such documentation is available, you may obtain refusal signature from the guardian as long as you do so in good faith and do not have any evidence or knowledge that the person is misrepresenting himself as a legal guardian of the patient.

4. Health Care Agent (“Attorney-in-Fact”):
   A. A person appointed by the patient in a durable power of attorney document may refuse care on behalf of the patient if the power of attorney contains such authorization.
   B. Attempt to obtain a copy of the durable power of attorney document to attach to the patient care report (PCR). If no such documentation is available, you may obtain refusal signature from a health care agent (“attorney-in-fact”) as long as you do so in good faith and do not have any evidence or knowledge that the person is misrepresenting himself as the health care agent or “attorney-in-fact” of the patient.

IV. Managing Incompetent Patients and Patients who lack Medical or Situational capacity:

1. Take all reasonable steps to secure treatment or transportation for a patient who is legally or mentally incompetent to refuse care, but do not put yourself or your crew in jeopardy.

2. The Metropolitan Police Department should be summoned to the scene to assist with patients that you believe may be mentally incompetent and
3. If a patient lacks medical or situational capacity, and no other authorized individual is available to provide a refusal signature, the patient may be treated and transported as long as you act in good faith and without knowledge that the patient or authorized individual would refuse care. Patients may be transported against their objections if they lack medical or situational capacity to refuse care.

V. Refusal Procedures:

1. If the patient does not speak English as a primary language and requests language translation services, the language line will be used for formal translation services.

2. If patient refuses care, or insists on being transported to a facility that is on closure or a facility other than the destination recommended by EMS personnel, have the patient or designee complete the refusal of treatment or transport section of the patient care report (PCR).

   A. Conduct a thorough patient assessment to include vital signs and blood glucose level.

   B. Inform the patient that units responded to the scene for the purpose of providing emergency medical care and with the expectation of terminal outcome that the patient would accept transport to the hospital for further evaluation and treatment.

   C. Review form with patient or designee. If required the body of the text shall be read aloud to the patient.

   D. Provide detailed explanation of possible risks and danger signs to patient or other designee.

   E. Inform the patient to call 911, call their doctor or go to an emergency department if symptoms persist or get worse or any of the danger signs you inform them of appear.

   F. Obtain the signature of the patient or designee. If the patient refuses to sign, document this fact on the patient care report (PCR).

   G. Have the patient or designee date the patient care report (PCR).

   H. Obtain signature of a witness; preferably the witness should be someone who witnessed your explanation of risks and benefits to the patient, and who watched the patient sign the form. Witnesses may
include law enforcement personnel. All witnesses should be 18 years of age or older if possible.

I. Contact the EMS Liaison Officer or Battalion EMS Supervisor to provide an update via radio consultation confirming that all evaluation and inclusion criteria have been met. If a Battalion EMS Supervisor is on the scene, providers may dispense with the radio consult.
Air-Medical transport may be utilized when available if conditions are favorable to reduce transport time for critically ill or injured patients. It is important to consider the risk/benefit ratio when making this decision.

**Basic considerations for air transport:**

- Would the amount of time needed to transport a patient by ground transportation to an appropriate medical facility pose a threat to the patient’s survival and/or recovery?
- Would weather, road conditions, or other factors affecting the use of ground transportation seriously delay the patient’s access to tertiary medical care?
- Does the available ground ambulance have the clinical skills, equipment or extra personnel to care for the patient during transport from the scene?
- If the seriously injured patient is trapped, would the extrication time allow for the helicopter to arrive at the scene and speed delivery of the patient to a trauma receiving facility?

**Indications for requesting Aeromedical evacuation of a patient include:**

- Patient injury evaluation by the first-arriving Paramedic meets criteria for trauma center destination.
- The scene of injury is more than 30 minutes lights-and-siren driving time to the trauma center destination (distance, traffic, and weather conditions considered).
- Patient extrication, vital on-scene care, and ground transport time is estimated to be greater than the time span from requesting Aeromedical service to Aeromedical patient arrival at the trauma center.
- A Mass-Casualty Incident (MCI) in which awaiting sufficient numbers of ground transport units for critical patient(s) would result in a transport time delay that exceeds the time span from request of Aeromedical service to Aeromedical patient arrival at the designated trauma center. In this situation Aeromedical Unit should transport to a distant tertiary care center if all possible to allow local resources to be used by ground units.

**Contraindications for requesting Aeromedical evacuation of a patient include:**

- Patients in cardiac arrest
- Patients contaminated by hazardous materials
- Patients with violent or erratic behavior
Helicopter safety and landing zones:

- When a helicopter has been requested, indicate a safe landing zone by taking into account, crowds, trees and overhead hazards.
- Never approach a helicopter until instructed by the flight crew to do so.
- If the rotors are turning, never approach a helicopter from the rear or from above.
Medical Control may be contacted at any step in patient care, and if a patient’s condition is unusual and is not covered by a specific protocol. When a patient’s presentation is atypical and the protocol treatment may not be the best treatment for the patient or in any situation where the EMS provider is not sure about the best treatment for the patient contact Medical Control.

Each hospital will serve as its own Medical Control for patients being transported to them. **Children’s National Medical Center (H02)** will be the designated Medical Control for **ALL** Pediatric patients. When Medical Control is required, providers should ask to speak to the Emergency Physician. If genuinely unable to contact Medical Control, proceed with standing orders only, **DO NOT** initiate Medical Control options. Providers should make every effort to utilize Hospitals 5, 8 or 13 as a back-up for adult patients. In the event of a communications failure, notify the receiving Emergency Department and the ELO upon arrival.

**Purpose of Medical Control contact:**

- EMS personnel will provide care within their scope of practice and will follow D.C. Fire and EMS orders when delivering EMS care.
- Medical Control must order any ALS or BLS treatment (medication or procedure) that EMS provides when that treatment is not included in or is a deviation from the approved protocols.
- In certain circumstances, as defined by the protocols, Medical Control shall be contacted by EMS (BLS or ALS) personnel.
- Protocols cannot adequately address every possible patient scenario. EMS personnel can contact Medical Control when confronted with a situation that is not addressed by the protocols or when the EMS personnel have any doubt about the appropriate care for a patient.

**Contact with Medical Control may be particularly helpful in the following situations:**

- Patients with time-dependent illnesses or injuries who may benefit from transport to a specific facility with special capabilities (e.g. acute stroke, acute ST-elevation MI).
- Patients with conditions that have not responded to the usual protocol treatments.
- Patients with unusual presentations that are not addressed in protocols.
- Patients with rare illnesses or injuries that are not frequently encountered by EMS personnel.
- Patients who may benefit from uncommon treatments (e.g. unusual overdoses with specific antidotes).
I. Initial Scene Survey and Size Up

1. Survey the scene for possible hazards and re-survey periodically.
2. Protect yourself first, then victims, from hazards. Do not become a victim.
3. Identify all potential patients. Refer to MCI Bulletin if greater than 9 patients.
4. In cases of a lightning strike a reverse triage process should be utilized and patients in cardiac arrest should be treated first.
5. Summon additional resources as necessary to manage the incident. Additional resources include, but are not limited to: fire, rescue, advanced life support, or law enforcement.
6. Assess mechanism of injury and/or nature of illness.
   - Medical – determine nature of the illness from the patient, family or bystanders. Why EMS was activated?
   - Trauma – determine the mechanism of injury from the patient, family or bystanders, and inspection of the scene.
7. If injury or illness is the result of exposure to a hazardous chemical, the patient should be completely decontaminated before treatment.
8. Patients that are identified to be unresponsive and do not have a witness to attest as to the mechanism of the change in mental status shall be treated as if they have a cervical spinal injury. Appropriate spinal immobilization precautions shall be employed while the assessment and care is being performed.

II. Primary Patient Assessment

1. Form a general impression of the patient (Critical, In Distress, or Non-Critical) with the understanding that management of scene time is critical when managing major trauma patients.
2. Assess mental status (AVPU)
   - A----Alert
   - V----Responsive to verbal stimulus
   - P----Responsive to painful stimulus
   - U----Unresponsive
4. Determine the chief complaint/apparent life threats.
Immediate Recognition and Action Plan

1. If the patient is unresponsive and presents with apnea or agonal respirations immediately assess for the presence of a pulse. If a pulse is absent, initiate CPR and proceed with resuscitation. If the patient is very cold due to hypothermia, assess the pulse for 45 seconds before determining that a pulse is absent. If the patient meets criteria for Presumed Dead on Arrival (PDOA) do not initiate resuscitation.

2. Identify active hemorrhage and control bleeding by applying a pressure dressing or tourniquet as needed.

3. Utilize an Impedance Threshold Device (ResQPOD™) for patients eight (8) years of age or older in a non-traumatic cardiac arrest (If available). Remove the device immediately in the event of a Return of Spontaneous Circulation (ROSC).

4. CPR should be continued until an AED becomes available and is readied for use.

5. Defibrillate as applicable and refer to appropriate treatment protocol.

Airway

1. Assess airway status. If cervical spinal trauma is suspected, manually stabilize the spine. If the airway is blocked use a jaw thrust to relieve the obstruction.

2. Inspect the mouth for foreign objects, vomitus or blood. If present, remove it, or suction as needed. Utilize mechanical aids such as direct laryngoscopy (ALS), or any other approved method of obstruction relief.

3. When the airway is open, insert an oral or nasopharyngeal airway as tolerated. If the patient is pulseless and/or apneic, insert the King Airway as the primary airway of choice. BLS measures should be left in place as long as the device continues to be effective. ALS providers should immediately attempt to intubate using the Endotracheal Tube if BLS measures are deemed ineffective.

4. If none of these are successful, advanced life support providers should consider advanced airway alternatives such as needle cricothyroidotomy.

Breathing and Ventilation

1. Assess rate, rhythm, and quality of breathing. If the patient’s respiratory rate is normal or near normal, administer oxygen as per the specific protocol.
2. If the patient’s respiratory rate is unusually rapid or slow for their age, the quality of respiration is insufficient, or if the patient is not breathing, ventilate with a bag-valve-mask (BVM) every 6 seconds or ten times a minute.

3. Seal sucking wounds with an occlusive dressing.

4. Splint flail segments with a taught heavy bulky dressing.

5. If tension pneumothorax is suspected, ALS providers should immediately perform a needle thoracostomy of the affected side. Perform bilateral needle thoracostomy for patients in cardiac arrest with chest trauma.

6. Frequently reassess the patient’s breathing and intervene as necessary.

7. Continuous Quantitative Waveform Capnography (ETCO₂) shall be utilized for any patient with moderate-severe respiratory distress, any patient requiring ventilatory assistance via BVM, or any patient that has been intubated with a King Airway or Endotracheal Tube.

8. Any patient that has been intubated with a King Airway or Endotracheal Tube shall have a cervical collar applied (full spinal immobilization is not required) with the expressed intent of stabilizing the head and neck to assist in stabilizing the airway and maintaining the flow and stabilization of an IV line that may have been established in the external jugular vein.

Circulation

1. Identify active hemorrhage and control bleeding by applying a pressure dressing or tourniquet as needed.

2. Heart rate: compare to normal rate for age and situation.

3. Central/truncal pulses (radial, brachial, femoral, carotid): strong, weak or absent.

4. Distal/peripheral pulses: present/absent, thready, weak, or strong.

5. Check perfusion by evaluating skin color, temperature, and moisture.

6. Hydration status: anterior fontanel in infants, mucous membranes, skin turgor, crying tears, urine output history.

7. Identify the priority of the patient based on assessment findings.
Disability
1. Evaluate neurological status by noting:
   - Mental status and level of consciousness.
   - Presence or absence of movement in the extremities, either spontaneously or in response to stimuli.
   - Pupil size and reactivity.
   - General evidence of trauma to the head or neck.
2. Initiate spinal movement restrictions, if indicated.

Expose and Examine
1. Remove as much clothing as necessary to determine the presence or absence of an emergency condition or injury.
2. Perform a rapid full body scan and identify injuries. Treat life threatening conditions as they are recognized. Inspect and palpate each of the major body systems for the following:
   - D -- Deformities
   - C -- Contusions
   - A -- Abrasions
   - P -- Penetrations/punctures
   - B -- Burns
   - T -- Tenderness
   - L -- Lacerations
   - S -- Swelling/edema
   - I -- Instability
   - C -- Crepitus

Categorize Complaint and Determine Transport Priority
2. Establish if the patient’s complaint is medical or traumatic in nature. Proceed to appropriate assessment pathway.
III. History Taking

1. Investigate the chief complaint and history of the present illness or event. You should use the mnemonic, “OPQRST-I” to evaluate any kind of pain.
   - Onset – When did the pain/discomfort begin?
   - Provocation/Palliative – What worsens or lessens the pain/discomfort?
   - Quality – What does the pain/discomfort feel like?
   - Region/Radiation/Referral – Where is the pain/discomfort? Does it move anywhere?
   - Severity – How severe is the pain/discomfort?
   - Timing – How long/often has this been occurring?
   - Interventions – Any intervention performed prior to EMS arrival and any effect they may have had?

2. Inquire about pertinent past medical history. You may use the acronym, “SAMPLE”.
   - Signs/Symptoms
   - Allergies
   - Medication
   - Past medical history
   - Last oral intake
   - Events leading up to illness or injury

3. Inquire about pertinent negatives as they can frequently narrow the focus of treatment. Pertinent negatives should be recorded in the patient care report.

IV. Secondary Assessments

Medical Complaints

1. Assess Vital Signs and blood glucose level.
2. Use appropriate monitoring devices to monitor the patient such as EKG (4-lead and 12-lead), Temperature, Pulse oximetry with Carbon Monoxide probe, and/or Continuous Quantitative Waveform Capnography (ETCO₂).
3. Inquire about current health status.
5. Conduct a focused physical examination.
6. Based on the formulated impression refer to the appropriate treatment protocol.

**Trauma Complaints**

1. Perform primary assessment, initial stabilization and load into Transport unit and start transport for all Patients that satisfy criteria for Field Trauma Triage Algorithm.
2. Assess Vital Signs and blood glucose level.
3. Perform a detailed focused physical examination while en route to the hospital or at the landing zone (fly-out) only after lifesaving assessments and interventions have been completed.
4. Based on the formulated impression refer to the appropriate treatment protocol.
5. Do not delay transport to initiate IV therapy.

**Baseline Vital Signs and EKGs**

1. Reassess respiratory rate, depth, quality, and rhythm (pattern).
2. Reassess pulse rate, rhythm, and quality. **DO NOT** utilize the pulse oximeter or the EKG tracing as the sole means for determining pulse rate.
3. Skin color, temperature and moisture.
4. **PEDS** - Capillary refill status.
5. At a minimum limb lead EKG monitoring should be completed at an early phase of patient evaluation. EKG assessment is essential when managing patients reporting complaints such as:
   - Chest discomfort of any kind.
   - Respiratory distress/shortness of breath.
   - Upper back pain.
   - Neck or jaw pain.
   - Epigastric discomfort.
   - Syncope / Near Syncope.
   - Acute onset of general malaise or weakness.
6. A 12 lead EKG will be obtained on patients with any one of the complaints mentioned in line item # 5 and who is greater than 30 years of age and reports to have a history of any one of the following cardiac risk factors:

- Coronary Artery Disease
- Hypertension
- Family History of Cardiac Issues
- Use of recreational drugs
- Use of medications not prescribed to that individual
- Is a member of an at risk population

Patients with complaints consistent with suspected cardiac etiology or Acute Coronary Syndrome (ACS) who are 30 years of age or older and have risk factors noted above must be transported ALS unless Medical Control approves the downgrade of the patient to BLS. All patients in which EKG monitor is utilized or a 12 Lead EKG is obtained will have such data uploaded to the electronic medical record.

7. Obtain blood pressure. The initial blood pressure shall be obtained by auscultation on all patients. Subsequent blood pressures can be obtained manually or by electronic non-invasive blood pressure devices.

8. Obtain Blood Glucose reading unless procedure is declined by the patient.

9. Vital signs should be monitored at a minimum of every 5 minutes for all critical patients and every 15 minutes for all other patients.

10. In addition to obtaining vital signs, providers shall perform these additional skills to assist with patient assessment as needed:

- Pulse Oximetry.
- EKG: 4-lead and 12-lead.
- Continuous Quantitative Waveform Capnography (ETCO₂).
- Temperature, as needed.
- Carbon Monoxide (RAD 57 or Lifepak 15 with Rainbow probe).
Normal Vital Signs

<table>
<thead>
<tr>
<th></th>
<th>Respirations</th>
<th>Pulse</th>
<th>Systolic BP*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td>12 - 20</td>
<td>60 -100</td>
<td>90 - 140</td>
</tr>
<tr>
<td>Adolescent</td>
<td>12 - 24</td>
<td>60 -100</td>
<td>&gt;90</td>
</tr>
<tr>
<td>Children (1 to 10 years)</td>
<td>22 - 34</td>
<td>80 -140</td>
<td>&gt;75</td>
</tr>
<tr>
<td>Infants (1 month to 1 year)</td>
<td>24 - 40</td>
<td>90 -150</td>
<td>&gt;70</td>
</tr>
<tr>
<td>Neonate (0 to 28 days)</td>
<td>30 - 60</td>
<td>100 -160</td>
<td>&gt;60</td>
</tr>
</tbody>
</table>

* For children 1 to 10 years of age, you can determine the lower limit of an acceptable blood pressure using the following formula:

\[
\text{Minimal systolic blood pressure} = 70 + (2 \times \text{age in years}).
\]

V. Focused Physical Examination

1. Performed to detect non-life threatening conditions and to provide care for those conditions/injuries. Perform enroute to the medical facility if the patient is unstable.

   **Head**
   1. Inspect facial features for symmetry.
   2. Note color of face.
   3. Note presence of swelling or excessive perspiration.
   4. Assess the pupils and observe their size, equality and reactivity.
   5. Inspect ear canals for discharge or presence of fluids.
   6. If evidence of head trauma, have suction ready and prepare for seizure activity.

   **Neck**
   1. Note the trachea’s position.
   2. Inspect the neck of the upright patient for jugular venous distention.
   3. Observe supra-sternal areas for retractions or use of accessory muscles.
Chest
1. Assess rate, depth, quality, and pattern of breathing.
2. Observe chest wall movement for symmetry, and auscultate breath sounds on both sides of the chest and anterior and posterior if the situation allows. Inspect the integrity of the chest wall.
3. Inspect and palpate for indwelling medical devices.

Abdomen and Pelvis
1. Assess the abdomen for pain, tenderness, swelling, guarding, or distention.
2. Palpate for the presence of rigidity, pulsations, masses, distention, rigidity and rebound tenderness.
3. Inspect and palpate for indwelling medical devices.
4. Using gentle pressure, evaluate the pelvis for crepitus and instability.

Extremities
1. Palpate distal pulses and evaluate skin presentation and temperature.
2. Inspect and palpate extremities for tenderness, gross deformity, swelling, lacerations and abrasions. Note motor, sensory, and vascular integrity in each extremity. Dress and splint extremity injuries as required and as time allows. When possible, elevate injured extremities.

Back
1. Examine the patient’s back, if possible, for gross deformities or penetrating injuries.
2. Initiate spinal movement immobilization if indicated.

VI. Reassessment
1. To effectively maintain awareness of changes in the patient’s condition, repeated assessments are essential and should be performed:
   - **Unstable patient**: at least every 5 minutes
   - **Stable patient**: at least every 15 minutes
2. Repeat the primary assessment.
3. Reassess circulation including pulses, hemorrhage control and skin perfusion.
4. Re-establish patient priority.
5. Reassess and record vital signs.
6. Repeat focused assessment regarding patient complaint or injuries.
7. Assess interventions.
8. Assess response to management.
9. Maintain or modify management plan.

VII. Transport Decision

**Adult Patients**

1. Major trauma patients should be transported to one of the designated adult trauma centers.
2. Burn patients are to be transported to the Burn Center at the Washington Hospital Center entering through MedStar (H04)
3. Burn patients with critical trauma other than the burns should be transported to the closest available burn center for the management of life threatening conditions.
4. Patients presenting with signs and symptoms that lead to a clinical impression of acute myocardial infarction (AMI) or STEMI should be transported to the closest STEMI referral center that is capable of emergent Percutaneous Coronary Angioplasty
5. Patients presenting with signs and symptoms that lead to a clinical impression of a CVA or TIA should be transported to the closest appropriate stroke receiving center.

**Pediatric Patients**

1. Major trauma and burn patients less than 15 years of age should be transported to Children’s National Medical Center (H02).
2. Major trauma and burn patients 15 years of age or greater (adult sized) should be transported to a trauma or burn facility capable of handling adult patients.
3. Medical or minor trauma patients less than 18 years of age should be transported to a medical facility capable of handling pediatric patients.
4. Sexual assault patients less than 18 years of age should be transported to Children’s National Medical Center (H02)

**Special Situations**

1. Patients with isolated eye trauma should be transported to Howard University Hospital. If significant trauma is associated the patient should be transported to the closest major trauma facility.
2. Patients with an amputation should be transported to the closest trauma facility.

3. Adult sexual assault patients who have sustained major single or multiple system trauma should be transported to the closest trauma facility. Adult sexual assault patients with no trauma or minor trauma will be transported to Washington Hospital Center (H13).

4. Patients with left ventricular assist devices (LVAD) should be transported to an LVAD referral facility. Currently the only facility in the District of Columbia is Washington Hospital Center (H13).

VIII. Considerations

1. For the purposes of determining pediatric versus adult dosing for medication the following criteria is to be applied:
   - Pediatric doses apply to pediatric patients weighing less than 45 kg (100 lbs.).
   - For pediatric patients equal to or greater than 45 kg (100 lbs.), utilize adult dosing.
   - Where applicable and available, the Broselow Tape, pediatric dose cards and/or electronic application should be utilized.
This protocol establishes standard practices for airway management and oxygen therapies. Unless otherwise indicated in a specific protocol, the mechanisms and therapeutic modalities in this protocol will be universally applicable.

**ALL PROVIDER LEVELS**

1. Patients that are identified to be unresponsive and do not have a witness to attest as to the mechanism of the change in mental status shall be treated as if they have a cervical spine injury. Appropriate spinal immobilization precautions shall be employed while the airway is being assessed and managed.

2. If cervical spine trauma is indicated, cervical spine stabilization will be maintained and the modified jaw thrust will be used to open the airway.

3. If cervical spine injury is not indicated, either the head tilt–chin lift method or modified jaw thrust method may be utilized to open the airway.

4. If the airway is obstructed refer to the **Obstructed Airway protocol**.

5. Suction the airway as needed. The tongue-jaw lift maneuver should be utilized to facilitate suctioning.

### Suctioning Time Limits

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Child</th>
<th>Infant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>15 s</td>
<td>10 s</td>
<td>5 s</td>
</tr>
</tbody>
</table>

**Placement of Airway Adjuncts**

1. An oropharyngeal airway (OPA) or King Airway should be sized and inserted if a gag reflex is absent.

2. If the patient has an intact gag reflex, a nasopharyngeal airway (NPA) should be sized, lubricated, and inserted. Use of the nasopharyngeal airway is contraindicated in patients with:
   - Head trauma with epistaxis
   - Potential basilar skull fracture
   - History of fractured nasal bone
   - Significant head or facial trauma or bleeding
Artificial Ventilation and Assisted Ventilation

1. If spontaneous respirations are insufficient or absent provide ventilatory assistance via BVM with supplied oxygen. Insufficient respiratory effort includes but is not limited to:
   - Less than
     - 8 respirations per minute in adults or;
     - Below the lower limits of normal limits for pediatric patients
   - Greater than:
     - 26 respirations per minute in adults or;
     - above the higher limits of normal for pediatric patients
   - No visible chest rise with inspiratory effort
   - Pulse Oximetry reading of less than 90% SpO₂ after oxygen therapy without a corresponding rise in SpO₂

2. Patients requiring artificial ventilation or assisted ventilations shall be ventilated with a bag valve mask (BVM) with 100% supplemental oxygen at the following rates:

<table>
<thead>
<tr>
<th></th>
<th>Ventilation Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adult</strong></td>
<td>1 breath every 6 – 8 seconds</td>
</tr>
<tr>
<td><strong>Child</strong></td>
<td>1 breath every 3 – 5 seconds</td>
</tr>
<tr>
<td><strong>Infant</strong></td>
<td>1 breath every 3 – 5 seconds</td>
</tr>
</tbody>
</table>

3. If a tracheostomy tube is present, attach the BVM to the 15 mm adapter of the tracheostomy tube. Close and seal the patient’s mouth and nose before providing ventilations if no tracheostomy cuff is present. If the patient has a stoma and no tracheostomy tube is present, use a pediatric mask to form a seal over the stoma and ventilate with the appropriate BVM. Close and seal the patient’s mouth and nose before ventilating. Release the seal of patient’s mouth and nose to allow for exhalation.

4. Ventilations should be delivered over 1-2 seconds in sufficient volume to produce visible chest rise.

5. Routine hyperventilation and hyperinflation must be avoided.

Supplemental Oxygen Therapy

1. Administer supplemental oxygen via an appropriate device and at a flow rate sufficient enough to maintain a SpO₂ >94%. Patients should not routinely be given oxygen if oxygen saturation is adequate with a SpO₂ >94%.
2. Nebulized medications shall be driven by a flow rate of 10 liters per minute (lpm) or as prescribed by the manufacturer’s recommendations.

3. Patients exhibiting signs of moderate to severe respiratory distress due to pulmonary edema or near drowning should be placed on the Continuous Positive Air Pressure (CPAP) system.
   - ALS providers should apply the nasal cannula ETCO2 device before placing the CPAP mask into position.
   - Where indicated, nebulizer systems shall be inserted as part of the in-line circuit of the CPAP system. The oxygen flow rate driving the nebulized medication shall remain at 10 lpm or as prescribed by the manufacturer’s recommendations.

4. If the patient has a stoma or tracheostomy, a tracheostomy mask may be used as the delivery device. If a tracheostomy mask is not available, a non-rebreather mask (NRB) should be placed over the opening.

---

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Patients requiring advanced airway control due to the ineffectiveness of BLS measures should be intubated via either the oropharyngeal or nasopharyngeal route.

2. During early resuscitation phases of patients in cardiac arrest, the King Airway shall be used as the primary airway. If the King LT(S)-D airway is used and suction is available, the gastric contents can be suctioned via an 18 gauge French suction catheter inserted through the suction channel at first practicable opportunity.

3. If a tracheostomy is present and ventilatory support is required, insert a 6.0 or smaller Endotracheal Tube into the tracheostomy until the cuff is barely visible. Inflate the cuff until a seal is formed.

4. Intubation with a King Airway or ET Tube requires the attachment of continuous quantitative waveform capnography. ETCO₂ readings should be maintained at a level of 35-45 mmHg.

5. **Needle Thoracostomy** should be employed on patients with clinical indications of tension pneumothorax. **Bilateral Needle Thoracostomies** should be performed on any patient that is in cardiac arrest secondary to trauma and has associated chest injuries. Tension pneumothorax is a clinical diagnosis and should be managed when signs and symptoms are recognized. ALS providers should **not delay management** waiting for tracheal shift to manifest.

6. Refer to the **Medication Facilitated Intubation protocol** as required.
7. **Needle Cricothyroidotomy** should be implemented when indicated if upper airway is obstructed despite interventions.
After assessment of a patient, the ALS or BLS provider must assign a treatment priority. The following examples of priorities are not inclusive and sound judgment should be used when assessing patients.

I. **Priority 1: Unstable Patients**

1. Cardiac Arrest.
2. Post arrest with successful resuscitation.
3. Unconscious or GCS <13 and does not respond to therapy.
4. Moderate to severe respiratory distress with a respiratory rate >24, cyanosis, use of accessory muscles, or altered mental status.
5. Hypotensive (BP <90 systolic) with signs and symptoms of hypoperfusion.
6. Hypertensive (BP >220 systolic or >120 diastolic) with altered mental status or neurological deficit.
7. Cardiac related chest pain unrelieved by therapy with hypotension or cardiac dysrhythmia.
8. Suspected acute myocardial infarction.
9. Obstructed or uncontrolled airway.
10. Continuous vaginal hemorrhage with signs and symptoms of hypoperfusion.
11. Abnormal deliveries.
12. Evidence of prolapsed cord.
15. Status epilepticus.
16. Uncontrolled hemorrhage following trauma.
17. Multiple trauma patient(s).
18. Unstable chest injuries.
19. Penetrating wounds head, neck, chest, abdomen or pelvis.
20. Burn patients:
   - Respiratory burns.
   - 2\(^{nd}\) degree burn with greater than 20% BSA any age.
   - Any 3\(^{rd}\) degree burn larger than 1% BSA, or the size of the patient’s hand.
   - Electrical burns.
Chemical burns.

2\textsuperscript{nd} or 3\textsuperscript{rd} degree burns hands, face, feet or perineum.

21. Acute neurological deficit less than four (4) hours.
22. Unstable fracture with neurovascular compromise.
23. Any patient that is deemed unstable by the senior provider.

II. Priority 2: Potentially Unstable Patients

1. Cardiac related chest pain.
2. Respiratory distress (mild to moderate).
3. Hypertensive (BP >220 systolic or >120 diastolic) without signs and symptoms.
4. Patients involved in trauma with a GCS of 15, without signs and symptoms of hypoperfusion and associated with one of the below:
   - MVC >40 mph
   - Hit by vehicles >20 mph
   - Patients thrown from moving vehicles
   - Rollover MVC
   - Falls ≥20 feet without altered mental status or hypoperfusion
5. Burn patients.
   - 2\textsuperscript{nd} degree burns 10-20\% BSA any age.
6. Any patient that is deemed potentially unstable by the senior provider.

III. Priority 3: Stable Patients

1. Uncomplicated fractures.
2. Minor burns.
3. Lacerations requiring suturing, with bleeding controlled.
4. Seizure patients with a return of a GCS 15.
5. Any patient that is deemed stable by the senior provider.
## Medical Facility Hospital Designation and Fire and EMS Capability Chart

**Effective Date:** April 15, 2015  
**Revision Date:** March 31, 2015

### Medical Facility

<table>
<thead>
<tr>
<th>Hospital Number</th>
<th>Adult Medical</th>
<th>Adult Major Trauma &gt;14 yrs</th>
<th>Ped. Major Trauma 14 yrs</th>
<th>Critical Burns</th>
<th>STEMI / ROSC Facility</th>
<th>Stroke Center</th>
<th>Hyperbaric Medicine</th>
<th>Obstetrics</th>
<th>Adult Sexual Assault Center</th>
<th>Ped. Sexual Assault Center</th>
<th>Eye Trauma</th>
<th>LVAD Center</th>
<th>Adult Psychiatric</th>
<th>Pediatric Psychiatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Medical Center</td>
<td>01</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Childrens National Medical Center</td>
<td>02</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Medstar</td>
<td>04</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Howard University Hospital</td>
<td>05</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Psychiatric Institute of Washington</td>
<td>06</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Georgetown University Hospital</td>
<td>07</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>George Washington University Hospital</td>
<td>08</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Childrens National @ United Medical Center</td>
<td>09</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Providence Hospital</td>
<td>10</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Sibley Hospital</td>
<td>12</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Washington Hospital Center</td>
<td>13</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Veterans Administration Hospital</td>
<td>15</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Prince Georges Hospital Center</td>
<td>16</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Holy Cross Hospital</td>
<td>17</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Washington Adventist Hospital</td>
<td>19</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Southern Maryland Hospital</td>
<td>20</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fort Washington Hospital</td>
<td>21</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Suburban Hospital</td>
<td>22</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Walter Reed National Military Medical Center</td>
<td>23</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Doctors Hospital</td>
<td>25</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Virginia Hospital Center</td>
<td>26</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Inova Alexandria Hospital</td>
<td>27</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Inova Fairfax Hospital</td>
<td>29</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fort Belvoir Medical Center</td>
<td>39</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Inova Mount Vernon Hospital</td>
<td>43</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

---

Effective Date: April 15, 2015  
Revision Date: March 31, 2015  
Version: 2.1  
Page 30
This protocol applies to patients experiencing a non-traumatic cardiac arrest. For pediatric patients weighing >45 kg the adult resuscitation guidelines should be followed. If the patient meets the criteria for being presumed dead on arrival (PDOA), resuscitative efforts shall not be attempted and notification of law enforcement shall be made. If at any time the patient has a return of spontaneous circulation (ROSC), refer to the ROSC protocol.

1. Initiate General Assessment and Universal Patient Care ensuring that the patient is pulseless and apneic or agonal.
2. Initiate immediate CPR (PIT CREW concept) and support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. For non-traumatic patients eight (8) years of age or older, attach Impedance Threshold Device (ResQPOD™) and ventilate in conjunction with timing light. Remove immediately if Return of Spontaneous Circulation (ROSC) occurs.
4. Attach AED or Monitor/Defibrillator, analyze the rhythm, and defibrillate as indicated. If “no shock” is advised or indicated, immediately continue CPR. Repeat rhythm assessments every 2 minutes.
5. Establish an IV of Normal Saline KVO. EM
ts who have completed the IV training module and Advanced EMTs may initiate IV access
   ➢ If peripheral IV access in the antecubital space or external jugulars capable of supporting a large gauge IV catheter is not immediately accessible then ALS providers and Advanced EMTs should immediately obtain IO access.
   ➢ IO at the Humerus (preferred) or Tibial site can be the first access procedure especially if insertion of an IV would disrupt CPR.
6. As soon as a mechanical external compression device (i.e. Lucas 2) becomes available the device can be employed as the primary means of providing chest compressions.

1. Monitor/Defibrillator operations should be conducted in the manual mode with CPR Metronome activated.
2. If a King Airway is not in place, insert a **King Airway** and monitor with on Continuous Quantitative Waveform Capnography (ETCO$_2$). Endotracheal Intubation should be attempted if BLS measures are determined to be ineffective or the airway cannot be secured via BLS interventions. **Do not interrupt CPR to intubate.**

3. Administer **Epinephrine** every 3-5 minutes for the duration of the arrest:

<table>
<thead>
<tr>
<th>Causes</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypovolemia</td>
<td>Normal Saline Boluses</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Ventilate with 100% Oxygen</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Calcium Chloride and Sodium Bicarbonate. After administration of either medication ensure that the IV line is completely flushed</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>Dextrose</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Remove clothing with gradual re-warming. Handle patient gently</td>
</tr>
<tr>
<td>Hydrogen Ion (acidosis)</td>
<td>Normal Saline Boluses. Sodium Bicarbonate</td>
</tr>
<tr>
<td>Tension Pneumothorax</td>
<td>Needle Thoracostomy</td>
</tr>
<tr>
<td>Cardiac Tamponade</td>
<td><strong>Normal Saline Boluses and rapid transport. In-hospital pericardiocentesis</strong></td>
</tr>
</tbody>
</table>

4. Consider **Sodium Bicarbonate 1 mEq/kg IV/IO** if the patient is believed to have one of the following conditions:

- Chronic Renal Failure
- Hyperkalemia
- Tricyclic Anti-Depressant Overdose
- Suspected case of Excited Delirium

- **Sodium Bicarbonate should not be routinely used in cases of extended down time.**

5. Identify and treat the following contributing factors (6 H and 5 T’s):
6. For patients in PEA, consider **Dopamine infusion 5-20 mcg/kg/min** after numerous doses of Epinephrine have been administered.

7. **Etomidate 0.3 mg/kg IV/IO, maximum of 30 mg** may be needed for sedation if patient regains consciousness or shows signs of pain during mechanical CPR.

**MEDICAL CONTROL OPTIONS**

1. Consider termination of resuscitation efforts per **Termination of Resuscitation** protocol if patient remains in Asystole
This protocol applies to patients that are pulseless and exhibiting a wide complex tachycardia or ventricular fibrillation. For pediatric patients weighing > 45 kg adult resuscitation guidelines should be followed. If at any time the patient has a return of spontaneous circulation (ROSC), refer to the ROSC protocol. Patients that are successfully resuscitated from a VF / VT pre-hospital arrest MUST be transported to a STEMI receiving facility.

### ALL PROVIDER LEVELS

1. Initiate Universal Patient Initiate General Assessment and Universal Patient Care ensuring that the patient is pulseless and apneic or agonal.

2. Initiate immediate CPR (PIT CREW concept) and support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.

3. For non-traumatic patients eight (8) years of age or older, attach Impedance Threshold Device (ResQPOD™) and ventilate in conjunction with timing light. Remove immediately if Return of Spontaneous Circulation (ROSC) occurs.

4. Attach the AED or Monitor/Defibrillator as soon as the device is available and analyze the rhythm. If “no shock” is advised or indicated, immediately continue CPR. Repeat rhythm assessments every 2 minutes.

5. If a shock is required, Re-start CPR and charge device. Defibrillate via the AED or Monitor/Defibrillator and continue with rhythm assessments every 2 minutes. BLS providers are to continue with “shock” and CPR therapy for the remainder of the arrest, until the rhythm is no longer “shockable” or until patient care is taken over by ALS providers.

6. Establish an IV of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

   - If peripheral IV access in the antecubital space or external jugulars capable of supporting a large gauge IV catheter is not immediately accessible then ALS providers and Advanced EMTs should immediately obtain IO access.

   - IO at the Humerus (preferred) or Tibial site can be the first access procedure especially if insertion of an IV would disrupt CPR

7. As soon as a mechanical external compression device (i.e. Lucas 2) becomes available the device can be employed as the primary means of providing chest compressions.

8. **Etomidate 0.3 mg/kg IV/IO, maximum of 30 mg** may be needed for sedation if patient regains consciousness or shows signs of pain during mechanical CPR.
1. If a King Airway is not in place, insert a King Airway and monitor with continuous quantitative waveform capnography (ETCO₂). Endotracheal Intubation should be attempted if BLS measures are determined to be ineffective. Do not interrupt CPR to intubate.

2. Monitor/Defibrillator operations should be conducted in the manual mode. Defibrillate as appropriate:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>360 J</td>
<td>2 J/kg (manual) or AED</td>
</tr>
</tbody>
</table>

3. Administer Epinephrine every 3-5 minutes for the duration of the arrest:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine 1:10,000 1 mg IV/IO or 1:1,000 2 mg ET diluted with 5 ml of Normal Saline</td>
<td>Epinephrine 1:10,000 0.01 mg/kg IV/IO or 1:1,000 0.1 mg/kg ET diluted with 1-5 ml of Normal Saline</td>
</tr>
</tbody>
</table>

4. Repeat defibrillation for recurrent VF/VT after every 2 minute cycle of quality CPR and after each drug administration is circulated for at least 60 seconds:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>360 J</td>
<td>4 J/kg</td>
</tr>
</tbody>
</table>

5. Administer Amiodarone (primary) or Lidocaine repeat medication in 5 minutes:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
</table>
   | Amiodarone Initial dose: 300 mg IV/IO  
   Second dose: 150 mg IV/IO in 5 minutes  
   Third dose: 150 mg IV/IO in 5 minutes | Amiodarone Initial dose: 5 mg/kg IV/IO up to the adult dose.  
Additional doses: 5 mg/kg IV/IO to a maximum total dose 15 mg/kg |

Or if Amiodarone not available
6. Consider **Magnesium Sulfate** for suspected polymorphic V-tach (Torsades de Pointes) or hypomagnesaemia:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lidocaine</strong></td>
<td><strong>Lidocaine</strong></td>
</tr>
<tr>
<td>Initial dose: 1 mg/kg IV/IO</td>
<td>Initial dose: 1 mg/kg IV/IO</td>
</tr>
<tr>
<td>Additional doses: 1 mg/kg IV/IO to a maximum total dose 3 mg/kg</td>
<td>Additional doses: 1 mg/kg IV/IO to a maximum total dose 3 mg/kg</td>
</tr>
</tbody>
</table>

7. Consider **Sodium Bicarbonate 1 mEq/kg IV/IO** if the patient is believed to have one of the following conditions:

- Chronic Renal Failure
- Hyperkalemia
- Tricyclic Anti-Depressant Overdose
- Suspected case of Excited Delirium

  ❖ **Sodium Bicarbonate should not be routinely used** in cases of extended down time.

8. Adult patients remaining in refractory VFib/VTach after a total of four (4) defibrillation attempts shall have **Double Sequential Defibrillation** performed at **360 joules** when a second defibrillator or an AED becomes available.

MEDICAL CONTROL OPTIONS

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients who have a return of spontaneous circulation (ROSC) after cardiac arrest. Patients that are successfully resuscitated from **ANY** pre-hospital arrest, regardless of initial rhythm, **MUST** be transported to a STEMI receiving facility.

### ALL PROVIDER LEVELS

1. Remove the Impedance Threshold Device (ITD) if previously utilized.
2. Initiate General Assessment and Universal Patient Care.
3. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
4. Initiate advanced airway management if the airway cannot be managed properly utilizing BLS airway maintenance.
   - ALS providers should utilize advanced airway management with ET intubation and monitor with continuous quantitative waveform capnography (ETCO₂), maintaining a level of 35-45 mmHg.
5. Establish an IV of Normal Saline if not previously performed. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.** Provide Normal Saline Boluses if hypoperfusion is present:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

### ADVANCED LIFE SUPPORT PROVIDERS

1. Provide continuous EKG monitoring.
2. Obtain a **12 lead EKG** if time and patient condition permits. If a STEMI is indicated the, the EKG should be transmitted if practicable and the receiving facility must be notified.
3. If the patient was resuscitated following an episode of VF/VT and is without profound bradycardia or high-grade heart block (2nd degree Type II or 3rd degree or Idioventricular rhythm) administer Amiodarone Infusion or Lidocaine bolus. Note: Continue using the anti-arrhythmic medication that was administered during resuscitation.
Amiodarone
150 mg slow infusion. Mix 150 mg in 100 ml of Normal Saline. Utilize a 10 gtt set and infuse at 100 gtt/minute over 10 minutes

Or
if Amiodarone not available

Lidocaine
0.5 mg/kg IV/IO repeated every 5 minutes, up to a maximum total dose 3 mg/kg

4. If bradycardia persists refer to the Bradycardia Protocol.

5. Administer a Dopamine infusion 5-20 mcg/kg/min for persistent hypoperfusion.

6. Administer an Epinephrine infusion for heart transplant recipients or persistent hypoperfusion:

Epinephrine infusion 2-10 mcg/min

9. Consider Pain Management with Fentanyl / Morphine or sedation with Etomidate 0.3 mg/kg IV/IO, maximum of 30 mg if patient regains consciousness or shows signs of pain during mechanical CPR.

MEDICAL CONTROL OPTIONS

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients with a pulse, experiencing a wide complex tachycardia with or without hemodynamic compromise.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient in a position of comfort.
4. Establish an IV of Normal Saline KVO or Saline Lock. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*

### ADVANCED LIFE SUPPORT PROVIDERS

1. Provide **continuous EKG monitoring.**
2. Obtain **12 lead EKG** pre-treatment and post-treatment if time and patient condition permit.

**Management of the unstable patient**

3. Proceed immediately to **synchronized cardioversion** if the patient:
   - has a GCS ≤14
   - appears hemodynamically unstable
   - reports active chest pain
   - exhibits significant shortness of breath
   - If time and patient condition permit, the patient should be sedated prior to the application of electrical therapy.

4. Sedate with **Midazolam (Versed):**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midazolam (Versed)</td>
<td>Midazolam (Versed)</td>
</tr>
<tr>
<td>2-5 mg IV/IN, up to a maximum dose of 10 mg</td>
<td>0.1 mg/kg IV/IN, up to a maximum single dose of 5 mg</td>
</tr>
</tbody>
</table>
5. Perform **Synchronized Cardioversion** for patients that are unstable:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>200 J, 300 J and 360 J</td>
<td>0.5 J/kg, 1 J/kg, and 2 J/kg</td>
</tr>
</tbody>
</table>

6. If the rhythm converts to a non-lethal, narrow complex rhythm **without** the presence of a high degree heart block then administer **Amiodarone** or **Lidocaine**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>Contact Medical Control</td>
</tr>
<tr>
<td>150 mg slow infusion. Mix 150 mg in 100 ml of Normal Saline. Utilize a 10 gtt set and infuse at 100 gtt/minute over 10 minutes</td>
<td></td>
</tr>
<tr>
<td>May repeat once in 10 minutes</td>
<td></td>
</tr>
</tbody>
</table>

**Or**

**if Amiodarone not available**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lidocaine</td>
<td></td>
</tr>
<tr>
<td>1 mg/kg IV/IO followed by 0.5 mg/kg every 5 minutes, up to a maximum total dose 3 mg/kg</td>
<td>Lidocaine 1 mg/kg IV/IO every 5 minutes, up to a maximum total dose 3 mg/kg</td>
</tr>
</tbody>
</table>

7. Obtain a 12 lead EKG and monitor the patient’s EKG and vital signs.

**Management of the stable patient**

1. If the rhythm is **regular with monomorphic** appearance administer **Adenosine**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenosine</td>
<td>Contact Medical Control</td>
</tr>
<tr>
<td>First dose: 6 mg rapid IV followed by a rapid 20 ml Normal Saline bolus</td>
<td></td>
</tr>
<tr>
<td>Second dose: 12 mg rapid IV after 2 minutes if the rhythm fails to convert after the initial dose</td>
<td></td>
</tr>
</tbody>
</table>
2. If the rhythm appears irregular or the Adenosine fails to convert the tachycardia administer **Amiodarone**. May repeat one time in 10 minutes:

<table>
<thead>
<tr>
<th></th>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>150 mg slow infusion. Mix 150 mg in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 100 gtts/minute over 10 minutes</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

**Or**

if Amiodarone not available

<table>
<thead>
<tr>
<th></th>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lidocaine</td>
<td>1 mg/kg IV/IO followed by 0.5 mg/kg every 5 minutes, up to a maximum total dose 3 mg/kg</td>
<td>1 mg/kg IV/IO every 5 minutes, up to a maximum total dose 3 mg/kg</td>
</tr>
</tbody>
</table>

3. If the rhythm is polymorphic V-tach, (Torsades de Pointes) or hypomagnesaemia is suspected administer **Magnesium Sulfate**:

<table>
<thead>
<tr>
<th></th>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium Sulfate</td>
<td>2 gm slow IV/IO Infusion. Mix 2 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 100 gtts/min over 10 minutes</td>
<td>Contact Medical Control</td>
</tr>
</tbody>
</table>

4. If at any time during the administration of a medication infusion or re-evaluation, the patient begins to deteriorate or exhibit signs of tachycardia related cardiovascular compromise, revert to immediate **Synchronized Cardioversion**.
1. Additional sedation with Midazolam (Versed) IV/IN.

2. **Pediatric Patient:** Adenosine initial dose: **0.1 mg/kg rapid IV/IO** if required
   second dose: **0.2 mg/kg rapid IV/IO**.

3. **Pediatric Patients:** For the management of Torsades de Pointes
   **Magnesium Sulfate 25-50 mg/kg IV** over 20 minutes, up to a maximum
   single dose of **2 gm**.
This protocol applies to patients exhibiting a narrow complex supraventricular
tachycardia with significantly elevated heart rates with or without hemodynamic
compromise. The following heart rates will serve as triggers for management:

- Adults greater than 150 BPM
- Adolescents and Children (ages 1-15) greater than 180 BPM
- Infants (12 months or younger) greater than 220 BPM

**ALL PROVIDER LEVELS**

1. Initiate Universal Patient Care. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient in a position of comfort.
4. Establish an IV of Normal Saline KVO or Saline Lock. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide continuous EKG monitoring.
2. Obtain 12 lead EKGs pre-treatment and post-treatment if time and patient condition permit.

**Management of unstable patients**

3. Proceed immediately to synchronized cardioversion if the patient:
   - has a GCS ≤14
   - appears hemodynamically unstable
   - reports active chest pain
   - exhibits significant shortness of breath
   - **If time and patient condition permit, the patient should be sedated prior to the application of electrical therapy.**
4. Sedate with Midazolam (Versed):

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midazolam</td>
<td>2-5 mg IV/IN, up to a maximum</td>
<td>0.1 mg/kg IV/IN, up to a maximum</td>
</tr>
<tr>
<td></td>
<td>dose of 10 mg</td>
<td>single dose of 5 mg</td>
</tr>
</tbody>
</table>

5. Perform Synchronized Cardioversion for patients that are unstable:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>200 J, 300 J and 360 J</td>
<td>0.5 J/kg, 1 J/kg and 2 J/kg</td>
</tr>
</tbody>
</table>

6. If the rhythm converts to a non-lethal rhythm, monitor the patient’s EKG and vital signs.

**Management of the stable patient**

If the patient is in a narrow complex tachycardia without evidence of A-Fib / A-Flutter and is hemodynamically stable without critical signs and symptoms attempt vagal maneuvers first.

7. Administer Adenosine IV in the absence of atrial fibrillation, atrial flutter or multifocal atrial tachycardia (MAT).

- **Withhold Adenosine if the patient has a history of Wolff Parkinson White Syndrome (WPW) or if delta waves are present**

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenosine</td>
<td>First dose: 6 mg rapid IV followed by a</td>
<td>Contact Medical Control</td>
</tr>
<tr>
<td></td>
<td>rapid 10-20 ml Normal Saline flush</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Second dose: 12 mg rapid IV after 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>minutes if the rhythm fails to convert</td>
<td></td>
</tr>
<tr>
<td></td>
<td>after the initial dose</td>
<td></td>
</tr>
</tbody>
</table>
8. If the Adenosine fails to slow the rate administer **Diltiazem IV:**

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial dose:</strong> 0.25 mg/kg IV over 2 minutes</td>
<td>Not Indicated</td>
</tr>
<tr>
<td>15 minutes after first dose</td>
<td></td>
</tr>
<tr>
<td><strong>Second dose:</strong> 0.35 mg/kg IV over 2 minutes</td>
<td></td>
</tr>
</tbody>
</table>

**A-FIB, A-Flutter, and Multifocal Atrial Tachycardia (MAT)**

9. Administer **Diltiazem IV** for the management of symptomatic:
   - atrial fibrillation
   - atrial flutter
   - multifocal atrial tachycardia (MAT)

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial dose:</strong> 0.25 mg/kg IV over 2 minutes</td>
<td>Not Indicated</td>
</tr>
<tr>
<td>15 minutes after first dose</td>
<td></td>
</tr>
<tr>
<td><strong>Second dose:</strong> 0.35 mg/kg IV over 2 minutes</td>
<td></td>
</tr>
</tbody>
</table>

10. If at any time during medication administration or re-evaluation the patient begins to deteriorate or exhibit signs of rate related cardiovascular compromise, revert to immediate **Synchronized Cardioversion** per steps # 4 and # 5 in management of the unstable patient presenting with narrow tachycardia.

11. If at any time after the administration of Diltiazem (Cardizem) the patient becomes profoundly hypotensive (SBP ≤80), administer **Calcium Chloride 1 gram slow IVP.**

**MEDICAL CONTROL OPTIONS**

1. **Pediatric Patient: Adenosine**
   - **initial dose:** 0.1 mg/kg rapid IV/IO if required
   - **second dose:** 0.2 mg/kg rapid IV/IO.
This protocol applies to patients experiencing bradycardia for their specific age group with signs and symptoms of hypoperfusion and/or hypoventilation.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. For patients <12 months of age with signs and symptoms of hypoperfusion and a heart rate of <60 beats per minute:
   - Initiate 2 minutes of aggressive oxygenation / ventilation.
   - If no increase in heart rate immediately begin chest compressions.
4. Establish an IV of Normal Saline KVO or Saline Lock. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*
5. If the patient presents with signs and symptoms of hypoperfusion administer Normal Saline Boluses:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 1000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide continuous EKG monitoring.
2. Obtain 12 lead EKG’s pre-treatment and post-treatment if time and patient condition permit.

**Symptomatic with presence of high degree heart block**

3. Proceed immediately to Transcutaneous Pacing (TCP) if the patient is symptomatic with a high-degree heart block (2nd degree Type II or 3rd degree).

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate 80, 20 mA. Increase at 5 mA increments until capture is obtained with a corresponding palpable pulse</td>
<td>Rate 100, 5 mA. Increase at 5 mA increments until capture is obtained with a corresponding palpable pulse</td>
</tr>
</tbody>
</table>
4. Sedate with **Midazolam (Versed)** at first practicable opportunity:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam</strong></td>
<td><strong>Midazolam</strong></td>
</tr>
<tr>
<td>2-5 mg IV/IN, up to a</td>
<td>0.1 mg/kg IV/IN, up to</td>
</tr>
<tr>
<td>maximum dose of 10 mg</td>
<td>a maximum single dose</td>
</tr>
<tr>
<td></td>
<td>of 5 mg</td>
</tr>
</tbody>
</table>

**Symptomatic in absence of high degree heart block**

5. If the patient is symptomatic **without** high-degree heart block (2\(^{nd}\) degree Type II or 3\(^{rd}\) degree) administer **Atropine IV or Epinephrine IV**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atropine</strong></td>
<td><strong>First line: Epinephrine 1:10,000</strong></td>
</tr>
<tr>
<td>0.5 mg IV. Repeat in</td>
<td>0.01 mg/kg IV/IO</td>
</tr>
<tr>
<td>5 minutes if the patient remains symptomatic</td>
<td>If bradycardia is due to increased vagal tone or primary AV block administer <strong>Atropine 0.02 mg/kg IV/IO</strong></td>
</tr>
<tr>
<td></td>
<td>Minimum dose: 0.1 mg</td>
</tr>
<tr>
<td></td>
<td>Maximum dose: 0.5 mg</td>
</tr>
</tbody>
</table>

6. If the patient remains symptomatic, consider a sedation option if time and patient condition permit.

- **Sedate with Midazolam (Versed):**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam</strong></td>
<td><strong>Midazolam</strong></td>
</tr>
<tr>
<td>2-5 mg IV/IN, up to a</td>
<td>0.1 mg/kg IV/IN, up to</td>
</tr>
<tr>
<td>maximum dose of 10 mg</td>
<td>a maximum single dose</td>
</tr>
<tr>
<td></td>
<td>of 5 mg</td>
</tr>
</tbody>
</table>

- **Initiate Transcutaneous Pacing (TCP):**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rate 80, 20 mA.</strong></td>
<td><strong>Rate 100, 5 mA.</strong></td>
</tr>
<tr>
<td>Increase at 5 mA</td>
<td>Increase at 5 mA</td>
</tr>
<tr>
<td>increments until</td>
<td>increments until</td>
</tr>
<tr>
<td>mechanical capture is</td>
<td>mechanical capture is</td>
</tr>
<tr>
<td>obtained</td>
<td>obtained</td>
</tr>
</tbody>
</table>
7. **Epinephrine infusion** for persistent hypoperfusion and/or Bradycardia:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine infusion 2-10 mcg/min</td>
<td>Epinephrine infusion 0.1-1 mcg/kg/min</td>
</tr>
</tbody>
</table>

- For pediatric patients: If <10 kg mix 0.4 mg 1:1,000 in a 100 ml NS for a concentration of 4 mcg/ml. Infuse with a 60 gtts set for the desired dose. If >10 kg mix 0.8 mg 1:1,000 in a 100 ml NS for a concentration of 8 mcg/ml. Infuse with a 60 gtts set for the desired dose.

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for additional doses of **Midazolam (Versed)**.
This protocol applies to adult patients with non-traumatic chest pain that is suspected cardiac in etiology. The overall goal is to provide therapy in an effort to reduce ischemia, provide pain relief and rapidly identify and treat a patient suffering from a suspected cardiac event.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen if Oxygen Saturation by pulse oximetry is less than 94%.
3. Place the patient in a position of comfort.
4. Administer **Aspirin 324 mg PO** (chewed and swallowed) if not taken during the previous 24 hours or has no known allergy. *(Contact Medical Control for pediatric patients).*
5. BLS providers should assist patients in taking their own previously prescribed **Nitroglycerin SL 0.4 mg** or may use EMS stock medications if the patient’s prescribed Nitroglycerin is not available. **BLS providers can only** assist the patient with **one dose of 0.4 mg Nitroglycerin SL**.
   - **Caution:** Withhold Nitroglycerin and consult Medical Control if:
     - The patient meets pediatric criteria.
     - The patient has a systolic blood pressure ≤110 mmHg or HR<60.
     - The patient has taken erectile dysfunction medications within the past 24 hours (i.e. Viagra, Cialis, or Levitra)
6. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG monitoring.** Treat life threatening dysrhythmias as indicated.
2. Obtain a **12 lead EKG** pre-treatment and post-treatment. If myocardial injury is suspected because of ST elevation which is evident in two or more contiguous leads, the patient shall be transported to the nearest cardiac interventional facility (STEMI Facility). The EKG indicating a STEMI should be transmitted to the receiving facility and the hospital should be notified as soon as practicable. **Note:** A 12-lead EKG **must be done prior to administering nitroglycerin in order to rule out right-sided or posterior AMIs.**
3. If the EKG shows S-T elevation in leads II, III, and AVF and is suggestive of an acute inferior MI or lead V4R indicates a right sided MI or posterior MI withhold Nitroglycerin and provide a fluid bolus of 1 liter of Normal Saline. In cases of suspected right sided or posterior MI, narcotic analgesia may only be used with Medical Control orders.

4. Continuously assess lung sounds and monitor vital signs before and after administration. Administer additional Normal Saline Boluses of 250 ml as needed to maintain or restore perfusion in cases of hypoperfusion with or without right ventricular involvement (RVI). Maximum total of 2000 ml.

5. Administer Nitroglycerin 0.4 mg SL every 3-5 minutes as long as the patients symptoms persist and the systolic blood pressure is ≥110 mmHg.

6. Apply Nitroglycerin paste 1” for persistent symptoms after two (2) SL doses of Nitroglycerin have been previously administered. Ensure that the systolic blood pressure is ≥110 mmHg prior to application.

7. Administer Fentanyl or Morphine Sulfate for chest pain that is not relieved by Nitroglycerin. Titrate for relief of discomfort with repeat dosing as needed every 5-10 minutes as long as SBP ≥110 mmHg.

   ➢ If the EKG shows Inferior, RVI, or Posterior MI or if the patient exhibits signs / symptoms of hypoperfusion Contact Medical Control for Fentanyl / Morphine Sulfate.

   ➢ Withhold from patients suffering from suspected or actual cocaine induced chest pain with agitation.

   ➢ In patients 65 years old and greater consider an initial dose of half your normal adult dose when administering opiates (Fentanyl / Morphine).

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl</td>
<td>Contact Medical Control</td>
</tr>
<tr>
<td>25-50 mcg IV per dose every 5 minutes to a maximum of 200 mcg. Use 25 mcg for the elderly or a weight under 70 kg</td>
<td></td>
</tr>
</tbody>
</table>

or

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine Sulfate</td>
<td>Contact Medical Control</td>
</tr>
<tr>
<td>2 mg IV titrated to cessation of pain. Maximum total dose of 10 mg</td>
<td></td>
</tr>
</tbody>
</table>

Effective Date: April 15, 2015
Revision Date: March 31, 2015
For nausea / vomiting consider Ondansetron (Zofran) or Prochlorperazine (Compazine). May repeat once in 10 minutes if nausea/vomiting is not relieved:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric (ALS Only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran) 4 mg IV over 30 seconds</td>
<td>Ondansetron (Zofran) 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg</td>
</tr>
</tbody>
</table>

For nausea / vomiting consider Diphenhydramine 25 mg IV/IM followed by Prochlorperazine (Compazine) 10 mg IV/IM.

**MEDICAL CONTROL OPTIONS**

1. Midazolam (Versed) 2-5 mg IV/IN, up to a maximum 10 mg or Pediatric Patients: 0.1 mg/kg, up to a maximum single dose of 5 mg in lieu of Morphine Sulfate or Fentanyl, if chest pain is suspected due to CNS stimulants (i.e. cocaine, methamphetamine, etc.)

2. Additional doses of Fentanyl or Morphine Sulfate

3. Dopamine infusion 5-20 mcg/kg/min for persistent hypoperfusion.

4. Pediatric Patients: Morphine Sulfate 0.1 mg/kg slow IVP

5. Pediatric Patients: Fentanyl 1 mcg/kg IVP
## Wall affected | Leads | Artery(s) involved | Reciprocal changes
--- | --- | --- | ---
Anterior | V₂–V₄ | Left coronary artery, Left anterior descending (LAD) | II, III, AVF
Anterolateral | I, AVL, V₃–V₆ | Left anterior descending (LAD) and diagonal branches, circumflex and marginal branches | II, III, AVF
Anteroseptal | V₁–V₄ | Left anterior descending (LAD) |  |
Inferior | II, III, AVF | Right coronary artery (RCA) | I, AVL
Lateral | I, AVL, V₅, V₆ | Circumflex branch or left coronary artery | II, III, AVF
Posterior | V₈, V₉ | Right coronary artery (RCA) or circumflex artery | V₁–V₄ ST segment depression (R > S in V₁ and V₂).
Right ventricular | V₄R | Right coronary artery (RCA) | ----
This protocol applies to patients experiencing pulmonary edema secondary to congestive heart failure (CHF). The goal is to ultimately reduce the preload and afterload pressures of the myocardium. In pediatric patients, congenital heart defects are generally the culprit of CHF. Contact medical control before any medication therapy is rendered to pediatric patients.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. If the patient is conscious and in moderate to severe respiratory distress with adequate respiratory effort, apply **Continuous Positive Airway Pressure Device (CPAP)** and titrate to a pressure of:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 cmH$_2$O</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

- Before applying the CPAP face piece place the nasal cannula ETCO$_2$ device on the patient. This will allow for the introduction of additional Oxygen and eventual monitoring via continuous quantitative waveform capnography (ETCO$_2$) without having to remove the face piece.

4. Place the patient in a position of comfort.
5. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

### ADVANCED LIFE SUPPORT PROVIDERS

1. Administer **Nitroglycerin**. ALS providers may administer 1$^{st}$ dose even before IV access is established.

   **Caution - Withhold Nitroglycerin or consult Medical Control if:**
   - The patient has a systolic blood pressure $\leq 110$ mm/Hg.
   - The patient has taken erectile dysfunction medications within the past 24 hours (i.e. Viagra, Cialis, or Levitra).
2. Provide **continuous EKG and quantitative waveform capnography monitoring** (ETCO\(_2\)) via nasal cannula device.

3. Apply **Nitroglycerin paste**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroglycerin Paste 1” for persistent symptoms. Ensure that the systolic blood pressure is ≥110 mmHg prior to application.</td>
<td>Not indicated</td>
</tr>
</tbody>
</table>

4. Administer **Enalaprilat IV** if SBP ≥110 mmHg and no known sensitivity to ACE inhibitors (i.e. Lisinopril, Captopril, and Monopril):

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enalaprilat 1.25 mg IV</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

5. In instances where bronchospasm is present with wheezing, **Albuterol 2.5 mg** via nebulizer in line circuit with CPAP.

6. Obtain a **12 lead EKG** if time and patient condition permits. If myocardial injury is suspected because of ST elevation which is evident in two or more contiguous leads or chest pain is present, administer **Aspirin 324 mg PO** and transport to the nearest cardiac interventional facility (STEMI Facility).

### MEDICAL CONTROL OPTIONS

1. Consider **Lasix 20-40 mg IV** if signs of fluid overload present.

2. Consider **Lasix for Pediatric Patients: 0.5 mg/kg IV**.

3. Consider **Midazolam (Versed) 2-5 mg IV/IN, up to a maximum of 10 mg or Pediatric Patients: 0.1 mg/kg IV up to a maximum single dose of 5 mg** for severe anxiety titrated to anxiety reduction with a noted decrease in anxiety related tachycardia.
This protocol applies to patients with a suspected or actual foreign body airway obstruction or airway obstructions due to trauma, burns, or severe anaphylactic reactions. Do not delay transport for patients that are unconscious with a complete airway obstruction. Perform BLS and/or ALS skills en route to the medical facility.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.

2. If the patient is experiencing an incomplete / partial airway obstruction, encourage the patient to cough in an attempt to relieve the obstruction.

3. If the patient is conscious and the airway is completely obstructed due to a foreign body, perform BLS obstructed airway techniques until the obstruction is relieved or the patient goes unconscious.

4. If the patient is unconscious, perform BLS obstructed airway techniques. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.

5. Provide immediate transportation to the nearest appropriate medical facility if the foreign body obstruction is not relieved or closed due to trauma or severe anaphylaxis. Monitor the patient for cardiac arrest.

**ADVANCED LIFE SUPPORT PROVIDERS**

1. If the patient’s airway is still obstructed due to a foreign body and is unconscious, perform the following advanced airway techniques in order:
   - Perform Direct Laryngoscopy and remove any foreign body obstruction seen with Magill forceps if possible.
   - Perform an emergent Needle Cricothyroidotomy. *This is the last resort when a foreign body airway obstruction is present.*

2. If the patient’s airway is completely obstructed due to trauma, burns, or severe anaphylaxis:
   - Perform an emergent Needle Cricothyroidotomy.

**MEDICAL CONTROL OPTION**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients experiencing respiratory distress associated with Asthma or COPD.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
   - For patients with a history of COPD, administer the patients prescribed dose of Oxygen. If severe distress is present, administer 100% supplemental Oxygen and monitor respiratory effort and rate.
3. Place the patient in a position of comfort.
4. If the patient presents with respiratory distress with suspected bronchospasm/wheezing, administer Albuterol:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albuterol 2.5 mg via nebulizer</td>
<td>Albuterol 2.5 mg via nebulizer</td>
</tr>
</tbody>
</table>

5. If the patient continues to exhibit or report respiratory distress with bronchospasm/wheezing administer a combination of Albuterol and Ipratropium Bromide (Atrovent) via nebulizer one time only for pre-hospital care.

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albuterol 2.5 mg nebulized and Atrovent 500 mcg nebulized</td>
<td>Albuterol 2.5 mg nebulized and Atrovent 500 mcg nebulized</td>
</tr>
</tbody>
</table>

   - If the patient is in extremis or does not clear after the first nebulized Albuterol treatment ALS care shall be immediately initiated.
   - BLS providers should contact medical control for orders for additional Albuterol 2.5 mg via nebulizer if the patient’s symptoms persist and ALS care is not immediately available.
6. For COPD patients experiencing significant respiratory distress, consider **Continuous Positive Airway Pressure Device (CPAP)** and start at a pressure of $5 \text{ cmH}_2\text{O}$ with an in-line nebulizer.

- Before applying the CPAP face piece place the nasal cannula ETCO$_2$ device on the patient. This will allow for the introduction of additional Oxygen and eventual monitoring via continuous quantitative waveform capnography (ETCO$_2$) without having to remove the face piece.

- Some COPD patients have lung problems that may be worsened by CPAP. If the patient worsens on CPAP, remove the device immediately.

7. If the patient still presents with respiratory distress and is in extremis, administer **Epinephrine IM** in the lateral aspect of the patient’s thigh:

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine 1:1,000</td>
<td>Epinephrine 1:1,000</td>
</tr>
<tr>
<td>BLS or ALS: 0.3 mg via Auvi-Q</td>
<td>BLS or ALS: ≤3 y.o. 0.15 mg IM via Auvi-Q</td>
</tr>
<tr>
<td>ALS: 0.3-0.5 mg IM (ALS)</td>
<td>ALS: 0.01 mg/kg IM up to a maximum single dose 0.5 mg</td>
</tr>
</tbody>
</table>

8. Establish an **IV** of Normal Saline KVO or Saline Lock for patients that are experiencing significant respiratory distress and those with a significant cardiac history. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

<table>
<thead>
<tr>
<th><strong>ADVANCED LIFE SUPPORT PROVIDERS</strong></th>
</tr>
</thead>
</table>

1. Provide **continuous EKG** and **continuous quantitative waveform capnography (ETCO$_2$)**.

2. For patients who appear dehydrated and are without signs of pulmonary edema consider a single **Normal Saline Bolus**:

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml</td>
<td>20 ml/kg</td>
</tr>
</tbody>
</table>
Patients should be treated based on the level of distress exhibited and their response to therapies. **Providers should immediately proceed with treatments as indicated by the categories:**

For patients experiencing **MILD DISTRESS**:

1. Providers may repeat **Albuterol 2.5 mg via nebulizer** to a total of 3 doses or 7.5 mg.
2. Administer **Prednisone PO**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone 60 mg PO</td>
<td>Contact Medical Control</td>
</tr>
</tbody>
</table>

For patients experiencing **SEVERE DISTRESS**:

1. Administer nebulized **Racemic Epinephrine**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Racemic Epinephrine 0.5 ml unit dose</td>
<td>Racemic Epinephrine</td>
</tr>
<tr>
<td>mixed in 3 ml of Normal Saline</td>
<td>Less than 5 kg: 0.25 ml mixed in 3 ml Normal Saline</td>
</tr>
<tr>
<td></td>
<td>5 kg or greater: 0.5 ml Unit dose mixed in 3 ml of Normal Saline</td>
</tr>
</tbody>
</table>

2. Administer **Methylprednisolone (Solu-Medrol)**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solu-Medrol 125 mg IV/IM</td>
<td>Solu-Medrol 2 mg/kg IV/IM, up to a maximum single dose of 125 mg</td>
</tr>
</tbody>
</table>

3. If IV access is not available or patient can tolerate PO delivery then administer **Prednisone PO**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone 60 mg PO</td>
<td>Contact Medical Control</td>
</tr>
</tbody>
</table>
4. If no or minimal improvement with other therapies consider administering Magnesium Sulfate:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium Sulfate 2 gm slow IV Infusion. Mix 2 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 50 gtts/min over 20 minutes.</td>
<td>Contact Medical Control</td>
</tr>
</tbody>
</table>

5. Once air movement has improved, continue with Albuterol 2.5 mg via nebulizer as needed.

For patients with IMPENDING RESPIRATORY FAILURE

1. For adult patients, mix Racemic Epinephrine (0.5 ml), Albuterol (2.5 mg) and Ipratropium Bromide (500 mcg if not previously administered) in a “super neb” and deliver via an in-line nebulizer device. Consider use of CPAP for COPD patients in extremis with inline nebulizer system.

2. Continue to deliver nebulized treatments (Albuterol) via the CPAP circuit until the patient improves or need for ventilatory support and intubation arises.

3. If after previous therapies the SpO₂ cannot be maintained above 90% with ventilatory assistance or CPAP then refer to the Medication Facilitated Intubation protocol as applicable.

MEDICAL CONTROL OPTIONS

1. Consider additional doses of Epinephrine 1:1,000 IM.

2. Pediatric Patients: Magnesium Sulfate 25-50 mg/kg IV over 20 minutes, up to a maximum single dose of 2 gm.
This protocol applies to patients that present with a loud cough that mimics the “bark of a seal”, respiratory distress, grunting, wheezing or stridor on inspiration. The major concern of this illness is the possibility of airway obstruction.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Move the patient to a cool environment.
4. If the patient presents with respiratory distress with clinical evidence of croup, administer **Normal Saline 3 ml** via Nebulizer. Repeat 2 additional times as necessary if the patient improves with the initial administration.
5. Consider establishing an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG and continuous quantitative waveform capnography (ETCO₂).**
2. If **stridor** is present administer nebulized **Racemic Epinephrine:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Racemic Epinephrine 0.5 ml unit dose mixed in 3 ml of Normal Saline</td>
<td>Racemic Epinephrine Less than 5 kg: 0.25 ml mixed in 3 ml Normal Saline 5 kg or greater: 0.5 ml unit dose mixed in 3 ml of Normal Saline</td>
</tr>
</tbody>
</table>

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients who exhibit signs and symptoms of respiratory failure with impending or actual respiratory arrest.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. If a narcotic (opiate) overdose is suspected, administer **Naloxone (Narcan):**
   - Respiratory arrest or insufficient ventilation
   - Pinpoint Pupils
   - GCS less than 13

   (If a definitive airway (King or ET Tube) is already in place and ventilation is adequate **DO NOT** administer Narcan)

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Naloxone (Narcan):</strong></td>
<td><strong>Naloxone (Narcan):</strong></td>
</tr>
<tr>
<td><strong>BLS:</strong> 2 mg IN only, may repeat twice at the same dose</td>
<td><strong>ALS only:</strong> 0.1 mg/kg IV/IN or IM, up to a maximum single dose of 2 mg</td>
</tr>
<tr>
<td><strong>AEMT or ALS:</strong> 2 mg IV/IN or IM. If no response from the initial dose within 5 minutes, repeat 4 mg IV/IN and titrate to effect thereafter if indicated</td>
<td></td>
</tr>
</tbody>
</table>

   - Patients receiving Narcan should receive care at the ALS level and should be transported to the hospital for further evaluation and treatment.
4. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG and continuous quantitative waveform capnography (ETCO₂).**
2. Initiate advanced airway management if the airway cannot be managed properly utilizing BLS airway maintenance.
   - If the patient is intubated via ET intubation, withhold further treatments of Narcan and transport the patient with supported ventilations.
3. If the patient has an intact gag reflex and muscle tone that will inhibit oral intubation immediately refer to the Medication Facilitated Intubation Protocol.

MEDICAL CONTROL OPTIONS

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients who are experiencing abdominal pain. There are many causes of abdominal pain and vomiting, some of which are life threatening. See Abdominal Pain Differential sheet. Obtain thorough history to identify the cause:

- GI or urinary tract (kidney stone)
- GI bleeding
- Referred Cardiac pain
- Aortic aneurysm or rupture
- Possible Pregnancy / Ectopic
- Recent trauma / surgery
- Pain associated with passing blood, syncope, and diaphoresis

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient in a position of comfort.
4. Establish an IV of Normal Saline KVO or Saline Lock. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*
5. If the patient presents with signs and symptoms of hypoperfusion administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>
1. For nausea / vomiting consider **Ondansetron (Zofran)** or **Prochlorperazine (Compazine)**. Repeat one time in 10 minutes if nausea or vomiting is not relieved:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric (ALS Only)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ondansetron (Zofran)</strong></td>
<td>4 mg IV over 30 seconds</td>
<td><strong>Ondansetron (Zofran)</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.15 mg/kg IV over 30 seconds.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maximum single dose 4 mg</td>
</tr>
</tbody>
</table>

or

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diphenhydramine (Benadryl)</strong></td>
<td>25 mg IV followed by</td>
<td><strong>Prochlorperazine (Compazine)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Prochlorperazine (Compazine)</strong></td>
<td>10 mg IV</td>
</tr>
<tr>
<td></td>
<td>Not Indicated</td>
<td></td>
</tr>
</tbody>
</table>

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for pain management as needed.
This protocol applies to patients that present with altered mental status, syncope or unconsciousness that is non-traumatic.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care and rule out trauma as a suspected etiology. If stroke is suspected, proceed to Brain Attack / CVA Protocol.

2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.

3. Place the patient in a position of comfort if possible.

4. Ensure that a blood glucose reading is obtained.

5. If the patient:
   - Is greater than 8 years of age with a blood glucose level of <70 mg/dl.
   - Displays signs and symptoms of hypoglycemia
   - Is conscious enough to swallow and can maintain their own airway.
   - Administer Oral Glucose 24-50 gm SL or one single dose tube. Advanced-EMTs and ALS providers may proceed directly to intravenous interventions.

6. If a narcotic (opiate) overdose is suspected, administer Naloxone (Narcan):
   - Respiratory arrest or insufficient ventilation
   - Pinpoint Pupils
   - GCS less than 13

   (If a definitive airway (King or ET Tube) is already in place and ventilation is adequate DO NOT administer Narcan)

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naloxone (Narcan): BLS: 2 mg IN only, may repeat twice at the same dose</td>
<td>Naloxone (Narcan): ALS only: 0.1 mg/kg IV/IN or IM, up to a maximum single dose of 2 mg</td>
</tr>
<tr>
<td>AEMT or ALS: 2 mg IV/IN or IM. If no response from the initial dose within 5 minutes, repeat 4 mg IV/IN and titrate to effect thereafter if indicated</td>
<td></td>
</tr>
</tbody>
</table>

- Patients receiving Narcan should receive care at the ALS level and should be transported to the hospital for further evaluation and treatment.
7. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

8. If the patient presents with signs and symptoms of hypoperfusion administer **Normal Saline Boluses**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

9. After successful treatment of a hypoglycemic diabetic emergency, the patient may refuse further treatment or transport if all of the following criteria are met:
   - Patient must be on injectable therapy not oral therapy for refusal.
   - Patient is at least 18 years of age with a GCS 15.
   - After a repeated physical assessment, the patient’s blood sugar is within an acceptable range (>70 mg/dl).
   - Have no other signs and symptoms of illness (i.e. chest pain).
   - Patient must be observed to eat without vomiting and can be supervised by a responsible adult.
   - Patient must not be driving a vehicle or operating machinery.

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG monitoring**. Treat life threatening dysrhythmias as indicated.

2. If the event is suspected cardiac related, obtain **12 lead EKG’s** pre-treatment and post-treatment if possible.

3. Identify and treat the following contributing factors.

<table>
<thead>
<tr>
<th>Causes</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol, Acidosis</td>
<td>Normal Saline Boluses and oxygen</td>
</tr>
<tr>
<td>Epilepsy, Encephalitis</td>
<td>refer to the Seizure protocol</td>
</tr>
<tr>
<td>Insulin</td>
<td>Normal Saline Boluses and Dextrose as indicated</td>
</tr>
</tbody>
</table>
4. If the patient’s blood glucose level is <70 mg/dl administer **Dextrose**:

<table>
<thead>
<tr>
<th></th>
<th>Adult (&gt;12 yrs) &lt;70 mg/dl</th>
<th>Pediatric (ALS Only) (1 mo.-12 yrs)&lt;60 mg/dl</th>
<th>Neonate (ALS Only) (&lt;1 mo.)&lt;45 mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>50%</td>
<td>25 gm IV/IO</td>
<td>25% 2 ml/kg IV/IO</td>
<td>10% 5 ml/kg IV/IO</td>
</tr>
</tbody>
</table>

**Dextrose Dilution Procedures**

- **D25W** - Waste 25 ml D50W. Use pre-filled syringe (with remaining 25 ml) to withdraw 25 mL of NS from IV bag. Gently agitate syringe to mix solution.
- **D10W** - Waste 40 ml D50W. Use pre-filled syringe (with remaining 10 ml) to withdraw 40 mL of NS from IV bag. Gently agitate syringe to mix solution.

5. If IV access is unobtainable, administer **Glucagon**:

<table>
<thead>
<tr>
<th></th>
<th>Adult (≥25 kg)</th>
<th>Pediatric (ALS Only) (≤25 kg)</th>
<th>Neonate (ALS Only) (&lt;25 kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg</td>
<td>1 mg IN/IM</td>
<td>1 mg IN/IM</td>
<td>0.5 mg IM</td>
</tr>
</tbody>
</table>

6. If the patient is hyperglycemic infuse **Normal Saline**:

<table>
<thead>
<tr>
<th>Known Diabetic History</th>
<th>No Known Diabetic History</th>
</tr>
</thead>
<tbody>
<tr>
<td>if BGL ≥400 mg/dl</td>
<td>if BGL ≥300 mg/dl</td>
</tr>
</tbody>
</table>

**Administer a Normal Saline 500 ml bolus** followed by a drip of 100 ml/hour. **Pediatric Patients**: Administer 10 ml/kg bolus and contact **Medical Control**.
1. Contact Medical Control for further orders as necessary.
The protocol applies to patients suffering from anaphylaxis as a result of an allergic reaction to a known or unknown allergen. It is imperative that when looking for signs and symptoms, to be cognizant that 10-20% of all anaphylaxis cases will not present with hives or other skin manifestations. Signs and symptoms of anaphylaxis / allergic reaction may include oral manifestations such as; itching of the lips, tongue and palate; edema of the lips and tongue or a metallic taste in the mouth. Skin related manifestations may include flushing, itching, hives, swelling or rash. Respiratory manifestations may include difficulty speaking, wheezing, stridor, or dyspnea. GI/GU manifestations include nausea and vomiting, diarrhea and abdominal cramping or pain.

1. Initiate General Assessment and Universal Patient Care and determine a suspected cause of the reaction.

2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.

3. Removed rings and any constrictive jewelry.

4. Place the patient in a position of comfort. If signs of hypoperfusion exist, place the patient in the shock position if possible.

5. Administer Epinephrine IM in the lateral thigh area if patient presents with any two of the following signs or symptoms:
   - Hives or itching
   - Stridor
   - Hypotension
   - Abdominal Pain
   - Diarrhea
   - Sensation of swelling in mouth, tongue, or throat

   ➢ BLS providers shall use the Epinephrine Auto-injector:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine 1:1,000</td>
<td>Epinephrine 1:1,000</td>
</tr>
<tr>
<td>BLS or ALS: 0.3 mg via Auvi-Q</td>
<td>BLS or ALS: ≤3 y.o. 0.15 mg IM via Auvi-Q</td>
</tr>
<tr>
<td>ALS: 0.3-0.5 mg IM (ALS)</td>
<td>ALS: 0.01 mg/kg IM up to a maximum single dose 0.5 mg</td>
</tr>
</tbody>
</table>
6. Establish an IV of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

7. If the patient presents with signs and symptoms of hypoperfusion administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

8. If the patient presents with respiratory distress with suspected bronchospasm (wheezing), administer a combination of **Albuterol** and **Ipratropium Bromide (Atrovent)** via nebulizer **one time only for pre-hospital care**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albuterol 2.5 mg nebulized and Atrovent 500 mcg nebulized</td>
<td>Albuterol 2.5 mg nebulized and Atrovent 500 mcg nebulized</td>
</tr>
</tbody>
</table>

- BLS providers can administer one additional **Albuterol 2.5 mg** via nebulizer if bronchospasm is still present.
- ALS providers may repeat **Albuterol 2.5 mg via nebulizer** as required.

9. **Advanced EMTs and ALS providers** administer **Diphenhydramine (Benadryl):**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric (ALS Only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine (Benadryl) Mild to Moderate Reaction: 50 mg IV/IM</td>
<td>Diphenhydramine(Benadryl) 1 mg/kg IV/IM, up to a maximum single dose of 50 mg</td>
</tr>
<tr>
<td>Moderate to Severe Reaction: 75 mg IV/IM</td>
<td></td>
</tr>
</tbody>
</table>
ADVANCED LIFE SUPPORT PROVIDERS

1. Provide **continuous EKG monitoring**. If the patient receives multiple doses of Epinephrine institute **12 lead EKG monitoring**.

2. Provide **continuous nebulized Albuterol** treatments until bronchospasms are resolved.

For patients experiencing **MODERATE to SEVERE REACTION**

3. Administer **Methylprednisolone (Solu-Medrol)**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylprednisolone (Solu-Medrol) 125 mg IV/IM</td>
<td>Methylprednisolone (Solu-Medrol) 2 mg/kg IV/IM, up to a maximum single dose of 125 mg</td>
</tr>
</tbody>
</table>

4. **Epinephrine** IM may be repeated once in 5 minutes following the initial dose if no or little improvement is noted:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine 1:1,000 BLS or ALS: 0.3 mg via Auvi-Q ALS: 0.3-0.5 mg IM (ALS)</td>
<td>Epinephrine 1:1,000 BLS or ALS: ≤3 y.o. 0.15 mg IM via Auvi-Q ALS: 0.01 mg/kg IM up to a maximum single dose 0.5 mg</td>
</tr>
</tbody>
</table>

5. If the patient is taking βeta blockers or does not respond to the Epinephrine therapy administer **Glucagon**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucagon 2 mg IV/IO/IN/IM</td>
<td>Contact Medical Control</td>
</tr>
</tbody>
</table>

MEDICAL CONTROL OPTIONS

1. **Epinephrine infusion 2-10 mcg/min** for persistent symptoms or hypoperfusion.
This protocol is specific to patients who have ingested antipsychotic medications. Side effects of these medications may include extrapyramidal symptoms, orthostatic hypotension, and sedation. Extrapyramidal symptoms may include involuntary muscle movements, tremors, rigidity, and muscle contractions. These symptoms are side effects of medications commonly used in therapy for managing psychotic and schizophrenic mental health conditions. A history of psychotic mental health issues and any combination of these side effects should be indicators for treatment under this protocol.

Common Antipsychotics include: Prolixin, Thorazine, Mellaril, Haldol, Risperidol, Geodon, Seroquel, and Zyrexa

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care and determine a suspected cause of the reaction.

2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.

3. **Advanced EMTs and ALS providers** administer Diphenhydramine (Benadryl) to relieve the patient’s discomfort:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine (Benadryl) 50 mg IV/IM</td>
<td><strong>Contact Medical Control</strong></td>
</tr>
</tbody>
</table>

4. Establish an IV of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

5. If the patient presents with signs and symptoms of hypoperfusion administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td><strong>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</strong></td>
</tr>
</tbody>
</table>
ADVANCED LIFE SUPPORT PROVIDERS

1. Provide continuous EKG monitoring.

MEDICAL CONTROL OPTIONS

1. Contact Medical Control for further orders when necessary.
This protocol applies to adult patients exhibiting signs and symptoms of a cerebral vascular accident. Treatment for strokes is time dependent, and should be started at a stroke center. In many cases, it will be up to the hospital providers to verify precisely when the patient had first onset of new symptoms. Fire and EMS providers should provide and document any information they have regarding time last known well.

ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care to FAST Assessment tool:

   **Pre-hospital Stroke Screen (FAST)**

   Obtain history from the patient, family members, or other persons who are present on the scene.
   - Patient has one or more of the following new abnormalities.
     - Facial weakness or droop on left or right side
     - Arm and/or Leg weakness (drifts or falls)
     - Speech-slurred or impaired
     - Time at baseline or symptom-free and awake
   - Record contact information for witness of last known well time. (Cell Phone) if not accompanying patient during transport.

2. Support airway and provide supplemental Oxygen only if the measured Pulse Oximetry is less than 94%.

3. Baseline and follow up neurological assessments should be completed utilizing the Cincinnati Stroke Scale. Establish time of onset of the symptoms.

4. Ensure that a blood glucose reading is obtained.

5. If the patient:
   - Blood glucose level of <70 mg/dl.
   - Displays signs and symptoms of hypoglycemia
   - Can maintain their own airway and swallow secretions.

   Administer Oral Glucose 24-50 gm SL or one single dose tube in the buccal space (space in the cheek). Advanced-EMTs and ALS providers should proceed directly to intravenous interventions.
6. Place the patient in a position of comfort. Patient should be supine head at level of trunk or place head of bed elevated to 30 degrees. If speech impaired or concern for aspiration Keep NPO (Nothing by Mouth).

7. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

8. If the patient’s SBP is less than 90 mm/Hg administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>250 ml</strong> as needed to maintain a SBP 100-120 mm/Hg. Maximum total of <strong>2000 ml</strong></td>
<td><strong>20 ml/kg</strong> as needed to maintain or restore perfusion. Maximum of <strong>3 boluses</strong></td>
</tr>
</tbody>
</table>

9. Pre-notify the medical facility and be sure to include vital signs and suspected time of onset of symptoms to allow activation of the stroke team.

10. Transport immediately to a primary stroke receiving center.

---

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG and continuous quantitative waveform capnography (ETCO₂) monitoring.** If Cushing’s Triad is noted ventilate to maintain a SPCO₂ of 30-35 mmHg. Signs include the following:
   - High Systolic BP with decreasing Diastolic pressure (elevated pulse pressure)
   - Bradycardia
   - Onset of irregular breathing pattern

2. If Patient needs to be intubated consider use of Medication Facilitated Intubation Protocol.

3. If the blood glucose level is <70 mg/dl, administer **Dextrose:**

<table>
<thead>
<tr>
<th><strong>Adult</strong> (&gt;12 yrs) &lt;70 mg/dl</th>
<th><strong>Pediatric (ALS Only)</strong> (1 mo.-12 yrs)&lt;60 mg/dl</th>
<th><strong>Neonate (ALS Only)</strong> (&lt;1 mo.)&lt;45 mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>50% 25 gm IV/IO</td>
<td>25% 2 ml/kg IV/IO</td>
<td>10% 5 ml/kg IV/IO</td>
</tr>
</tbody>
</table>
4. If IV access is unobtainable, administer **Glucagon**:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric (ALS Only) (≥25 kg)</th>
<th>Pediatric (ALS Only) (&lt;25 kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>1 mg IN/IM</td>
<td>1 mg IN/IM</td>
<td>0.5 mg IM</td>
</tr>
</tbody>
</table>

5. If seizure activity is witnessed refer to **Seizure protocol**.

6. If SBP is greater than 220 mmHg or DBP is greater than 120 mmHg contact **Medical Control** for orders before administering **Labetalol 10 mg IV**.

7. For nausea / vomiting consider **Ondansetron (Zofran) or Prochlorperazine (Compazine)**. Repeat one time in 10 minutes if nausea or vomiting is not relieved:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran)</td>
<td>4 mg IV over 30 seconds</td>
<td>Ondansetron (Zofran) 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg</td>
</tr>
</tbody>
</table>

**or**

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine (Benadryl)</td>
<td>25 mg IV followed by Prochlorperazine (Compazine) 10 mg IV</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

**MEDICAL CONTROL OPTIONS**

1. If SBP is greater than 220 mmHg or DBP is greater than 120 mmHg consider an initial dose of **Labetalol 10 mg IV** which may be repeated one time in 10 minutes as needed.
This protocol applies to adult patients experiencing an isolated hypertension emergency without signs and symptoms of CVA (Stroke). Patients exhibiting signs / symptoms of an acute hypertensive emergency generally present with headache or blurred vision. If the patient’s blood pressure is ≥220 systolic and/or ≥120 diastolic consider therapy.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. If signs / symptoms of CVA are present, refer to the Brain Attack / CVA protocol.
3. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
4. Place the patient in a position of comfort.
5. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

### ADVANCED LIFE SUPPORT PROVIDERS

1. Provide continuous EKG monitoring.
2. Administer Labetalol IV if the patient exhibits signs and symptoms of hypertensive crisis with a blood pressure of ≥220 systolic and/or ≥120 diastolic after two consecutive readings (second blood pressure reading should be taken manually). Patients with signs and symptoms of Brain Attack/CVA must have Medical Control approval prior to administration:

   **Adult**
   - **Labetalol**
   - 10-20 mg slow IVP over 1-2 minutes.
   - May repeat dosage two additional times in 5 minute intervals as long the SBP remains >180 mmHg

   **Pediatric**
   - Contact Medical Control

### MEDICAL CONTROL OPTIONS

1. Consider **Nitroglycerin 0.4 mg SL.**
2. Consider **Nitroglycerin Paste 1”** for persistent symptoms.
This protocol applies to patients exhibiting signs and symptoms of hypoperfusion that is non-traumatic in nature.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient in the shock position unless respiratory distress is present; then the preferred method shall be the position of comfort. If the patient is pregnant place the patient in the left lateral position.
4. Establish an IV of Normal Saline KVO. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*
5. If the patient presents with signs and symptoms of hypoperfusion aggressively administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG and continuous quantitative waveform capnography (ETCO₂).**
2. Obtain a **12 lead EKG** if time and patient condition permits. If an acute coronary syndrome is confirmed, revert to the Acute Coronary Syndrome (ACS) protocol.
3. Consider IO access if the patient exhibits altered mental status or is profoundly hypotensive and IV access has not been obtained.
4. **Dopamine infusion 5-20 mcg/kg/min** for persistent hypoperfusion after sufficient volume replacement.

**MEDICAL CONTROL OPTIONS**

1. Consider **Epinephrine Infusion** for persistent hypoperfusion.
This protocol applies to patients experiencing an acute onset of severe pain. Patients with head injuries, diminished level of consciousness, respiratory depression, abdominal pain, multi-system trauma and hypotension are excluded from this protocol. Providers must use sound judgment when determining if a patient is indeed a candidate for pain management. Patients that will likely require pain management will often include those experiencing a sickle cell crisis, kidney stones, burns and isolated musculoskeletal injuries.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Evaluations of the pain scale will be conducted before and after the introduction of therapies.

### Wong/Baker FACES Pain Rating Scale (Ages 3 and up)

- **0** - No hurt
- **2** - Hurts little bit
- **4** - Hurts little more
- **6** - Hurts even more
- **8** - Hurts whole lot
- **10** - Hurts worst

### Infant and Toddler Pain Rating Scale

- **0** - Restful, sleep
- **1 - 2** Quiet, awake, calm face
- **3 - 4** Restless, occasional grimace or whimper
- **5 - 6** Irritable with intermittent crying and occasional grimace (easily consolable)
- **7 - 8** Frequent crying, constant grimace, tense muscles (difficult to console)
- **9 - 10** Constant high-pitched cry, thrashing of limbs, constant grimace (unable to console)

3. For sickle cell patients administer 100% via NRB. Support the airway per Supplemental Oxygen protocol.
4. Place the patient in a position of comfort.
5. Establish an IV of Normal Saline KVO or Saline Lock. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*

6. Sickle cell patients experiencing severe pain, administer a Normal Saline Bolus:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>500 ml</td>
<td>20 ml/kg</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Continuous quantitative waveform capnography (ETCO$_2$) should be instituted on patients treated under this protocol.

2. Any patient receiving analgesia under this protocol must be transported to the hospital.

3. For pain management consider **Fentanyl** or **Morphine Sulfate**.

   ➢ If the patient exhibits signs / symptoms of hypoperfusion Contact Medical Control for Fentanyl / Morphine Sulfate:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl</td>
<td>25-50 mcg IV per dose every 5 minutes to a maximum of 200 mcg. Use 25 mcg for the elderly or a weight under 70 kg</td>
<td>Fentanyl 1 mcg/kg IV/IO/IN up to a maximum single dose of 50 mcg</td>
</tr>
<tr>
<td></td>
<td>Contact Medical Control for additional doses</td>
<td></td>
</tr>
</tbody>
</table>

   or

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>2 mg IV. Repeat as needed until pain is relieved or a maximum of 10 mg is reached</td>
<td>Morphine 0.1 mg/kg IV until pain is relieved or a maximum single dose of 10 mg is reached</td>
</tr>
<tr>
<td>An additional dose of 2 mg up to a maximum single dose of 10 mg may be repeated one time after 10 minutes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In patients 65 years old and greater consider an initial dose of half your normal adult dose when administering opiates (Fentanyl / Morphine).

4. Consider administration of **Ketamine** for pain if **Fentanyl** or **Morphine** is unavailable:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine 0.2 mg/kg IV/IO/IM administered over 1 minute. May repeat once in 5 minutes as needed</td>
<td>Contact Medical Control for orders and anticipate 0.1-0.2 mg/kg IV/IM/IO</td>
</tr>
</tbody>
</table>

5. For nausea / vomiting consider **Ondansetron (Zofran) IV** or **Prochlorperazine (Compazine)**. Repeat one time in 10 minutes if nausea or vomiting is not relieved:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran) 4 mg IV over 30 seconds</td>
<td>Ondansetron (Zofran) 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg</td>
</tr>
<tr>
<td>or</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine (Benadryl) 25 mg IV followed by Prochlorperazine (Compazine) 10 mg IV</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

**MEDICAL CONTROL OPTIONS**

1. If the patient has sustained multisystem trauma and is maintaining a SBP >100 mmHg analgesia may be considered.
This protocol is specific to patients that have a known medical history of adrenal insufficiency. Providers should pay particular attention to Medic Alert® bracelets and necklaces if the patient is found unresponsive. Adrenal insufficiency results when the body does not produce the essential life sustaining hormones cortisol and aldosterone, which are vital to maintaining blood pressure, cardiac contractility, and water and salt balance.

Adrenal insufficiency can be caused by a number of medical conditions:

- Congenital or acquired disorders of the adrenal gland
- Congenital or acquired disorders of the pituitary gland
- Long term use of steroids (COPD, asthma, rheumatoid arthritis, and transplant recipients)

Acute adrenal insufficiency can result in refractory shock or death in patients on a maintenance dose of hydrocortisone sodium succinate (Solu-Cortef®) or prednisone that experience illness or trauma and are not given supplemental doses hydrocortisone.

A booster dose of hydrocortisone should be given to patients with known adrenal insufficiency that has the following illnesses or injuries:

- Shock/hypoperfusion (any cause)
- Multi-system trauma
- Hyperthermia or hypothermia
- Partial or Full thickness burns >5% BSA
- Vomiting/Diarrhea with S/Sx of by dehydration
- Medication Facilitated Intubation (Etomidate may precipitate an adrenal crisis)

<table>
<thead>
<tr>
<th>Shock/hypoperfusion (any cause)</th>
<th>Fever &gt;100.4° F and ill-appearing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multi-system trauma</td>
<td>Multiple long bone fractures</td>
</tr>
<tr>
<td>Hyperthermia or hypothermia</td>
<td>Respiratory distress</td>
</tr>
<tr>
<td>Partial or Full thickness burns</td>
<td>Drowning</td>
</tr>
<tr>
<td>&gt;5% BSA</td>
<td></td>
</tr>
<tr>
<td>Vomiting/Diarrhea with S/Sx of</td>
<td></td>
</tr>
<tr>
<td>by dehydration</td>
<td></td>
</tr>
<tr>
<td>Medication Facilitated Intubation</td>
<td>(Etomidate may precipitate an adrenal crisis)</td>
</tr>
</tbody>
</table>

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Identify and treat the underlying condition per the appropriate protocol.
4. Ensure that a blood glucose reading is obtained.
5. If the patient:
   - Is greater than 8 years of age with a blood glucose level of <70 mg/dl.
   - Displays signs and symptoms of hypoglycemia
   - Is conscious enough to swallow and can maintain their own airway.
     ❖ Administer **Oral Glucose 24-50 gm SL** or one single dose tube.
       Advanced-EMTs and ALS providers may proceed directly to intravenous interventions.

6. Establish an IV of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

7. If the patient presents with signs and symptoms of hypoperfusion administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG and continuous quantitative waveform capnography (ETCO₂).**

2. Consider IO access if the patient exhibits altered mental status or is profoundly hypotensive and IV access has not been obtained.

3. Obtain a **12 lead EKG** if time and patient condition permit.

4. Administer **Hydrocortisone Sodium Succinate (Solu-Cortef®):**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone Sodium Succinate (Solu-Cortef) 100 mg IV/IO or IM</td>
<td>Hydrocortisone Sodium Succinate (Solu-Cortef) 2 mg/kg IV/IO or IM Maximum dose of 100 mg</td>
</tr>
</tbody>
</table>

- ALS and Advanced-EMT providers are directed to administer the patient’s personal **Hydrocortisone Sodium Succinate (Solu-Cortef® emergency kit** if the medication is not readily available from DCFEMS medical supply services.
5. If blood glucose level is <70 mg/dl administer **Dextrose**:

<table>
<thead>
<tr>
<th></th>
<th>Adult (&gt;12 yrs) &lt;70 mg/dl</th>
<th>Pediatric (ALS Only) (1 mo.-12 yrs)&lt;60 mg/dl</th>
<th>Neonate (ALS Only) (&lt;1 mo.)&lt;45 mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>50% 25 gm IV/IO</td>
<td>25% 2 ml/kg IV/IO</td>
<td>10% 5 ml/kg IV/IO</td>
<td></td>
</tr>
</tbody>
</table>

**Dextrose Dilution Procedures**

- **D25W** - Waste 25 ml D50W. Use pre-filled syringe (with remaining 25 ml) to withdraw 25 ml of NS from IV bag. Gently agitate syringe to mix solution.
- **D10W** - Waste 40 ml D50W. Use pre-filled syringe (with remaining 10 ml) to withdraw 40 ml of NS from IV bag. Gently agitate syringe to mix solution.

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary
This protocol applies to patients with unusually prolonged altered mental status after seizure activity, and patients experiencing multiple or continuous seizure activity.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care and protect the patient from injury.
2. Consider manual stabilization and spinal immobilization if the possibility of suspected head or c-spine injury exists.
3. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
4. Ensure that a blood glucose reading is obtained.
5. If the patient:
   - Is greater than 8 years of age with a blood glucose level of <70 mg/dl.
   - Displays signs and symptoms of hypoglycemia
   - Is conscious enough to swallow and can maintain their own airway.
   - Administer Oral Glucose 24-50 gm SL or one single dose tube. Advanced-EMTs and ALS providers may proceed directly to intravenous interventions.
6. Establish an IV of Normal Saline KVO or Saline Lock. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide continuous EKG and continuous quantitative waveform capnography (ETCO₂).
2. If the patient’s blood glucose level is <70 mg/dl, administer Dextrose:

<table>
<thead>
<tr>
<th>Adult (&gt;12 yrs) &lt;70 mg/dl</th>
<th>Pediatric (ALS Only) (1 mo.-12 yrs)&lt;60 mg/dl</th>
<th>Neonate (ALS Only) (&lt;1 mo.)&lt;45 mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>50% 25 gm IV</td>
<td>25% 2 ml/kg IV</td>
<td>10% 5 ml/kg IV</td>
</tr>
</tbody>
</table>
3. If IV access is unobtainable, administer Glucagon:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric (ALS Only) (≥25 kg)</th>
<th>Pediatric (ALS Only) (&lt;25 kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg IN/IM</td>
<td>1 mg IN/IM</td>
<td>0.5 mg IM</td>
</tr>
</tbody>
</table>

4. If the patient is experiencing active seizure activity or presents with status epilepticus, administer Midazolam (Versed):

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
</table>
| Intranasal dose: (10 mg IN 5 mg each nostril). Contact Medical Control for additional doses
  OR
  Intramuscular: 5 or 10 mg IM
  OR
  Intravenous dose: 2-5 mg IV/IO every 2 minutes to a maximum of 10 mg until cessation of visible seizure activity |
| Midazolam
  Intranasal dose: 0.2 mg/kg IN to a maximum dose of 5 mg. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses
  OR
  Intravenous dose: 0.1 mg/kg IV/IO, up to a maximum single dose of 2 mg. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses |
5. If eclampsia is suspected, administer a **Magnesium Sulfate infusion:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Magnesium Sulfate 4 gm infusion.</strong> Mix 4 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 50 gtts/min. May be repeated one time and infused until cessation of visible seizure activity.</td>
<td>Not indicated</td>
</tr>
</tbody>
</table>

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients suffering from a suspected heat related emergency. Hyperthermic reactions generally relate to heat cramps, heat exhaustion or in severe cases, heat stroke.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. If heat exhaustion or cramps are suspected, move the patient to a cool environment and obtain a temperature.
3. Place the patient in a position of comfort. If signs of hypoperfusion exist, place the patient in the shock position if possible.
4. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
5. If heat stroke is suspected, initiate immediate aggressive cooling techniques such as removing as much clothing as possible, cold packs at the groin, under the axilla and around the neck; covering the patient with a cool wet sheet and set windows and ventilation system in the EMS unit to provide mechanical cooling.
6. Establish an IV of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**
7. If the patient presents with signs and symptoms of hypoperfusion, administer Normal Saline Boluses:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide continuous EKG monitoring. Treat life threatening dysrhythmias as indicated.
2. Administer **Ondansetron (Zofran)** or **Prochlorperazine (Compazine)** for nausea/vomiting. Repeat one time in 10 minutes if nausea or vomiting is not relieved:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran) 4 mg IV over 30 seconds</td>
<td>Ondansetron (Zofran) 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg</td>
</tr>
</tbody>
</table>

**or**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine (Benadryl) 25 mg IV followed by Prochlorperazine (Compazine) 10 mg</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

3. If seizure activity is witnessed refer to the **Seizure protocol**.

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients suffering from cold-related emergencies such as mild frostbite to severe hypothermia. Hypothermia is defined as a core temperature below 95°F. Moderate to severe hypothermia often presents with altered mental status and occasionally a decreased pulse, respiratory rate and blood pressure. Patients in cardiac arrest with suspected severe hypothermia shall not be considered dead until re-warming has been completed at a medical facility.

1. Initiate General Assessment and Universal Patient Care and handle the patient gently.
2. Remove any wet clothing and cover the patient in blankets to prevent heat loss.
3. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
4. If the patient is in cardiac arrest, attach AED/Monitor Defibrillator and analyze the rhythm. If the AED advises “shock advised” ensure that all providers are clear of the patient and depress the shock button. If no response from the first defibrillation, defer from further attempts until the patient’s core temperature is increased.
   - ALS providers should utilize their manual cardiac monitor / defibrillator and defibrillate if the patient is in a “shockable” rhythm. Immediately continue CPR post defibrillation:
     - Adult: 360 J
     - Pediatric: AED or 2 J/kg (manual)
5. If the patient:
   - Is greater than 8 years of age with a blood glucose level of <70 mg/dl.
   - Displays signs and symptoms of hypoglycemia
   - Is conscious enough to swallow and can maintain their own airway.
     - Administer Oral Glucose 24-50 gm SL or one single dose tube. Advanced-EMTs and ALS providers may proceed directly to intravenous interventions.
5. Establish an IV of Normal Saline KVO and infuse warm IV fluids if possible. EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.
6. If the patient presents with signs and symptoms of hypoperfusion, administer Normal Saline Boluses:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain</td>
<td>20 ml/kg as needed to maintain</td>
</tr>
<tr>
<td>or restore perfusion.</td>
<td>or restore perfusion.</td>
</tr>
<tr>
<td>Maximum total of 2000 ml</td>
<td>Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. If the patient’s blood glucose level is <70 mg/dl, administer Dextrose:

<table>
<thead>
<tr>
<th>Adult (&gt;12 yrs) &lt;70 mg/dl</th>
<th>Pediatric (ALS Only) (1 mo.-12 yrs)&lt;60 mg/dl</th>
<th>Neonate (ALS Only) (&lt;1 mo.)&lt;45 mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>50% 25 gm IV</td>
<td>25% 2 ml/kg IV</td>
<td>10% 5 ml/kg IV</td>
</tr>
</tbody>
</table>

**Dextrose Dilution Procedures**

- **D_{25}W** - Waste 25 ml D_{50}W. Use pre-filled syringe (with remaining 25 ml) to withdraw 25 ml of NS from IV bag. Gently agitate syringe to mix solution.
- **D_{10}W** - Waste 40 ml D_{50}W. Use pre-filled syringe (with remaining 10 ml to withdraw 40 mL of NS from IV bag. Gently agitate syringe to mix solution.

2. Provide continuous EKG monitoring.

3. If the patient is suffering from severe hypothermia (at the hospital, this patient will likely be found to have a temperature of <86°F or 30°C) and in cardiac arrest, withhold medication delivery until the patient is re-warmed in the medical facility.

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients suffering from an accidental or intentional submersion in any liquid. Pre-hospital management of these patients shall be directed toward correcting the hypoxia associated with drowning. All patients suffering from a drowning or near drowning episode should be transported to a medical facility. In the event of cold water drowning, the patient shall not be considered deceased until re-warming has been completed at a medical facility.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Consider manual stabilization and spinal immobilization if the possibility of suspected head or c-spine injury exists.
3. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
4. If the patient is conscious and presents with rales and adequate respiratory effort, apply Continuous Positive Airway Pressure Device (CPAP) and titrate to a pressure of:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 cmH₂O</td>
<td>Medical Control required</td>
</tr>
</tbody>
</table>

5. If hypothermia is suspected, refer to the Hypothermia protocol.
6. If the patient is in cardiac arrest, follow the appropriate Cardiac Arrest protocol.
6. Establish an IV of Normal Saline KVO. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*
7. If the patient presents with signs and symptoms of hypoperfusion, administer Normal Saline Boluses:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>
1. Provide **continuous EKG monitoring**.
2. If the patient is experiencing **severe respiratory distress** or presents with impending respiratory failure refer to the **Medication Facilitated Intubation protocol**.

**MEDICAL CONTROL OPTIONS**

1. Additional dose of Etomidate **up to 10 mg IV**.
2. Additional dose of Midazolam (**Versed**) for sedation.
This protocol applies to patients that have been exposed to a poison, overdosed on a medication or exhibits signs and symptoms related to the effects of drug abuse. This protocol establishes therapeutic pathways for patients with suspected overdose of medicinal agents. If possible, transport any medication bottles or pills, tablets, or capsules with the patient.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care and attempt to identify any medications or products taken or exposed to. Save samples and/or bottles if possible.

2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.

3. Ensure that a blood glucose reading is obtained.

4. Contact Poison Control on channel H-11 or call 1-800-222-1222 for assistance in managing specific overdoses. Any medication interventions recommended by Poison Control must first be approved by Medical Control.

5. Administer Naloxone (Narcan) if a narcotic (opiate) overdose is suspected and the patient has any two of the following:
   - Pinpoint pupils
   - GCS < 13
   - Respiratory depression

(If a definitive airway (King or ET Tube) is already in place and ventilation is adequate **DO NOT** administer Narcan)

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Naloxone (Narcan):</strong></td>
<td>BLS: 2 mg IN only, may repeat twice at the same dose</td>
<td>ALS only: 0.1 mg/kg IV/IN or IM, up to a maximum single dose of 2 mg</td>
</tr>
<tr>
<td><strong>Naloxone (Narcan):</strong></td>
<td>AEMT or ALS: 2 mg IV/IN or IM. If no response from the initial dose within 5 minutes, repeat 4 mg IV/IN and titrate to effect thereafter if indicated</td>
<td></td>
</tr>
</tbody>
</table>

- Patients receiving Narcan should receive care at the ALS level and should be transported to the hospital for further evaluation and treatment.
6. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

7. If the patient presents with signs and symptoms of hypoperfusion administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

### ADVANCED LIFE SUPPORT PROVIDERS

1. Provide **continuous EKG monitoring and continuous quantitative waveform capnography (ETCO₂).**

2. If organophosphate poisoning is suspected refer to the **Organophosphate/Carbamate/Nerve Agent poisoning protocol.**

3. If seizure activity is witnessed refer to the **Seizure protocol.**

4. Consider specific toxicology antidotes when the patient displays critical signs and symptoms:
   - **Sodium Bicarbonate** for tricyclic antidepressant (TCA) overdose:
     | Adult          | Pediatric       |
     |----------------|-----------------|
     | Sodium Bicarbonate 1 mEq/kg IV | Sodium Bicarbonate 1 mEq/kg IV |
   - **Calcium Chloride** for calcium channel blocker overdose:
     | Adult          | Pediatric       |
     |----------------|-----------------|
     | Calcium Chloride 1 gram slow IV | Calcium Chloride 20 mg/kg slow IV |
   - **Glucagon IV** for βeta blocker overdose:
     | Adult          | Pediatric       |
     |----------------|-----------------|
     | Glucagon 1 mg IV every 5 minutes up to a maximum total dose of 3 mg | Glucagon 1 mg IV every 5 minutes maximum total dose of 3 mg |

5. If bradycardia is present, immediately refer to the **Bradycardia protocol.**
1. If the patient is hypotensive and does not respond to fluid resuscitation, consider a **Dopamine infusion** in the range of **5-20 mcg/kg/min**.
Patients presenting with Excited Delirium often present with mental status changes, severe agitation, and violent bizarre behavior with symptoms of extreme sympathetic nervous system activation. This is a potentially fatal condition with rapid onset. In most Excited Delirium cases there is an abnormality with the regulation of the dopamine neurotransmitter in the brain. The failure to up-regulate the dopamine transporter with chronic cocaine/drug abuse or psychosis treatment leads to a hyper-dopaminergic state and this in turn, leads to the psychotic symptoms and malignant hyperthermia. This protocol is meant to aggressively treat those patients who are extremely hard to manage due to extreme sympathetic nervous system activation and hyperthermia and not patients with mild to moderate behavioral issues due to intoxication or psychosis.

Common causes of excited delirium include:

- Stimulant Drug Abuse (Cocaine, PCP, Methamphetamine)
- Underlying psychiatric disease
- Non-compliance with medications to control psychosis or bipolar disorder
- Alcohol withdrawal

### ALL PROVIDER LEVELS

1. Assist law enforcement officials with rapid capture and physical restraint as required.

2. Restrain per Physical Restraint Protocol. These patients are to remain supine on the backboard at all times unless the airway needs to be cleared. **Patients that are restrained should never be placed in the prone or face down position nor have external pressure on the Chest that may impede respiration.**

3. Administer supplemental **Oxygen** via NRB mask at 15 lpm.

4. Initiate rapid cooling if Hyperthermic by:
   - Removing clothing
   - Douse skin with water
   - Apply Ice Packs to neck groin, axilla, and core trunk area.
   - Move the patient to a cool climate controlled environment

5. Ensure that Blood Glucose Level is obtained.
6. Establish an IV of Normal Saline and run Wide Open. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000 ml</td>
<td>20 ml/kg  as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

7. Initiate rapid transport. Do not delay transport waiting on the arrival of an ALS resource.

### ADVANCED LIFE SUPPORT PROVIDERS

1. Administer **Midazolam (Versed)** for sedation. May be administered immediately after restraint:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam</strong></td>
<td></td>
</tr>
<tr>
<td>Intranasal dose: 10 mg IN (5 mg each nostril). Contact Medical Control for additional doses</td>
<td>Midazolam Intranasal dose: 0.2 mg/kg IN to a maximum dose of 5 mg. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses</td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td>Intramuscular: 5 or 10 mg IM</td>
<td></td>
</tr>
<tr>
<td>OR</td>
<td></td>
</tr>
<tr>
<td>Intravenous dose: 2-5 mg IV/IO every 2 minutes to a maximum of 10 mg until cessation of visible seizure activity</td>
<td>Intravenous dose: 0.1 mg/kg IV/IO, up to a maximum single dose of 2 mg. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses</td>
</tr>
</tbody>
</table>

2. Provide **continuous EKG monitoring, pulse oximetry, and ETCO₂ monitoring.**
3. Administer Sodium Bicarbonate:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Bicarbonate 50 mEq IV/IO, slow push</td>
<td>Sodium Bicarbonate 1 mEq/kg IV/IO, slow push, Medical Control Required</td>
</tr>
</tbody>
</table>

4. If EKG anomalies such as a widening QRS, tall peaked T-Waves, or sudden cardiac death are noted, immediately administer the medications listed below before instituting the appropriate cardiac treatment algorithm.

- Repeat Sodium Bicarbonate 50 mEq IV/IO.
- Calcium Chloride 1 Gram IV/IO.
- Additional Fluid Bolus.

**MEDICAL CONTROL OPTIONS**

1. Additional doses of Midazolam (Versed) 2-5 mg IV/IO or Versed 5 mg IN.
This protocol applies to patients experiencing venomous or non-venomous, bites or stings from animals, snakes, or spiders.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Attempt to identify the insect, reptile or animal that caused the injury, if safe to do so. **DO NOT** transport a living snake/animal/spider to the hospital. Determine if the patient has access to anti-venom that can be transported to the hospital with them.
3. If an anaphylactic reaction occurs as a result of a bite or sting, refer to the *Allergic reaction / Anaphylaxis protocol*.
4. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
5. Remove any rings, bracelets, jewelry and constricting clothing from the affected extremity.
6. Have the patient remain calm and immobilize the affected extremity.
7. Do not apply tourniquets, cold packs, or make incisions around the affected area.
8. Contact Poison Control on channel **H-11** or call 1-800-222-1222 for assistance in managing specific envenomations. Any medication recommendations from Poison Control must first be approved by Medical Control.
9. Provide rapid transport to the appropriate medical facility if the patient is symptomatic. Notification to the receiving facility is required.
10. Establish an **IV** of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**
11. If the patient presents with signs and symptoms of hypoperfusion, administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>
1. Provide continuous EKG monitoring.

2. Administer Midazolam (Versed) for patients experiencing severe muscle spasms:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam</strong></td>
<td><strong>Contact Medical Control</strong></td>
</tr>
<tr>
<td>2-5 mg IV/IN, up to a maximum dose of 10 mg</td>
<td></td>
</tr>
</tbody>
</table>

1. Contact Medical Control for further orders when necessary.

2. To reduce localized pain, the following materials may be used to soothe the stings from Exotic Pets and Fish:

- **Dragon Fish**: Soak in hot water
- **Jellyfish**: Douse area with vinegar
- **Portuguese Man o' War**: Douse with salt water (from the aquarium tank), then soak in hot water

- These animals are commonly found in many private salt-water aquariums. Contact Poison Control on channel H-11 or call 1-800-222-1222 for assistance in managing specific envenomations. Any medication interventions recommended by Poison Control must first be approved by Medical Control.
I. General Indicators of Carbon Monoxide Exposure:

- Victims who have been rescued from or had a prolonged exposure to smoke at a fire ground.
- Victims who have been exposed to carbon monoxide due to other sources of incomplete combustion.
- Exposure or overdose to Methylene Chloride (commercial paint remover).

II. Clinical Indicators of Carbon Monoxide Exposure:

1. After a patient has been exposed to carbon monoxide, his/her symptoms may range from minimal to life threatening and may include:
   - Headaches
   - Chest pain
   - Errors in judgment
   - Cyanosis
   - Confusion
   - Seizures
   - Loss of coordination
   - Irritability
   - Loss of consciousness
   - Vomiting

III. Treatment and Transport Decision

1. The following percentages refer to the saturation percentage of CO (SpCO) in the hemoglobin. If the SpCO reading indicated a weak signal, the probe should be adjusted and readings should be confirmed on multiple separate fingers with the probe properly shielded.

<table>
<thead>
<tr>
<th>SpCo Level</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 3%</td>
<td>No treatment required</td>
</tr>
<tr>
<td>&lt;6%</td>
<td>No treatment required</td>
</tr>
<tr>
<td>4 - 12% without s/sx and no history of exposure</td>
<td>Observe and treat</td>
</tr>
<tr>
<td>12 - 25% with s/sx or history of exposure</td>
<td>Treat and transport</td>
</tr>
<tr>
<td>25% or greater regardless of s/sx</td>
<td>Treat and transport</td>
</tr>
</tbody>
</table>

2. If the patient meets any of the following criteria after a CO exposure consider transport to a hyperbaric facility as referenced in the hospital capability list regardless of measured CO level on the meter:
   - History of unconsciousness.
   - Objective neurologic deficit or altered mental status.
   - Chest pain or ischemic EKG changes.
   - Pregnant patient with CO level of >15% regardless of symptoms.
   - Pediatric patient with CO level of >15% regardless of symptoms.
   - Any patient with CO level of >25% regardless of symptoms.
ALL PROVIDER LEVELS

1. Remove the patient from the contaminated environment if safe to do so.
2. Initiate General Assessment and Universal Patient Care.
3. Monitor SpCO with a RAD-57 or other device. Provide frequent SpCO monitoring. Readings should be confirmed on two separate fingers with the probe properly shielded. If fingers are cold it may help to warm the hand prior to taking the reading.

   Note: Pulse oximetry monitors may give false SpO₂ readings in patients exposed to cyanide and/or carbon monoxide.

4. Administer supplemental Oxygen via NRB face mask with flow rate at 15 lpm or greater. Support airway per Airway Maintenance and Supplemental Oxygen protocol.
5. Establish an IV of Normal Saline KVO or Saline Lock. EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.
6. If the patient is unresponsive, the patient shall be transported to the closest hospital for their respective age category.
7. Pediatric Patients: Contact Medical Control to determine appropriate destination.

ADVANCED LIFE SUPPORT PROVIDERS

1. Provide continuous EKG, SpCO, and continuous quantitative waveform capnography (ETCO₂).
2. If the elevated SpCO reading is the result of smoke exposure refer to the Smoke Inhalation/Cyanide Exposure protocol.
3. Should the need for advanced airway management or ventilatory assistance maintain an ETCO₂ level of 30-35 mmHg.
4. Refer to the Medication Facilitated Intubation protocol as required.

MEDICAL CONTROL OPTIONS

1. Contact Medical Control for further orders when necessary.
Cyanide is a cellular toxin; it halts respiration at the cellular level. Cyanide may also be found in university laboratory facilities. This may be a common method of suicide attempt in those who have access to the substance, such as laboratory workers and chemists. Cyanide also has a significant role in causing death and incapacitation in fires. The speed of onset is related to the severity of exposure (inhalation or ingestion) and may have dramatic, immediate effects causing early hypertension with subsequent hypotension, sudden cardiovascular collapse or seizure/coma.

I. Non-specific and early signs of cyanide exposure:

1. The following are early signs and symptoms of cyanide exposure: anxiety, vertigo, weakness, headache, tachypnea, nausea, dyspnea, vomiting, and tachycardia.

II. Signs of Exposure to Higher Levels of Cyanide:

1. Any of the following signs and symptoms may indicate exposure to higher levels of cyanide:
   - Markedly altered level of consciousness.
   - Seizures.
   - Respiratory depression or respiratory arrest.
   - Hypotension.
   - Cardiac dysrhythmia (other than sinus tachycardia).
   - History of recent smoke inhalation.

III. Known Exposure to Cyanide:

1. If patient has reported oral cyanide ingestion or has a history of known exposure immediately progress to the administration of Hydroxocobalamin (Cyanokit) without delay. Do not wait for signs or symptoms to manifest or worsen.

   1. Remove the patient from the contaminated environment if safe to do so.
   2. Initiate General Assessment and Universal Patient Care.
   3. Administer supplemental Oxygen via NRB face mask with flow rate at 15 lpm or greater. Support airway per Airway Maintenance and Supplemental Oxygen protocol.
4. Monitor SpO₂ and SpCO when a RAD-57 or other device becomes available. Pulse oximetry monitors may give false SpO₂ readings in patients exposed to carbon monoxide (CO). If the patient’s fingers are cold then the hand should be warmed prior to taking the reading.

5. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

6. If the patient presents with signs and symptoms of hypoperfusion, administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG, SpCO, and continuous quantitative waveform capnography (ETCO₂).**

2. Administer **Hydroxocobalamin (Cyanokit)** if the patient:
   - Has a known exposure to cyanide
   - Suffered smoke inhalation with mental status changes
   - Suffered smoke inhalation with signs and symptoms of cyanide exposure
   - Requires intubation or artificial ventilation as a result of smoke inhalation
   - Is a burn patient that has mental status changes or requires artificial ventilation

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hydroxocobalamin</strong>&lt;br&gt;Initial dose is 5 gm IV over 15 minutes.&lt;br&gt;Each 2.5 gm vial of Hydroxocobalamin is to be reconstituted with 100 ml of NS and administered at 12-14 ml/minute&lt;br&gt;Administer first dose over 7-8 minutes and repeat the second dose</td>
<td><strong>Hydroxocobalamin</strong>&lt;br&gt;70 mg/kg IV, up to a maximum of 5 gm.&lt;br&gt;Each 2.5 gm vial of Hydroxocobalamin is to be reconstituted with 100 ml of NS and administered at 12-14 ml/minute&lt;br&gt;Administer partial or full dose as needed over 7-8 minutes. Repeat the second full or partial dose as needed</td>
</tr>
</tbody>
</table>
3. Refer to the **Medication Facilitated Intubation protocol** as required.

4. Should the need for advanced airway management or ventilatory assistance arise maintain an **ETCO₂** level of 30-35 mmHg.

5. Refer to the **Burn Management protocol** as required.

### MEDICAL CONTROL OPTIONS

1. **Dopamine infusion 5-20 mcg/kg/min** for persistent hypoperfusion.
This protocol applies to female patients that are in labor, with delivery of a newborn being imminent. The most important decision to make with a patient in labor is whether to attempt delivery in the field or transport the patient to the hospital. Factors that effect that decision include; number of previous deliveries, frequent contractions that are less than 2 minutes apart and lasting 30-45 seconds, crowning or bulging, or mother has the urge to push or move her bowels (Do not allow the patient to utilize the toilet).

1. Initiate General Assessment and Universal Patient Care.
3. Place the patient supine with knees widely separated. Elevated the patient’s buttocks if needed.
4. Carefully assist expulsion of the newborn from the birth canal in its natural progression. Do not push or pull the newborn.
5. As the head emerges, encourage the mother not to push so that the delivery process can continue slowly and with minimal trauma to the perineal area.
6. Once the head emerges, suction the newborns mouth then nose to clear secretions.
   ➢ If the cord is wrapped around the newborns neck, attempt to unwrap it from the neck. If unable to remove the cord, attach the 2 umbilical clamps and cut the cord between the clamps.
7. Gently guide the head downward until the upper shoulder delivers.
8. Gently guide the head upwards until the lower shoulder delivers.
9. Once delivery is accomplished, clamp the cord at 6” and 8” from the navel and cut between the clamps.
10. Dry and wrap the newborn in a blanket to preserve body temperature.
11. Record the delivery time and gender of the newborn.
12. Proceed immediately to Newborn Resuscitation Protocol if resuscitation is necessary.
13. Record APGAR score at 1 minute and at 5 minutes.
14. Ensure that the placenta is transported to the hospital with the mother and newborn if delivered prior to arrival at the hospital.
Generalized edema is usually the presenting sign and can be often noted in the patients face, hands, sacral area, lower extremities, and abdominal wall. Patient may also complain of a frontal lobe headache, blurred vision or any other visual disturbances, nausea, vomiting, irritability, difficulty breathing and hypertension.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
3. Place the patient in the left lateral recumbent position if possible.
4. During transport, dim the lights in the transport unit because bright lighting and loud noises can produce seizures in the pre-eclamptic patient.
5. Provide immediate transport to the closest appropriate facility.
6. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

### ADVANCED LIFE SUPPORT PROVIDERS

1. If the patient is experiencing active seizure activity, administer Midazolam (Versed):

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
</table>
| **Midazolam**  
Intranasal dose: **10 mg IN (5 mg each nostril)**. Contact Medical Control for additional doses  
**OR**  
Intramuscular: **5 or 10 mg IM**  
**OR**  
Intravenous dose: **2-5 mg IV/IO** every 2 minutes to a maximum of **10 mg** until cessation of visible seizure activity | **Midazolam**  
Intranasal dose: **0.2 mg/kg IN** to a maximum dose of **5 mg**. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses  
**OR**  
Intravenous dose: **0.1 mg/kg IV/IO**, up to a maximum single dose of **2 mg**. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses |
2. If eclampsia is suspected, administer **Magnesium Sulfate Infusion**:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium Sulfate 4 gm infusion. Mix 4 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 50 gtts/min. May be repeated one time and infused until cessation of visible seizure activity.</td>
<td>Not indicated</td>
</tr>
</tbody>
</table>

3. If equipment is available, obtain and document fetal heart tones.

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
A prolapsed cord occurs when the umbilical cord presents itself outside of the uterus while the fetus is still inside. It can happen when the water breaks – with the gush of water the cord comes along. Usually, thereafter the fetus will engage and squash the cord, cutting off oxygen supplies and leading to brain damage of the fetus.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient in the knee-chest position.
4. **Do not attempt to push the cord back into the vagina.** Wrap the cord in a saline soaked dressing.
5. Palpate the cord for a pulse. If no pulse is obtained, push the newborn’s head or presenting part back into mother only far enough to regain a pulse in the umbilical cord.
6. Provide immediate transport to the closest appropriate facility while maintaining pressure on the newborn.
7. Establish an IV of Normal Saline KVO or Saline Lock. *EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.*
When faced with a newborns limb as the presenting part, **DO NOT** attempt delivery and transport the patient immediately to the closest appropriate facility.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient supine with hips elevated.
4. Do not attempt to deliver the newborn in the pre-hospital setting.
5. Keep the patient calm and encourage her not to push during contractions.
6. Provide immediate transport to the closest appropriate facility.
When faced with a newborn patient buttock as the presenting part, let the delivery occur naturally and make certain that an open airway is accomplished until delivery is completed.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient supine with knees widely separated. Elevated the patient’s buttocks if needed.
4. Allow the delivery to proceed normally while supporting the newborn with the palm or your hand and arm.
5. If the head is not delivered within 3 minutes, place a gloved hand in the vagina, with your palm toward the newborn’s face utilizing a “V” technique with your fingers. Push the vaginal wall away from the newborn’s face to create a space until delivery of the head.
6. Check the cord to ensure that it is not wrapped around the newborn’s neck.
7. Provide immediate transport to the closest appropriate facility if there is a delay in delivery of the head.
Uterine inversion is a condition when the uterus protrudes through the vagina with the placenta still attached. This condition can produce severe hemorrhage and hypoperfusion.

ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient supine.
4. If the placenta is still attached, do not remove it.
5. Cover any protruding tissue lightly with moist sterile dressings.
6. Establish an IV of Normal Saline KVO. EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.
7. Administer Normal Saline Boluses at 250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml.
This protocol applies to female patients with unusually heavy vaginal bleeding as a result of pregnancy (abrupto placenta, placenta previa and uterine rupture), miscarriage or post-partum hemorrhage.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
2. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
3. Place the patient in the left lateral recumbent position if the patient is in the third trimester of pregnancy. If the patient is not in the third trimester and is exhibiting signs / symptoms of hypoperfusion, place the patient in the shock position.
4. In the event of active post-partum hemorrhage from the vagina, apply a firm uterine massage starting from the pubis toward the umbilicus clockwise.
5. In the event that the patient has experienced a miscarriage and the fetus is \( \leq 20 \) weeks in gestation:
   - Ensure that the fetus is pulseless and apneic. If so, do not attempt resuscitative measures.
   - If there is any question as to the approximate gestation of the fetus, provide resuscitative measures.
   - If the fetus presents with spontaneous respirations and/or pulses, provide newborn resuscitative measures and transport to the closest appropriate hospital. If there is a question as to whether the fetus is viable or not; contact Medical Control for direction.
6. In the event that the patient has experienced a miscarriage and the fetus is \( > 20 \) weeks in gestation:
   - Provide newborn resuscitative measures and transport to the closest appropriate hospital.
7. Establish an IV of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**
8. If the patient presents with signs and symptoms of hypoperfusion, administer **Normal Saline Boluses at 250 ml** as needed to maintain or restore perfusion. Maximum total of **2000 ml**.
This protocol applies to newborn patients who do not respond to initial stimulation and resuscitative efforts. Prompt initiation of resuscitative steps is critical to the successful outcome of a neonatal resuscitation.

### ALL PROVIDER LEVELS

1. Position the newborn on his/her back, with the neck in a neutral position.
2. Ensure a patent airway by gentle suctioning of the mouth then the nose utilizing a bulb syringe. If Meconium stained fluid is present, suction the patient’s hypopharynx.
   - ALS providers should utilize a **Meconium Aspirator** attached to an endotracheal tube. With the assistance of a laryngoscope and blade, insert the endotracheal tube into the trachea and suction while removing the tube. *Do not perform procedure in a newborn with a vigorous cry.*
3. Dry the infant, place on a dry blanket, cover the head and keep the infant warm.
4. Provide tactile stimulation if the newborn is not responding to drying.
5. If the infant is ventilating adequately, administer free flow (blow-by) 100% oxygen at a minimum of 6 liters per minute close to the face. If ventilations are inadequate or if the chest fails to rise, reposition the head and neck, suction, and initiate bag-valve-mask ventilations with high flow oxygen at 40-60 breaths per minute.
6. If heart rate 60-80 and rapidly rising:
   - Continue manual ventilation and supplemental oxygen.
7. If heart rate less than 60, or 60-80 and not rapidly rising:
   - Initiate CPR with bag-valve-mask ventilations with high flow oxygen.
8. Determine the 1-minute **APGAR score**. Repeat at the 5 minute interval.

<table>
<thead>
<tr>
<th>Test</th>
<th>0 Points</th>
<th>1 Point</th>
<th>2 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity (Muscle Tone)</td>
<td>Absent</td>
<td>Arms &amp; legs extended</td>
<td>Active movement with flexed arms &amp; legs</td>
</tr>
<tr>
<td>Pulse (Heart Rate)</td>
<td>Absent</td>
<td>Below 100 bpm</td>
<td>Above 100 bpm</td>
</tr>
<tr>
<td>Grimace (Response Stimulation or Reflex Irritability)</td>
<td>No Response</td>
<td>Facial grimace</td>
<td>Sneeze, cough, pulls away</td>
</tr>
<tr>
<td>Appearance (Skin Color)</td>
<td>Blue-gray, pale all over</td>
<td>Pink body and blue extremities</td>
<td>Normal over entire body – Completely pink</td>
</tr>
<tr>
<td>Respiration (Breathing)</td>
<td>Absent</td>
<td>Slow, irregular</td>
<td>Good, crying</td>
</tr>
</tbody>
</table>
ADVANCED LIFE SUPPORT PROVIDERS

1. Establish an IV/IO of Normal Saline and administer 10 ml/kg if ventilation and heart rate are not improving after 3 minutes.

2. Provide continuous EKG monitoring and treat life threatening dysrhythmias as indicated.

3. Perform ET Intubation if the patient does not respond to assisted ventilations and/or CPR after 3 minutes.

4. Administer Epinephrine 1:10,000 0.01 mg/kg IV/IO, if the heart rate remains <80 beats per minute after assisted ventilations and/or CPR for 3 minutes.

5. For suspected narcotic (opiate) overdose, administer Narcan 0.1 mg/kg IV/IO/ET.

MEDICAL CONTROL OPTION

1. Medical Control may request that providers obtain a blood sugar. If the result is low, and transport time is still lengthy, Medical Control may request that Dextrose 10% be administered to the newborn.
This protocol applies to patients with near or complete amputations.

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.

2. Control bleeding with:
   - Apply direct pressure and utilize a tourniquet early to decrease severe bleeding.

3. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.

4. Provide extremity splinting as required.

5. Care or the amputated part if recovered shall include:
   - Removing gross contaminate with saline.
   - Wrap the part in moist sterile dressings and place the part in a plastic bag or container.
   - If possible, place that bag or container into a separate bag or container with ice packs to keep the part cool. **Do not allow the part to freeze.**

6. Transport to the closest appropriate facility with trauma capabilities if the patient has abnormal vital signs, multi-system trauma or amputations of the toe or fingertip at the distal end.

7. Consider transportation to a specialty trauma facility for stable patients that present with the following:
   - Complete or incomplete amputation, de-gloving, crushing or de-vascularization injuries.
   - Specific injuries might include, complete or incomplete hand amputation, partial or complete proximal finger or thumb amputation at the joint that meets the hand, de-gloving, crushing or de-vascularization injuries of hand, clean cut amputation at the ankle.
   - **Ensure that the specialty trauma facility is notified.**

8. Establish an IV of Normal Saline KVO or Saline Lock. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**
9. If the patient presents with signs and symptoms of hypoperfusion, administer Normal Saline Boluses:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. For pain management consider Fentanyl or Morphine Sulfate.

- If the patient exhibits signs / symptoms of hypoperfusion Contact Medical Control for Fentanyl / Morphine Sulfate:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl 25-50 mcg IV per dose every 5 minutes to a maximum of 200 mcg Use 25 mcg for the elderly or a weight under 70 kg</td>
<td>Fentanyl 1 mcg/kg IV/IO/IN up to a maximum single dose of 50 mcg Contact Medical Control for additional doses</td>
</tr>
</tbody>
</table>

- In patients 65 years old and greater consider an initial dose of half your normal adult dose when administering opiates (Morphine / Fentanyl).

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine 2 mg IV. Repeat as needed until pain is relieved or a maximum of 10 mg is reached An additional dose of 2 mg up to a maximum single dose of 10 mg may be repeated one time after 10 minutes</td>
<td>Morphine 0.1 mg/kg IV until pain is relieved or a maximum single dose of 10 mg is reached</td>
</tr>
</tbody>
</table>
2. Consider administration of Ketamine for pain if Fentanyl or Morphine is unavailable:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine 0.2 mg/kg IV/IO/IM administered over 1 minute. May repeat once in 5 minutes as needed</td>
<td>Contact Medical Control for orders and anticipate 0.1-0.2 mg/kg IV/IM/IO</td>
</tr>
</tbody>
</table>

3. For nausea / vomiting consider Ondansetron (Zofran) IV or Prochlorperazine (Compazine). Repeat one time in 10 minutes if nausea or vomiting is not relieved.

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric (ALS Only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran) 4 mg IV over 30 seconds</td>
<td>Ondansetron (Zofran) 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg</td>
</tr>
</tbody>
</table>

or

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine (Benadryl) 25 mg IV followed by Prochlorperazine (Compazine) 10 mg IV</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

**MEDICAL CONTROL OPTION**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients sustaining burns as a result of thermal chemical or electrical components. Indications for referral to a burn center applies to patients with 2nd degree burns >10%, 3rd degree burns >1% in any patient, electrical injury (greater than 200 volts), suspected inhalation injury, or significant burns to the face/head, hands, feet major flexion joints or perineum. In the event that there is associated trauma to the burned patient, transport to the closest burn center for immediate care if unstable.

1. Remove the patient from the source of injury. Decontaminate if the injury occurred as a result of a hazardous material or chemical if safe to do so.
2. Initiate General Assessment and Universal Patient Care.
3. Support airway and provide supplemental Oxygen per Airway Maintenance and Supplemental Oxygen protocol.
4. If smoke inhalation is suspected, provide humidified Oxygen.
5. Remove items that may constrict swelling tissue.
6. Determine the degree and body surface area percentage burned.
7. If the burns are \( \leq 10\% \) body surface area, cover with Waterjel Emergency Burn Dressing or if not available sterile dressings soaked in a saline solution.
8. If the burns are >10% body surface area, cover with Waterjel Emergency Burn Dressing or if not available sterile dry dressings. Ensure that the patient is kept covered and warm to prevent the loss of body heat with mylar blanket.
9. Initiate advanced airway management if the airway cannot be managed properly utilizing BLS airway maintenance.
   - ALS providers should utilize advanced airway management with ET intubation and attach continuous quantitative waveform capnography (ETCO\(_2\)), maintaining a level of 35-45 mmHg. If ET intubation cannot be accomplished due to a completely obstructed airway, perform an emergent Needle Cricothyroidotomy.
   - Patients with Evidence of upper Airway Burn, changes in Voice, or stridor should be intubated early. Consider medication Facilitated intubation protocol.
10. Establish an IV of Normal Saline KVO. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**
11. If the patient presents with signs and symptoms of hypoperfusion, administer

Normal Saline Boluses:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Consider **continuous EKG monitoring** and **quantitative waveform capnography (ETCO₂)**.

2. Waterjel emergency burn dressings provide pain relief by efficient and effective cooling of the burn injury.

3. For further pain management consider **Fentanyl** or **Morphine Sulfate**.
   - If the patient exhibits signs / symptoms of hypoperfusion Contact Medical Control for Fentanyl / Morphine Sulfate:

   **Adult**
   - Fentanyl
   - 50-100 mcg IV per dose every 5 minutes to a maximum of 200 mcg
   - Use 25 mcg for the elderly or a weight under 70 kg

   **Pediatric**
   - Fentanyl 1 mcg/kg IV/IO/IN up to a maximum single dose of 50 mcg
   - Contact Medical Control for additional doses

   or

   **Adult**
   - Morphine 2 mg IV. Repeat as needed until pain is relieved or a maximum of 10 mg is reached
   - An additional dose of 2 mg up to a maximum single dose of 10 mg may be repeated one time after 10 minutes

   **Pediatric**
   - Morphine 0.1 mg/kg IV until pain is relieved or a maximum single dose of 10 mg is reached

   - In patients 65 years old and greater consider an initial dose of half your normal adult dose when administering opiates (Fentanyl / Morphine).
4. Consider administration of **Ketamine** for pain if **Fentanyl** or **Morphine** is unavailable:

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine</td>
<td>Contact Medical Control for orders and anticipate 0.1-0.2 mg/kg IV/IM/IO</td>
</tr>
<tr>
<td>0.2 mg/kg IV/IO/IM administered over 1 minute. May repeat once in 5 minutes as needed</td>
<td></td>
</tr>
</tbody>
</table>

5. For nausea / vomiting consider **Ondansetron (Zofran) IV** or **Prochlorperazine (Compazine)**:

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran) 4 mg IV over 30 seconds. May repeat in 10 minutes</td>
<td>Ondansetron (Zofran) 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine (Benadryl) 25 mg IV followed by Prochlorperazine (Compazine) 10 mg IV</td>
<td>Not Indicated</td>
</tr>
</tbody>
</table>

6. If the injury is associated with smoke inhalation and a decreased level of consciousness refer to the **Smoke Inhalation/Cyanide Exposure protocol**.
1. Contact Medical Control for further orders when necessary.
This protocol applies to patients sustaining injury as a result of high voltage electricity (>200 volts) or lightning strikes. In addition to burns, these patients have a high probability of cardiac rhythm disturbances and penetrating trauma as a result of the electrical injury.

1. Remove the patient from the source of injury, if safe to do so.
2. Initiate General Assessment and Universal Patient Care.
3. Consider spinal immobilization if the mechanism of injury exists.
4. If the patient is in respiratory arrest, initiate ventilatory support per the Airway Maintenance and Oxygen Therapy protocol.
5. If the patient is in cardiac arrest, initiate CPR and attached an AED as appropriate. Refer to the appropriate Cardiac Arrest protocol.
6. Administer supplemental Oxygen per the Airway Management and Oxygen Therapy protocol.
7. Establish an IV of Normal Saline KVO. EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.
8. If the patient presents with signs and symptoms of hypoperfusion, administer Normal Saline Boluses:
   
<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain or restore perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

9. All electrical injuries or burns should be transported to a specialty burn center.

1. Provide continuous EKG and continuous quantitative waveform capnography (ETCO₂).
2. Apply appropriate Cardiac Arrest protocol as applicable.
3. If the patient is hemodynamically stable refer to the Pain Management protocol.

1. Contact Medical Control for further orders when necessary.
Compartment Syndrome (CS) is a limb- and life-threatening condition seen when perfusion pressure falls below tissue pressure in a closed anatomical space. This can lead to tissue necrosis, permanent impairment, and eventually renal failure and death. All providers should maintain a high index of suspicion when dealing with complaints of severe extremity pain. Providers should be cognizant of pain, paresthesia, pallor, paralysis, pulselessness or poikilothermia (cold extremity) at or below the injury site. **All treatment should be initiated prior to extrication. This protocol should be initiated when 30% of the patient’s body mass is entrapped for greater than 15 minutes.**

Consider activation of the “Go Team” for a patient involved in an unusual extrication, prolonged crush injury, or possible field amputation. This team will bring the necessary equipment needed for unusual field care.

Common mechanisms of injury leading to Compartment Syndrome are:
- Long bone fractures
- High energy trauma
- Penetrating injuries / GSW’s / stab wounds
- Venous injury
- Crush injuries

**ALL PROVIDER LEVELS**

1. **Initiate General Assessment and Universal Patient Care.**
2. **Administer supplemental Oxygen** per the Airway Maintenance and Oxygen Therapy protocol.
3. **Remove constrictive clothing and jewelry.**
4. **If appropriate, consider activation of the “Go Team” from George Washington University Hospital (H08).**
5. **Establish at least one large bore IV/IO point of access. ** **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**
6. Administer **Normal Saline Boluses**:

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Administer 40 ml/kg fluid bolus prior to extrication. 20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>

7. Consider use of tourniquet above injury site prior to removal of crushed limb if it is deemed to be unsalvageable or rapid amount of blood loss is suspected.

8. Once extricated, **do not delay transport** to the closest available trauma facility.

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Provide **continuous EKG monitoring** and treat life threatening dysrhythmias as indicated. Hyperkalemia will manifest on the EKG tracing with peaked “T” waves and a widened “QRS” complex.

2. If the patient is hemodynamically stable, refer to the **Pain Management protocol**:

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl 25-50 mcg IV per dose every 5 minutes to a maximum of 200 mcg. Use 25 mcg for the elderly or a weight under 70 kg</td>
<td>Fentanyl 1 mcg/kg IV/IO/IN up to a maximum single dose of 50 mcg. Contact Medical Control for additional doses</td>
</tr>
</tbody>
</table>

**or**

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine 2 mg IV. Repeat as needed until pain is relieved or a maximum of 10 mg is reached. An additional dose of 2 mg up to a maximum single dose of 10 mg may be repeated one time after 10 minutes</td>
<td>Morphine 0.1 mg/kg IV until pain is relieved or a maximum single dose of 10 mg is reached</td>
</tr>
</tbody>
</table>
3. Consider Ketamine for pain management and sedation prior to extrication:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine 0.2 mg/kg IV/IO/IM administered over 1 minute. May repeat every 5 minutes for a total of three (3) doses to ensure provider safety during extrication.</td>
<td>Contact Medical Control for orders and anticipate 0.1-0.2 mg/kg IV/IM/IO. May only repeat with Medical Control Authorization</td>
</tr>
</tbody>
</table>

4. For nausea / vomiting consider Ondansetron (Zofran) IV or Prochlorperazine (Compazine). Repeat one time in 10 minutes if nausea or vomiting is not relieved:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran) 4 mg IV over 30 seconds</td>
<td>Ondansetron (Zofran) 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg</td>
</tr>
<tr>
<td>or</td>
<td></td>
</tr>
</tbody>
</table>

5. Consider Albuterol 2.5 mg via nebulizer to a total of 3 doses or 7.5 mg for suspected hyperkalemia.

6. Consider Sodium Bicarbonate if the time prior to extrication is greater than 30 minutes:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Bicarbonate 1 mEq/kg IV</td>
<td>Sodium Bicarbonate 1 mEq/kg IV</td>
</tr>
<tr>
<td>May be repeated at 0.5 mEq/kg after 10 minutes</td>
<td>Contact Medical Control for orders to repeat dose</td>
</tr>
</tbody>
</table>
7. Consider **Calcium Chloride** after extrication if the patient presents with ventricular ectopy:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium Chloride</td>
<td>Calcium Chloride</td>
</tr>
<tr>
<td>1 gram slow IV</td>
<td>20 mg/kg slow IV</td>
</tr>
</tbody>
</table>

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients with eye injuries as a result of trauma or burns (including pepper spray).

**ALL PROVIDER LEVELS**

**Management of Exposure to Chemical Agents**
1. All providers shall utilize proper PPE at all times.
2. Remove patient from exposure source if safe to do so.
3. Remove contact lenses if possible, keep the lenses moist with Normal Saline, and transport them with the patient.
4. Determine the chemical involved. If MSDS is available transport the MSDS with patient.
5. For significant eye pain, administer **2 drops of Tetracaine HCL** in the affected eye(s).
6. Irrigate the eye(s) immediately with Normal Saline for a minimum of 20 minutes utilizing a Morgan Lens, IV tubing or a nasal cannula.

**Management of Non-penetrating Foreign Object**
1. Irrigate the affected eye(s) with Normal Saline using IV tubing or a nasal cannula until the object is cleared.
2. For significant eye pain, administer **2 drops of Tetracaine HCL** in the affected eye(s).
3. The patient may report continued irritation even after the object is no longer present on the surface of the eye. This may be due to small abrasions on the surface of the eye. Transport these patients to an Emergency Department for further evaluation.

**Management of Trauma Related Eye Injury**
1. Do not irrigate or use Tetracaine HCL for penetrating eye trauma.
2. Stabilize any penetrating object(s) by best possible means.
3. Cover the injured eye. Do not use a pressure or absorbent dressing on any eye that may have ruptured, or have penetrating trauma.
4. Cover both eyes to limit movement.
5. Transport the patient with head elevated at least 30°
This protocol applies to patients injured as a result of trauma with a GCS of ≤15, penetrating injuries to the head, neck, chest, and abdomen, extremities proximal to the elbow or knee. Patients with 2 or more proximal long bone fractures flail chest, pelvic fractures, amputation or crush injuries proximal to the wrist or ankle and limb paralysis. Automobile crashes > 40 mph with major deformity to the vehicle >20 inches, intrusion into passenger compartment >12 inches, vehicle rollover and ejection from a vehicle. When in doubt, transport the patient to the closest open trauma center for evaluation and treatment. Patients less than 15 years of age should be transported to Children’s National Medical Center (CNMC).

ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
3. Administer supplemental Oxygen per Airway Management and Oxygen Therapy protocol.
4. Treat all life threatening injuries as soon as possible such as decompression of a tension pneumothorax (ALS), sealing of a sucking chest wound, stabilization of a flail chest, and stabilization of a protruding object from a head, neck, eye, chest or abdomen. Consider “load and go” option.
5. Establish 1 or 2 IV’s of Normal Saline. EMTs who have completed the IV training module and Advanced EMTs may initiate IV access. Do not delay transport to secure IV access. Perform venipuncture enroute to the trauma center.
6. If the patient presents with signs and symptoms of hypoperfusion, administer Normal Saline Boluses:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 ml as needed to maintain a blood pressure of at least 90 mmHg. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to maintain or restore perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>
1. If a tension pneumothorax is suspected, perform a **needle decompression** of the pleural space at the 4th intercostal space on the anterior axillary on the affected side utilizing a 14 gauge angiocath or commercial device.

2. Administer **Tranexamic Acid** for Adults (Age 15 or greater) in the setting of hemorrhagic shock from trauma with a suspected need for massive blood transfusion due to marked internal or external blood loss. The following criteria must be met prior to administration:
   - Must have obvious bleeding external wounds **neck to mid-thigh or suspected severe internal injuries** from blunt or penetrating trauma.
   - Trauma occurred within last 3 hours.
   - Must have sustained tachycardia 110 beats per minute and/or sustained hypotension with systolic blood pressure 90 mmHg or less.

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tranexamic Acid</strong></td>
<td><strong>Not Indicated</strong></td>
</tr>
<tr>
<td><strong>1 gm infusion.</strong> Mix 1 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 100 gtts/min over 10 minutes.</td>
<td></td>
</tr>
</tbody>
</table>

3. Consider analgesia per the **Pain Management** protocol.
   - If the patient exhibits signs / symptoms of hypoperfusion Contact Medical Control for Fentanyl / Morphine Sulfate.

4. Provide **continuous EKG monitoring** if time or conditions permit.

---

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
This protocol applies to patients in cardiac arrest as a result of penetrating or blunt trauma. Rapid assessment, airway management, critical interventional skills (needle decompression, etc.) and immediate transport to a trauma center is essential to improve the patient’s outcome. Patients less than 15 years of age should be transported to Children’s National Medical Center (CNMC).

ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Provide ventilatory support per the Airway Management and Oxygen Therapy protocol.
3. Initiate immediate high quality CPR. This will be 5 cycles of CPR:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30:2</td>
<td>15:2</td>
</tr>
</tbody>
</table>

➢ When performing compressions, providers are to “push hard and fast” allowing the chest to fully recoil.
5. If the arrest is believed to be medical in nature, attach AED and analyze the rhythm. If “no shock” is advised immediately continue CPR.
➢ ALS providers should utilize their manual cardiac monitor / defibrillator for all patients.
6. Immediately transport to the closest open trauma center.
7. Establish 1 or 2 IV/IO’s of Normal Saline. EMTs who have completed the IV training module and Advanced EMTs may initiate IV access. Do not delay transport to secure IV access. Perform venipuncture enroute to the trauma center.
8. Administer Normal Saline Boluses to treat hypovolemia:

<table>
<thead>
<tr>
<th></th>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>500 ml as needed to restore or maintain perfusion. Maximum total of 2000 ml</td>
<td>20 ml/kg as needed to restore or maintain perfusion. Maximum of 3 boluses</td>
</tr>
</tbody>
</table>
1. If the cardiac arrest is secondary to central core trauma, perform bilateral **needle thoracostomies** in the pleural space at the 4th intercostal space on the anterior axillary line on the affected side utilizing a 14 gauge angiocath or commercial device.

2. Interpret EKG and treat dysrhythmias according to the appropriate protocol.

1. Contact Medical Control for further orders when necessary.
This protocol applies to pregnant patients that are 20 weeks or greater in gestation. In the event of cardiac arrest secondary to trauma, these patients do not apply to the presumed dead on arrival (PDOA) protocol, except in instances where there is apparent dependent lividity and rigor mortis. These patients must be resuscitated and transported to the nearest trauma facility in an effort to save the unborn child.

**ALL PROVIDER LEVELS**

1. Initiate General Assessment and Universal Patient Care.
3. Administer supplemental Oxygen per the Airway Management and Oxygen Therapy protocol.
4. Treat all life threatening injuries as soon as possible such as decompression of a tension pneumothorax (ALS), sealing of a sucking chest wound, stabilization of a flail chest, and stabilization of a protruding object from a head, neck, eye, chest or abdomen. Consider “load and go” option.
5. Patients should be transported on their left side, either left lateral recumbent or tilted left on a long spine board to displace the uterus off the vena cava thus enhancing venous return (Supine Hypotensive Syndrome or Vena Cava Syndrome). **In cases of cardiac arrest or when airway maintenance requires the patient to be supine, tilting shall be omitted.**
6. Establish 1 or 2 IV/IO’s of Normal Saline. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access. Do not delay transport to secure IV access. Perform venipuncture enroute to the trauma center.**
7. If the patient presents with signs and symptoms of hypoperfusion, administer Normal Saline Boluses at 500 ml intervals as required to maintain a blood pressure of at least 90 mmHg. Maximum total of **2000 ml**. Reassess before and after every administration.

**ADVANCED LIFE SUPPORT PROVIDERS**

1. If a tension pneumothorax is suspected, perform a needle decompression of the pleural space at the 4th intercostal space at the anterior axillary on the affected side utilizing a 14 gauge angiocath or commercial device.
2. Perform bilateral needle decompressions for patients in cardiac arrest with trauma to the central core.
1. Contact Medical Control for further orders when necessary.
This protocol applies to patients with a suspected brain injury due to blunt or penetrating trauma. **Transport patients less than 15 years of age to Children’s National Medical Center (CNMC).**

### ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Ensure that spinal immobilization is performed. If isolated TBI is suspected, attempt to keep the head of the backboard elevated to reduce intracranial swelling.
3. Administer 100% **Oxygen** per Airway Management and Oxygen Therapy protocol. If respiratory effort is inadequate provide ventilatory assistance at 12 breaths per minute.
4. If the head injured patient has a Glasgow Coma Score of $\leq 8$ and one or more of the following signs of brain herniation is present, ventilate the patient at a rate of:

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 breaths per min.</td>
<td>25 breaths per min.</td>
</tr>
</tbody>
</table>

- Seizure activity.
- Pupils that are fixed or asymmetric (unequal).
- Abnormal flexion or extension (posturing).
- Hypertension and bradycardia (Cushing’s syndrome).
- Intermittent apnea (periodic breathing).

5. **Immediately transport to the closest open trauma center.**
6. Establish **IV** of Normal Saline. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access. Do not delay transport to secure IV access.** Perform venipuncture enroute to the trauma center.
7. Administer **Normal Saline Boluses:**

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 ml as needed to maintain a blood pressure of at least 90 mmHg. Maximum total of <strong>2000 ml</strong></td>
<td>20 ml/kg as needed to maintain or restore perfusion. <strong>Maximum of 3 boluses</strong></td>
</tr>
</tbody>
</table>
1. Do not perform Nasotracheal Intubation in pediatric patients or patients with maxial-facial trauma or evidence of a basilar skull injury.

2. Provide continuous EKG and continuous quantitative waveform capnography (ETCO²).

3. If the patient is experiencing active seizure activity, administer Midazolam (Versed):

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
</table>
| Midazolam
Intranasal dose: 10 mg IN (5 mg each nostril). Contact Medical Control for additional doses |
| OR |
| Intramuscular: 5 or 10 mg IM |
| OR |
| Intravenous dose: 2-5 mg IV/IO every 2 minutes to a maximum of 10 mg until cessation of visible seizure activity |
| Midazolam
Intranasal dose: 0.2 mg/kg IN to a maximum dose of 5 mg. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses |
| OR |
| Intravenous dose: 0.1 mg/kg IV/IO, up to a maximum single dose of 2 mg. Repeat once in 5 minutes until cessation of visible seizure activity Contact Medical Control for additional doses |

MEDICAL CONTROL OPTIONS

1. Contact Medical Control for further orders when necessary.
EMS providers shall immobilize the entire cervical and thoracic spine with a backboard, head rolls and c-collar on the following patients:

- Patient suffering from blunt trauma with an altered level of consciousness
- Patient has spinal pain or tenderness to palpation of the spine.
- Patient has neurological complaints (e.g.: numbness or motor weakness)
- Patient has anatomic deformity of the spine
- High energy mechanism of injury and any of the following:
  - Drug or alcohol intoxication
  - Inability to communicate
  - Significant Distracting Injury.

Patients with penetrating trauma to the head, neck or torso and NO EVIDENCE of neurological compromise SHOULD NOT be immobilized on a backboard. Such procedures delay rapid transport and have no proven benefits.

Patients not meeting any of the above criteria shall be evaluated against the selective spinal immobilization algorithm. Spinal precautions can be maintained by application of a rigid cervical collar and securing the patient firmly to the EMS stretcher*, and may be most appropriate for:

- Patients who are found to be ambulatory at the scene
- Patients who must be transported for a protracted period of time, particularly prior to Interfacility transfer.
- Patients for whom a backboard is not otherwise indicated.

EMS providers may withhold spinal immobilization under the following application of the selective spinal immobilization algorithm and the end-point is “Consider no immobilization”; and the patient meets all of the following criteria.

- Normal level of consciousness (GCS = 15)
- No spine tenderness to palpation
- No neurologic findings or complaints
- No significant distracting injury
- No intoxication (Drugs or alcohol)
- Ability to actively provide history and participate in exam
- No complaint of neck pain on movement

Whether or not a backboard is used, attention to spinal precautions among at-risk patients is paramount. These include application of a cervical collar, adequate security to a stretcher*, minimal movement/transfers and maintenance of inline stabilization during any necessary movement/transfers.

* Proper securing to the stretcher includes the use of 5-point restraints and head blocks with tape.

** Algorithm may be applied to patients 2 years of age or older.
High mechanism of injury suggestive of spinal injury includes, but is not limited to:

- Violent impact to the head, neck, torso, or pelvis.
- Unresponsive with any history of a fall
- Shallow-water diving incident.
- Moderate to high speed motor vehicle incident.
- Fall from 2 times height of the patient.
- Pedestrian struck by a vehicle.
- Axial load or injury resulting from diving into water.
- Explosion.
- Penetrating trauma in or near the spine.
- Ejection from a vehicle.
- Sports injury to the head or neck with spinal pain or neurological deficit.

**Low risk mechanism of injury?**

**NO** → **IMMOBILIZE**

**YES** → **Reliable patient history/examination?**

**NO** → **SPINAL PRECAUTIONS**

**YES** → **Normal sensory/motor examination?**

**NO** → **SPINAL PRECAUTIONS**

**YES** → **Spinal pain or tenderness?**

**YES** → **SPINAL PRECAUTIONS**

**NO** → **Consider NO immobilization**

- Alert and oriented.
- Not intoxicated.
- No active psychological/psychiatric problems.
- No significant loss of consciousness
- No significant distracting injuries.
- Able to communicate adequately.

- Symmetrical movement of all extremities.
- No deficits of light touch.

- Palpate entire axial spine.
- May need to log roll patient.
- Neck pain upon axial compression (push gently on top of the head)
Measure vital signs and level of consciousness

Glasgow Coma Scale ≤13
Systolic Blood Pressure <90 mmHg
Respiratory rate <10 or >29 breaths per minute adult
<20 in infant <1 year or need ventilator support

Assess anatomy of injury

- All penetrating injuries to head, neck, torso and extremities proximal to the elbow or knee
- Chest wall instability or deformity (e.g., flail chest)
- Two or more proximal long bone fractures
- Crushed, degloved, mangled, or pulseless extremity
- Amputation proximal to wrist or ankle
- Pelvic fractures
- Open or depressed skull fracture
- Paralysis

Assess mechanism of injury and evidence of high-energy impact

- All penetrating injuries to head, neck, torso and extremities proximal to the elbow or knee
- Falls
  - Adults: >20 feet (one story is equal to 10 feet)
  - Children: >10 feet or two or three times the height of the child
- High-risk auto crash
  - Intrusion, including roof: >12 inches occupant site; >18 inches any site
  - Ejection (partial or complete) from automobile
  - Death in same passenger compartment
  - Vehicle telemetry data consistent with a high risk of injury
- Auto vs. pedestrian/bicyclist thrown, run over, or with significant (>20 mph) impact
- Motorcycle crash >20 mph

Assess special patient or system considerations

- Older adults
  - Risk of injury/death increases after age 55 years
  - SBP <110 might be represent shock after age 65 years
  - Low impact mechanisms (e.g. ground level falls) might result in severe injury
- Pediatric Patients <15 years (14 yrs age or younger)
  - Should be triaged preferentially to pediatric capable trauma centers
  - Anticoagulants and bleeding disorders
  - Patients with head injury are at high risk for rapid deterioration
- Burns
  - Without other trauma mechanism: triage to a burn facility
  - With trauma mechanism: triage to trauma center
- Pregnancy >20 weeks
- EMS provider judgment

Transport according to protocol

When in doubt transport to a trauma facility

Adopted from CDC Guidelines for Field Triage of Injured Persons, 2011

Effective Date: April 15, 2015
Revision Date: March 31, 2015
Version: 2.1
Page 143
This protocol applies to patients exhibiting behavior that presents a danger to self and others. Careful assessment is required to determine the cause of the mental disturbance. In all cases, substance induced disorders (alcohol intoxication or drugs) organic causes (cerebral lesions), endocrine emergencies (hypoglycemia or hyperglycemia), hypoxia or trauma must be ruled out to determine if the condition is truly psychological. Excited Delirium is a condition in which a person is in a psychotic state or extremely agitated. The person's inability to process rational thought precludes normal de-escalation procedures alone. High body temperatures and instant tranquility (this is when a previously combative patient becomes quiet and docile) in these patients are key findings in predicting a high risk of sudden death in excited delirium. Ensure that law enforcement is summoned to all responses involving potentially combative patients.

ALL PROVIDER LEVELS

1. Initiate General Assessment and Universal Patient Care.
2. Attempt to de-escalate verbally aggressive behavior with a calm and reassuring approach and manner. Utilize family members or friends known to the patient if it is safe to do so.
3. Do not leave the patient alone unless there is a risk or harm to pre-hospital personnel or others.
4. Support airway and provide supplemental oxygen per the Airway Maintenance and Supplemental Oxygen protocol.
5. Place the patient in a position of comfort unless combative.
6. If patient restraint is necessary to prevent harm to the patient and others, provide soft four-point restraints or handcuffs (law enforcement) and transport the patient in a supine position. Do not transport the patient in a prone position or restrict the patient in taking full tidal volume breaths. Circulation and motor sensory function shall be checked every 5 minutes while in physical restraints.
7. Ensure that a blood glucose reading is obtained.
8. Consider use of Comprehensive Psychiatric Emergency Program (CPEP) if:
   - Age 18 or greater and less than age 65.
   - Vital signs and blood glucose level within normal ranges.
   - There is an isolated behavioral problem.
   - Transport should be completed by law enforcement.
   - No medical problems or injuries that need to be evaluated at the hospital.
1. If the patient continues to present a danger to self or others on scene due to combativeness, consider chemical sedation:

<table>
<thead>
<tr>
<th></th>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam</strong></td>
<td><strong>Intranasal dose:</strong> 10 mg IN (5 mg each nostril). Contact Medical Control for additional doses</td>
<td><strong>Pediatric</strong></td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Intramuscular</strong></td>
<td>5 or 10 mg IM</td>
<td><strong>Contact Medical Control</strong></td>
</tr>
<tr>
<td></td>
<td><strong>OR</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Intravenous</strong></td>
<td>dose: 2-5 mg IV/IO every 2 minutes to a maximum of 10 mg until cessation of visible seizure activity</td>
<td></td>
</tr>
</tbody>
</table>

2. Provide continuous EKG monitoring and pulse oximetry.

3. Any patients receiving medications for sedation shall be transported to the hospital by ALS resources for further medical evaluation.

**MEDICAL CONTROL OPTIONS**

1. Contact Medical Control for further orders when necessary.
This protocol addresses when field resuscitation may be discontinued. If the patient does not meet PDOA criteria, every effort should be made to resuscitate the patient. Studies have shown that rapid transport to a hospital after unsuccessful pre-hospital advanced cardiac life support (ACLS) field resuscitation rarely, if ever, results in survival to hospital discharge. These guidelines have been established to determine when terminating resuscitation in the field is appropriate. Medical Control contact must be made and agreed upon before resuscitation is actually terminated.

All of the following must be met to consider “Termination of Resuscitation”:

1. Pulseless and apneic prior to EMS arrival.
2. 18 years of age or older.
3. Patient is not visibly pregnant.
4. Adequate CPR is being performed.
5. Patient is not hypothermic due to an environmental extreme.
6. At least two rounds ACLS medications and subsequent procedures have been performed without return of spontaneous circulation (palpable pulses).
7. >20 minute resuscitation (by EMS) following appropriate pulseless protocol. Time starts when ALS provider care is initiated.
8. Successful placement of endotracheal tube or supraglottic airway (King Airway device), confirmed by approved methods (particularly Continuous Quantitative Waveform Capnography (ETCO₂).
10. Patient could not have been in a perfusing rhythm at any time.
11. Patient displays none of following rhythms at any time; ventricular fibrillation, ventricular tachycardia or pulseless electrical activity (PEA) ≥ 20/min.
12. Patient displays no signs of neurological function.
13. If cardiac arrest is witnessed by EMS personnel, full resuscitative efforts and transport will be initiated.
14. If the patient is in law enforcement custody, full resuscitative efforts and transport will be initiated.
15. May continue resuscitation efforts and transport the patient if provider safety becomes an issue.
16. May continue resuscitation efforts and transport the patient if the arrest occurred in a crowded public place.
Once Medical Control has granted Termination of Resuscitation:

1. Confirm the facility and name of the physician issuing the order to terminate resuscitation efforts.

2. If Termination of Resuscitation occurs at a licensed Health Care Facility (i.e. Nursing Home) the facility staff shall handle the death notification and law enforcement should not be contacted by EMS unless the death is traumatic or the result of a possible crime.

3. Immediately notify law enforcement and remain on the scene until they arrive for Termination of Resuscitation outside of a licensed Health Care Facility.

4. Do not remove any personal property or medical devices from the body for any reason (e.g. endotracheal tube/supraglottic airway, IV/IO, jewelry, etc.).

5. Document time of death, and badge number of the reporting law enforcement officer.

Dealing with family and loved ones:

1. Briefly describe the circumstances leading to the death. Avoid euphemisms such as “passed on” or “no longer with us.” Instead use the terms “death”, “dying” or “dead.”

2. Allow time for questions/discussion and for the shock to be absorbed. Make eye contact and consider sharing your feelings. Use phrases such as “you have our sincere sympathy.”

3. Allow the family to see the patient. Explain that medical equipment is still attached to the patient prior to the viewing.

4. The remains of the patient and any personal belongings shall be left at the scene and custody shall be transferred to the responding law enforcement officer.
This protocol addresses when field resuscitation should not be initiated. Sound judgment and assessment skill must be utilized when a patient is presumed dead on arrival (PDOA). If a patient is determined to be PDOA, the law enforcement officials (MPD, USPP, etc.) shall be requested to the scene to investigate and assume responsibility for the deceased person. Complete all necessary documentation and obtain the Law Enforcement Officer’s name and badge number on scene.

**ALL PROVIDER LEVELS**

1. Criteria for determining a patient presumed dead on arrival (PDOA) shall include those that are pulseless and apneic with one or more of the following:
   - Rigor Mortis.
   - Dependent Lividity.
   - Decomposition.
   - Traumatic injuries incompatible with life such as decapitation, or hemicorporectomy (the body below the lumbar spine is transected).
   - Incineration.
   - Submersion ≥24 hours.
   - Valid out-of-hospital DNR order is present.
   - A valid licensed physician, on scene orders that resuscitation not be attempted.

2. Adult Trauma patients should be rapidly assessed for signs of life. Resuscitation efforts may be withheld if the patient, on the arrival of the Fire-EMS personnel, is **apneic, pulseless, and without organized electrocardiographic activity** and there are no other signs of life such as spontaneous movement or pupillary response. Patients cannot have any following rhythms:
   - Ventricular fibrillation
   - Ventricular tachycardia
   - Pulseless electrical activity (PEA) ≥20/min

*National Association of EMS Physicians and American College of Surgeons Committee on Trauma “WITHHOLDING OF RESUSCITATION FOR ADULT TRAUMATIC CARDIOPULMONARY ARREST” Approved by the National Association of EMS Physicians Board of Directors May 16, 2012. Approved by the American College of Surgeons Committee on Trauma March 9, 2012. Received November 8, 2012; accepted for publication November 12, 2012; published online January 17, 2013.*
3. When the patient meets either of the above criteria, EMS personnel are not required to continue resuscitation efforts initiated by others. This includes bystander or health care facility CPR.

4. If the patient is pregnant >20 weeks in gestation or hypothermic, resuscitation efforts shall be provided and transport initiated to the closest appropriate facility unless criteria is met in line 1.
Any provider who is unwilling or unable to comply with a comfort care order for religious or moral reasons shall immediately notify their EMS employer in writing. Providers shall not be found to have committed an unprofessional act or to have violated any provision of the Emergency Medical Services Non-Resuscitation Procedures Law of 2001 (D.C. Law 13-224 and DC Code 7-651.01-15) because the provider resuscitates a patient.

I. Comfort Care Order

1. The Comfort Care Form is a distinctive form, sequentially numbered and printed on security paper.

2. The Comfort Care bracelet or necklace shall be made of metal.
   a. A plastic temporary bracelet and necklace may be used until the metal bracelet or necklace is received.

3. The Comfort Care Order shall include:
   a. A statement describing the specific medical or terminal condition of the patient, and the circumstances under which the patient shall not be resuscitated.
   b. The name of the patient and an ID number.
   c. The patient’s signature (if not incapacitated).
   d. Signed and dated by the attending physician of the patient.
   e. Attending physician’s license number and phone number.
   f. Name, signature and social security number of any authorized decision maker or surrogate.
   g. An engraving of the Comfort Care Order Number.

II. Revocation of the Comfort Care Order

1. The Comfort Care Order may be revoked at any time by the patient or authorized decision maker/surrogate by:
   a. Removing, cutting, destroying, defacing or discarding the Comfort Care bracelet or necklace.
   b. Directing another person to remove, cut, destroy, deface, or discard the Comfort Care bracelet or necklace in the presence of the patient or authorized decision maker/surrogate.
   c. Communicating directly to EMS providers the patient’s or authorized decision maker/surrogate’s intent to revoke the Comfort Care Order.
III. Decision to Withhold Resuscitation

1. Inspect the Comfort Care Order bracelet or necklace to see if it is intact or has been defaced. If the Order is intact, cease and withhold all resuscitation efforts.

2. If resuscitation has been initiated, order all efforts to cease after validating the CCO.

3. If resuscitation is withheld, document the presence of a DNR and the DNR bracelet tracking number on the PCR. If possible secure a copy of the DNR order.

4. Ensure the current emergency is related to the underlying terminal condition. If it is not, disregard the DNR-CCO and provide resuscitative efforts.
   a. Ex: Patient has a DNR-CCO for cancer, but is choking on food. In this case the DNR-CCO does not apply.

IV. Decision to Resuscitate

1. Resuscitate the patient if:
   a. The DNR-CCO is intact and not defaced, but the patient or authorized decision maker/surrogate orally requests that the patient be resuscitated.
   b. The DNR-CCO is not intact or has been defaced.
   c. If there is any doubt as to whether or not the DNR-CCO is intact or has been defaced.
   d. If the patient has attempted suicide, or is the victim of a homicide.

2. Notify the EMS Supervisor after the incident of any problems encountered.

V. Comfort Care Measures

1. The following interventions may be provided to a patient who is wearing a DNR-CCO that is intact and has not been defaced to provide comfort of care or alleviate pain:
   a. Clear the Airway
      i. Exclude artificial ventilation or airway adjuncts
   b. Suction as needed
   c. Provide oxygen
   d. Administer pain medication (may start an IV for analgesia)
e. Control bleeding  
f. Make comfort adjustments

VI. Reciprocity

1. All providers shall recognize a Comfort Care bracelet, necklace, or similar identifier issued by Maryland and Virginia as if issued in accordance with the Emergency Medical Services Non-Resuscitation Procedures Law of 2001 (D.C. Law 13-224 and DC Code 7-651.01-15) and shall act on the identifier in accordance with this act.

VII. Liability

1. No licensed health care professional, EMS personnel, health care facility, government entity, or government employee shall be subject to criminal or civil liability, or be found to have committed an unprofessional act because the person, in good faith, resuscitates, withholds or withdraws resuscitation, or participates in resuscitating or withholding or withdrawing resuscitation in accordance with the Emergency Medical Services Non-Resuscitation Procedures Law of 2001 (D.C. Law 13-224 and DC Code 7-651.01-15).

2. Any person who falsifies or forges a Comfort Care Order, willfully conceals or withholds personal knowledge of the revocation of a Comfort Care Order contrary to the wishes of a person who has executed a Comfort Care Order, or places a Comfort Care bracelet or necklace on a person for whom a Comfort Care Order has not been executed in accordance with the Emergency Medical Services Non-Resuscitation Procedures Law of 2001 (D.C. Law 13-224 and DC Code 7-651.01-15), and who, because of the forgery, concealment, withholding, or placement, directly causes resuscitation to be withheld or withdrawn from a person and the death of the person to be hastened shall be subject to prosecution for unlawful homicide pursuant to DCCode§22-2201.
Children with special health care needs refers to children who have or are suspected of having a serious or chronic condition of: physical, developmental, behavioral, or emotional health that requires health-related services of a type or amount beyond that generally required by children. Technology-assisted children refer to those children who depend on medical devices to support bodily function. In all cases utilize the caregiver to assist or perform necessary troubleshooting measures because they are often trained in performing those functions.

**Emergencies in Children with Ventilators**

<table>
<thead>
<tr>
<th>ALL PROVIDER LEVELS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Children on mechanical ventilation may exhibit sudden or gradual deterioration, cardiac arrest, increased oxygen demand, increased respiratory rate, retractions, and change in mental status.</td>
</tr>
<tr>
<td>2. Examine the child quickly for possible causes of distress which may be easily correctable (e.g. detached oxygen source) the caretakers will often have done this but double check.</td>
</tr>
<tr>
<td>3. Medications the child is presently taking may be the cause of deterioration.</td>
</tr>
<tr>
<td>4. Try to establish the child's baseline; the child may not look age appropriate.</td>
</tr>
<tr>
<td>5. If on a ventilator, remove the child from the ventilator and manually ventilate the child with a secure oxygen source; if the child improves there may be a problem with the ventilator or oxygen source.</td>
</tr>
<tr>
<td>6. Suction the child as accumulation of debris is a common cause of obstruction; if the tracheostomy tube has a cannula, remove it; if it is the cause of obstruction, there should be immediate improvement.</td>
</tr>
<tr>
<td>7. If still no improvement provide immediate transport to the closest appropriate facility.</td>
</tr>
<tr>
<td>8. Initiate appropriate resuscitation as needed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADVANCED LIFE SUPPORT PROVIDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. If there is no improvement the tube should be removed; attempt bag-valve mask ventilation; if another tube is available insert into the stoma and resume ventilation (a standard endotracheal tube may be used or the used tracheostomy tube after being cleaned).</td>
</tr>
<tr>
<td>2. If there is no improvement, immediately transport to the nearest appropriate medical facility and initiate appropriate resuscitation as needed.</td>
</tr>
</tbody>
</table>
Emergencies in Children with In-Dwelling Catheters

1. Children may have central lines in several locations and some complications are due to location; some central lines are located under the skin and can be felt but not seen.

2. The most common emergencies with central lines include blockage of the line, complete or partial accidental removal, or complete or partial laceration of the line.

3. Always evaluate a child for cardiovascular stability, as some complications may be life threatening.

4. Children may be experiencing complications from their underlying medical condition; ask caretakers about the child’s condition.

5. If the line is blocked, do not attempt to force the catheter open. Transport to a facility capable of managing central lines.

6. For complete removal, do not attempt to reinsert; transport to the nearest emergency department.

7. Infections are a common complication; don’t try to push a line back in, even if it is only slightly out.

8. For complete removal, maintain pressure on site until bleeding has stopped; transport child and catheter to nearest emergency department (part of the catheter may have broken off).

9. Always bring the line with you to the hospital.

10. For partial or complete laceration of the line, clamp proximally to laceration and transport child and catheter to the closest appropriate facility.

11. For children with sudden deterioration begin resuscitation and transport to the closest appropriate facility (child may have pneumothorax or internal bleeding).
Emergencies in Children with Gastrostomy Tubes

1. Children with gastrostomy tubes may have complications of obstruction or dislodgment; obstruction is usually not an emergency but the child may require transport; dislodgment is not life threatening but the tube should be replaced as soon as possible. Both conditions are easily recognized.

2. The child should be examined for any other possible problems.

3. Children who have problems with their tubes may have problems with regurgitation or aspiration.

4. Be aware of and address any other possible problems from their underlying medical condition.

5. Transport the child and the tube to the nearest facility capable of replacing the tube; this is not an emergency transport.

   ➢ Do not attempt to replace the tube; it is not as easy as it seems and there may be other complications.
All Fire/EMS personnel are required to report cases of suspected child / elder abuse or neglect to the Police agency responsible for the area in which the call occurred or the DC Child and family Services Agency (24 hour hotline at 202-671-7233). Do not initiate the report in front of the patient, parent, or caregiver. **DO NOT CONFRONT OR BECOME HOSTILE TO THE PARENT OR CAREGIVER.**

### ALL PROVIDER LEVELS

#### Physical Assessment Suggestive of Abuse:

1. Fractures in children under 2 years of age.
2. Repeated fractures not explained well.
3. Injuries in various stages of healing.
4. Frequent injuries.
5. Bruises or burns in patterns (e.g. iron or cigarette burns, cord marks, bite or pinch marks, and bruised to head, neck, back or buttocks).
6. Widespread injuries over the body.
7. Obvious physical neglect (malnutrition, lack of cleanliness).
8. Inappropriate dress (e.g. very little clothes in winter).

#### History Suggestive of Abuse:

1. The history does not match with the nature or severity of injury.
2. The parents’ and/or caregivers’ account is vague or changes.
3. The “accident” is beyond the capabilities of the patient (e.g. a 12 month old that burns self by turning on the hot water in the bath tub).
4. There is a delay in seeking help.
5. The parent and/or caregiver may be inappropriately unconcerned about the patient’s injury.

#### Characteristics of the Abused:

1. If less than 5 years old, is likely to be passive.
2. If over 5 years of age, is likely to be aggressive.
3. Does not look to the abuser for support, comfort, or reassurance.
4. May cry without any expectation of receiving help.
5. May be quiet and withdrawn.
6. May be fearful of the abuser.
Characteristics of the Abuser:

1. Crosses all religious, ethnic, occupational, educational, and socioeconomic boundaries.
2. May resent or reject the child.
3. May have feelings of worthlessness about self or about the child.
4. May have unrealistic expectations of what the child is capable of doing.
5. May be very critical of the child.
6. Oftentimes the abuser is repeating what was learned as a child (the abuser was more than likely abused as a child).
7. May be overly defensive rather than concerned.

Presentation:

The patient may present with patterned burns or injuries suggesting intentional infliction, such as, injuries in varying stages of healing, injuries scattered over multiple areas of the body, fractures or injuries inconsistent with stated cause of injury. The patient, parent, or caregiver may respond inappropriately to the situation. Malnutrition or extreme lack of cleanliness of the patient or environment may indicate neglect. Signs of increased intracranial pressure (bulging fontanel and altered mental status in an infant may suggest Shaken Baby Syndrome) may also be seen.

Patient Management:

1. Treat and stabilize injuries according to the appropriate Patient Care Protocol(s).
2. If sexual abuse is suspected, document the reasons for concern.
3. Document the following information on the Patient Care Report (PCR):
   - All verbatim statements made by the patient, the parent or caregiver(s) shall be placed in quotation marks, including statements about how the injury may have occurred.
   - Any abnormal behavior of the patient, parent(s), or caregiver(s) must be documented.
   - Document the condition of the environment and other residents that are present.
   - Document the time law enforcement was notified and the name and badge number of the officer completing the report.
   - Document the name of the hospital personnel that received the patient and any statements made.
   - Document the level / type of interaction between the patient and the caregiver(s).
Type and Use of Personal Protective Equipment

- Gloves - For any patient contact, and when cleaning/disinfecting contaminated equipment. Puncture resistant gloves will be worn in situations where sharp or rough edges are likely to be encountered, i.e., auto extrication.

- Face Mask & Eye Protection - Facial protection will be used in any situation where splash contact with the face is possible. This protection may be afforded by using both a face mask and eye protection, or by using a full-face shield. When treating a patient with a suspected or known airborne transmissible disease, N95 Respirators should be used. For respiratory illnesses (TB, SARS) it is beneficial to mask the patient with a surgical mask.

- Coverall/fluid resistant gowns - Designed to protect clothing from splashes, gowns may interfere with, or present a hazard to, the member in some circumstances. Structural firefighting gear also protects clothing from splashes and is preferable in fire, rescue, or vehicle extrication activities.

- Shoe/Head Coverings - Fluid barrier protection will be used if suspected contamination is possible.

General Precautions against disease

- If it's wet, it's infectious - use gloves.

- If it could splash onto your face, use eye shields and mask or full face shield.

- If it's airborne, mask yourself with N95 Respirator and the patient with surgical mask.

- If it can splash on your clothes, use a gown or structural firefighting gear.

- If it could splash on your head or feet, use appropriate barrier protection.

Post Exposure Management

- Provide first aid.

- Secure area to prevent further contamination. (Stop bleeding with direct pressure).

- Remove contaminated clothing and flush.

- Wash the contaminated area well with soap and water, or waterless hand cleanser, and apply and antiseptic.

- If the eyes, nose, or mouth are involved, flush them well with large amounts of water.
 Notification and relief of duty. The worker's supervisor should be immediately notified if a worker experiences an exposure involving potentially infectious source material. The supervisor should determine if the worker needs to be relieved of duty.

 Report the Exposure. The worker or immediate supervisor should promptly complete an Exposure Report appropriate for the agency, and submit it to the designated Infection Control Officer.

 Seek Medical Attention, Counseling, Consent and Testing per established policies and procedures.
Purpose:
To provide structure to the triage and treatment of persons involved in a multiple or mass casualty incident or a multiple patient scene. This guideline works in conjunction with EMS Operations Bulletin 1, Mass Casualty Incidents, which defines the other processes at an MCI outside patient treatment and triage. Consider contacting the DC Hospital Coalition Notification Center early in the incident for MCI’s at (877) 323-4262 or via TAC Channel H-3.

Responsibility:
All personnel are responsible for the information set forth in the following procedures. During an MCI primary care givers will be overwhelmed and all additional personnel will be expected to assist in the triage and treatment of patients.

Definitions:
A multiple or mass casualty incident is an emergency scene that creates a number of patients sufficient to significantly overwhelm available resources.

Multiple Casualty Incident: <9 patients (does not need to be declared)
Mass Casualty Incident: 9 or more patients (needs to be declared)

Triage: The process of sorting and categorizing patients based on the severity of their symptoms. Patients will be categorized into the four following groups. Each group has a color designation to assist in the rapid sorting of triaged patients.

- **Red** (Immediate) – Critically injured patients who must be transported as soon as resources allow.
- **Yellow** (Delayed) – Severely injured patients who must be evaluated and treated but may not need immediate treatment.
- **Green** (Minor) – Those patients who need minor treatment or prophylactic evaluation.
- **Black** (Deceased) – Patients who are or will be deceased with or without appropriate treatment.

Procedure:
Patients will be triaged according to START and JumpSTART triage criteria during every MCI. During primary triage, providers should spend no more than 30 seconds with each patient. Patients may be treated on scene only after all patients have been triaged and staged per Command. ALS providers should consider providing care at the BLS level in order to give care to as many patients as possible.
START Triage should be used for all adult patients

1. Walking wounded should be encouraged to congregate in a designated location under their own strength and triaged in the GREEN (minor) category.

2. Patients with no respiratory effort should be triaged in the BLACK (deceased) category following an attempt to open the airway.

3. Patients with difficulty in respirations, perfusion or mental status (RPM) as specified below should be triaged in the RED (immediate) category.
   - Respirations >30/min
   - Perfusion – No radial pulse or capillary refill times >2 seconds
   - Mental Status – Unable to follow simple commands

All patients who cannot walk, have respiratory effort, and do not meet criteria for the RED category should be triaged to the YELLOW (delayed) category.

START Triage Matrix

[Diagram showing triage matrix with decision paths for respirations, perfusion, and mental status leading to categories of immediate, minor, delayed, and non-salvageable.]
JumpStart Triage should be used for pediatric patients (≤14 years old)

JumpStart Pediatric MCI Triage © Matrix

- **Able to walk?**
  - Yes → **Minor** → **Secondary Triage**
  - No → **Breathing?**
    - Yes → **Position Airway** → **Breathing**
      - Apneic → **Immediate**
      - Palpable Pulse?
        - Yes → **Give 5 rescue breaths** → **Breathing**
          - Apneic → **Non-Salvageable**
        - No → **Non-Salvageable**
      - Palpable Pulse → **Immediate**
    - No → **Respiratory Rate**
      - < 15 or > 45 → **Immediate**
      - 15 - 45 → **Palpable Pulse?**
        - No → **Immediate**
        - Yes → **AVPU evaluation**
          - P (inappropriate), posturing or U → **Immediate**
          - A, V, or P (appropriate) → **Delayed**

©Lou Komig MD, 2002
1. Walking wounded should be encouraged to congregate in a designated location under their own power and triaged in the GREEN (minor) category.

2. Patients with no respiratory effort or peripheral pulse should be triaged in the BLACK (deceased) category.

3. Patients with difficulty in respirations, perfusion or mental status as specified below should be triaged in the RED (immediate) category.
   - Respirations >45/min or <15/min
   - Perfusion – No peripheral pulse or capillary refill times >2 seconds
   - Mental Status – unresponsive or responsive to painful stimulus

4. Patients with a peripheral pulse but without respiratory effort should receive 5 ventilations then categorized as RED (immediate) if respiratory effort resumes or BLACK (deceased) if apnea continues.

5. All patients who cannot walk, have respiratory effort, and do not meet criteria for the RED category should be triaged to the YELLOW (delayed) category.

Nerve Agent Specific Triage - refer to the Organophosphate, Pesticide and Nerve Agent Poisoning protocol for treatment therapies

<table>
<thead>
<tr>
<th>Triage for Nerve Agent Casualties</th>
</tr>
</thead>
</table>
| **Immediate (1)** | Effects - Unconscious, talking but not walking, moderate to severe effects in two or systems more systems (e.g., respiratory, GI, cardiac arrest. muscular, CNS)  
Clinical Signs - seizing or postictal, severe respiratory distress, recent cardiac arrest |
| **Delayed (2)** | Effects - recovering from agent exposure or antidote  
Clinical Signs - diminished secretions, improving respiration. |
| **Minor (3)** | Effects - walking and talking  
Clinical Signs - pinpoint pupils, runny nose, and mild to moderate difficulty breathing. |
| **Non-Salvageable (4)** | Effects - Unconscious  
Clinical Signs - Cardiac/respiratory arrest of long duration. |
**District of Columbia**  
**Fire and EMS Protocols**  
**Major Incident Operations**

**Initial Actions**

Rehab Officer
1. Confirm the crew has not been engaged in exertional activities for at least 10-15 minutes.
2. Ensure PPE is removed.
3. Log the crew into the REHAB sector.

Rehab Team(s)
1. Provide baseline assessment
   - Mental status
   - Confirm no medical complaints
   - Skin temperature and condition
   - Vital Signs (per Rehab bulletin)

---

**Rehabilitation Matrix**

Medical assessment within normal limits?
- Yes
  2. Implement passive cooling or warming based upon the environment.
  3. Rest for an additional 10-20 minutes.

- No
  1. Consider need to move to medical treatment.
  2. Implement active cooling or warming based upon the environment.
  3. Orally hydrate.
  4. Rest for 20 minutes
  5. Deny caffeine intake and tobacco product use.
  6. Conduct medical reassessment every 5 minutes.

**Medical assessment within normal limits?**
- Yes
  - Release from Rehab
    1. Instruct the crew to continue to orally hydrate.
    2. Advise the IC the crew is ready for reassignment.
    3. Log the crew out of the REHAB sector

- No
  1. Consider need to move to medical treatment.
  2. Continue active cooling or warming based upon the environment.
  3. Orally hydrate using sports drink.
  4. Rest an additional 10 minutes.
  5. Conduct medical assessment every 5 minutes.

**Medical assessment within normal limits?**
- Yes
  - Transport to ED or PFC
    1. Move to treatment area.
    2. Provide care per protocol.
    3. Notify the IC.

- No
Background:

Emergency operations can place extreme demands upon personnel. These demands include physical and mental stress as well as environmental dangers such as heat, humidity, cold or wind chill. Members who are not provided adequate rest and hydration during emergency operations and training exercises are at increased risk for illness or injury, and may jeopardize the safety and integrity of the operation. Rehabilitation is an essential element for any incident to prevent more serious conditions such as heat stroke from occurring.

Guidelines:

This protocol applies to all emergency operations and training exercises where strenuous physical activity or exposure to heat or cold exists. Members will be sent to the rehab area after:

- 1 SCBA bottle and/or 45 minutes of strenuous activity
- SCBA failure
- Signs and symptoms of fatigue
  - Weakness
  - Dizziness
  - Syncope
  - Chest pain
  - Shortness of breath
  - Altered mental status
  - Nausea/Vomiting
  - Muscle Cramps
- Any chief complaint
- Discretion of the Incident Commander

Evaluation:

After the initial evaluation, members will be reassessed after 20 minute rest periods. If vital signs have not returned to normal after two 20 minute rest periods, the member should be transported to the closest appropriate facility. Have the member remove all protective gear and assess the following.

- GCS and mental status
- Pupil response
- Skin condition
- Temperature
Lung sounds

Vital signs
- Heart rate
- Respiratory rate
- Pulse Oximeter
- Carbon Monoxide Oximeter
- Blood glucose level (as appropriate)

Vital Signs:
Members may not be returned to incident operations unless vital signs return to normal ranges. These parameters are:
- GCS = 15, Alert and Oriented to person/place/time/event.
- Temperature <100.6 F
- Heart Rate <100
- SpO2 >95%
- SpCO <6%
- No medical complaints or signs/symptoms or indications of trauma.

Burn Injuries:
- Any new burn injury is a categorical reason to deny release from the Rehabilitation. Burns should be evaluated and treated per the Burns protocol.
- All burn injuries sustained on operational scenes, regardless of degree and BSA, shall be transported to a specialty referral burn center for evaluation and treatment.
- All new burn injuries will be reported to the Incident Commander and the Safety Officer.

Treatment:
1. Rest period of 20 minutes without intense work and oral hydration.
2. Conduct the physical assessment. During fire ground operations pay particular attention to the wrists, neck, ears and face for burn injuries.
3. Evaluate vital signs and monitor as appropriate.
4. If elevated SpCO pulse oximetry reading is obtained provide Oxygen and refer to the Carbon Monoxide Exposure protocol.
5. If a medical complaint or an injury is reported or the assessment reveals a treatable condition refer to the appropriate treatment protocol.

6. Cooling
   - Remove from environment.
   - Air conditioning or shaded area.
   - Rinse with cool water.

7. Oral rehydration 1-2 quarts
   - Water
   - Electrolyte solution (Gatorade/Powerade)
   - 50/50 mixture of water with electrolyte solution
   - **No alcohol, caffeine, or carbonated beverages**

8. Nutrition
   - Energy bars
   - Granola or whole grain bars
   - Nuts

9. Additional 20 minute rest period(s).

10. If vital signs have not returned to normal ranges, establish an IV and transport to the closest appropriate facility. **EMTs who have completed the IV training module and Advanced EMTs may initiate IV access.**

11. If the patient presents with signs and symptoms of hypoperfusion, administer **Normal Saline Boluses at 250 ml** intervals as required to maintain or restore perfusion. Maximum total of **2000 ml**. Reassess before and after every administration.

**Documentation and Recordkeeping:**

1. General assessments/monitoring and ancillary rehabilitation activities will be recorded on the Rehabilitation Sector worksheets per EMS Operation Bulletin Number 4: Rehabilitation Procedures.

2. Assessments resulting in patient care other than the delivery of supplemental oxygen to manage mildly elevated SpCO levels that were corrected should be documented in a full Patient Care Report (PCR).

3. Any transport from the operational area creates the requirement for a full PCR or START Triage Tag (as appropriate).
Organophosphate, Pesticide and Nerve Agent Poisoning

Organophosphate and Carbamate Poisoning: Organophosphates and carbamates are widely used commercially and by consumers as insecticides for pets, homes, and businesses. These chemicals are among the most toxic currently used in pesticides. Both classes of compounds have similar pharmacological actions, in that they both inhibit the effects of acetylcholinesterase, which is an enzyme that degrades acetylcholine at nerve terminals. When acetylcholinesterase is inhibited, acetylcholine accumulates at the synapses, resulting in the characteristic S/S of organophosphate and carbamate poisoning.

Examples of Organophosphates and Carbamates:


The antidote kits are to be used in incidents of exposure to a nerve agent or organophosphate material. Auto-injectors contain Atropine Sulfate and Pralidoxime Chloride. Specific criteria will trigger this medical protocol.

- The decision to utilize the antidote should be based on clinical evaluation.
- Use of the antidote kit is to be based on signs and symptoms of the patient. Suspicion or the simple presence of a nerve agent is not sufficient reason to administer these medications.
- Use of antidotes will not protect responders from anticipated exposures.

Symptoms of a Nerve Agent, Organophosphate, and Carbamate Poisoning:

When a nerve agent is present, it interferes with the normal instructions of chemical transmitters that direct the muscle or gland to return to an unstimulated, relaxed state. The action of toxic nerve agents is to overstimulate the nerve endings and central nervous system. Overstimulation of the nervous system causes muscles and certain glands to overreact and cause predictable symptoms. The symptoms of the poisoned patient have been characterized by an acronym:

- **M** miosis (pinpoint pupils)
- **S** salivation (excessive drooling)
- **L** lacrimation (tearing)
- **U** urination (lose control of urine)
- **D** defecation / diarrhea
- **G** GI upset (cramps)
- **E** emesis (vomiting)
- **M** muscle (twitching, spasm, "bag of worms")
- **C** convulsions
RESPIRATION - difficulty breathing / distress (short of breath, wheezing).

AGITATION + CNS SIGNS - confusion, agitation, seizures, coma.

ALL PROVIDER LEVELS

1. Evacuation and decontamination procedures should be undertaken as soon as possible. Providers should be keenly aware of the possibility of cross-contamination and appropriate PPE should be employed.

2. Support the airway and provide supplemental Oxygen per the Airway Maintenance and Supplemental Oxygen protocol.
   - Providers should be prepared for the need to suction copious volumes of secretions.
   - If indicated, the King Airway may be utilized in the HAZ MAT "Hot Zone" for this particular clinical pathway and type of event.

3. Administer pre-packaged Nerve Agent Antidote Kits (NAAK) every 10-15 minutes, to a maximum of a total of three doses of auto-injectors. Repeat dosages will be administered until signs and symptoms show signs of improvement. Current products available for use include:
   - **DouDote™** Auto-injector via IM: the Doudote™ Auto-injector contains 2 mg of Atropine and 600 mg of Pralidoxime Chloride (2-PAM Chloride) combined in one auto-injector
     
     | **Adult** | **Pediatric** |
     |-----------|---------------|
     | One (1) **DouDote™** Auto-injector IM | Patients weighing 12 kg or greater: |
     | Administer one (1) **DouDote™** Auto-injector IM every 20 minutes. | **See Special Pediatric Instructions** noted below |

   - **Mark 1** NAAK consisting of two components:
     I. Atropine 2 mg auto-injectors IM
     II. 2-PAM Chloride 600 mg IM
c. CHEMPACK stores:
   I. Atropine 0.5 mg auto-injectors IM
   II. Atropine 1 mg auto-injectors IM
   III. Multidose vials of 2-PAM Chloride 1 gram Injectable
   IV. Multidose vials of Atropine Injectable

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atropine  (every 20 minutes)</td>
</tr>
</tbody>
</table>
|       | Ages less than 3 y.o.  
Administer one (1) Atropine 0.5 mg IM via AtroPen Auto-injector |
|       | Ages 3-7 y.o.  
Administer one (1) Atropine 1 mg IM via AtroPen Auto-Injector |
|       | Ages 8 y.o. or greater  
Administer one (1) Atropine 2 mg IM via Auto-injector |
|       | See Special Pediatric Instructions noted below |

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-PAM Chloride 600 mg IM via Auto-injector</td>
<td>2-PAM Chloride 600 mg IM via Auto-injector</td>
</tr>
</tbody>
</table>
| Administer one (1) dose every 10 minutes | Ages 3 y.o. or greater:  
Administer one (1) dose every 20 minutes |
| | See Special Pediatric Instructions noted below |

Special Pediatric Instructions:

If a WDM MCI event occurs and pediatric AtroPen auto-injectors are not readily available from the CHEMPACK cache then providers shall administer either one (1) DouDote™ auto-injector or one (1) complete Mark 1 kit to any pediatric patient who is displaying moderate/severe signs of nerve agent or organophosphate poisoning. Repeat dose every 20 minutes.
4. Seizure and fall precautions should be utilized.

**ADVANCED LIFE SUPPORT PROVIDERS**

1. Administer **Diazepam** or **Midazolam (Versed)** if the patient presents with any of the following:
   - seizure activity
   - unconsciousness
   - any form of visible muscle fasciculation
   - Any patient that has had a total of three DouDotes or Mark 1NAAKs administered.

<table>
<thead>
<tr>
<th>Adult</th>
<th>Pediatric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diazepam 10 mg IM via Auto-injector</td>
<td>Diazepam 0.3 mg/kg IV/IO or IM over 2-3 minutes Maximum single dose of 10 mg</td>
</tr>
</tbody>
</table>

2. Establish an **IV** of Normal Saline KVO or Saline Lock.

**Special: Mass Casualty Incident Exception**

When working under the direct supervision of an ALS provider, BLS providers may administer **Diazepam 10 mg IM via auto-injector**.
3. If auto-injectors are not utilized or all three auto-injector doses have been used, administer **Atropine 1-2 mg IV/IO every 10 minutes** as needed for the management of excessive secretions, pulmonary edema, hypotension, bradycardia, and ineffective ventilations.

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Atropine</td>
<td>Atropine</td>
</tr>
<tr>
<td>1-2 mg IV/IO or IM</td>
<td>0.05 mg/kg IV/IO every 20 minutes</td>
</tr>
</tbody>
</table>

**Adult**

**Pediatric**

Ondansetron (Zofran) may be used for the relief of nausea and vomiting. Repeat one time in 10 minutes if nausea or vomiting is not relieved.

<table>
<thead>
<tr>
<th><strong>Adult</strong></th>
<th><strong>Pediatric</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ondansetron (Zofran)</td>
<td>Ondansetron (Zofran)</td>
</tr>
<tr>
<td>4 mg IV over 30 seconds</td>
<td>0.15 mg/kg IV over 30 seconds</td>
</tr>
</tbody>
</table>

**Adult**

**Pediatric**

**MEDICAL CONTROL OPTIONS**

1. Additional doses of **DouDote™ Auto-injectors** or **the 2-Pam Auto-injectors** from the Mark 1 kit. (Use of additional Atropine is a standing order).

2. Additional administration of **Diazepam IM** or **Midazolam (Versed)** IN/IO/IM/IN.
## Mild Exposure:

<table>
<thead>
<tr>
<th>Signs/Symptoms</th>
<th>Mark 1 Kit (Atropine/2-Pam)</th>
<th>DuoDote</th>
<th>Diazepam or Midazolam</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Blurred vision</td>
<td>• One (1) Auto-Injector set: o Atropine 2mg IM o 2-Pam Chloride 600 mg IM</td>
<td>• 1 DuoDote™ injection into the mid-outer thigh if the patient experiences two or more MILD symptoms of nerve gas or insecticide exposure</td>
<td>• Not indicated with mild s/sx.</td>
</tr>
<tr>
<td>• Miosis</td>
<td>• Monitor for signs/symptoms every 5 minutes. Repeat dose at 10 minute intervals if no noted improvement or s/sx worsen.</td>
<td>• Wait 10 to 15 minutes for DuoDote™ to take effect. If, after 10 to 15 minutes, the patient does not develop any SEVERE symptoms, no additional DuoDote™ injections are recommended.</td>
<td></td>
</tr>
<tr>
<td>• Teary eyed</td>
<td>• Atropine, as needed every 10-15 minutes.</td>
<td>• Monitor for signs/symptoms every 5 minute. Repeat dose at 10 – 15 minute intervals if no noted improvement.</td>
<td></td>
</tr>
<tr>
<td>• Chest tightness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Unexplained Wheezing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Tremors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Acute onset of stomach cramps</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Nausea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Bradycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Moderate/Severe Exposure:

<table>
<thead>
<tr>
<th>Signs/Symptoms</th>
<th>Mark 1 Kit (Atropine/2-Pam)</th>
<th>DuoDote</th>
<th>Diazepam or Midazolam</th>
</tr>
</thead>
<tbody>
<tr>
<td>• SLUDGEM</td>
<td>• 3 Auto-Injectors Atropine (6 mg)/3 Auto-injectors 2-Pam (1.8 Grams)</td>
<td>• Three (3) DuoDote injections into the patient’s mid-outer thigh in rapid succession.</td>
<td>• One (1) Auto injector, Diazepam 10 mg IM or Midazolam 10 mg IM/IN or 2-5 mg IV/IO, max 10 mg to treat convulsions if suspected in the unconscious individual.</td>
</tr>
<tr>
<td>• Severe respiratory distress</td>
<td>• Monitor every 5 minutes</td>
<td>• No more than 3 doses of DuoDote should be administered.</td>
<td>• The effects of nerve agents and some insecticides can mask the motor signs of a seizure.</td>
</tr>
<tr>
<td>• AMS</td>
<td>• Atropine 1 - 2 mg IV/IO for management of continued s/sx.</td>
<td>• Atropine 1 - 2 mg IV/IO for management of continued s/sx.</td>
<td></td>
</tr>
<tr>
<td>• Respiratory arrest</td>
<td></td>
<td>• Medical Control may order additional doses of NAAKS.</td>
<td></td>
</tr>
<tr>
<td>• Seizures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Copious airway secretions</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Nerve Agent Specific Triage:

<table>
<thead>
<tr>
<th>Category</th>
<th>Effects</th>
<th>Clinical Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate (1)</td>
<td>Unconscious, talking but not walking, moderate to severe effects in two or systems more systems (e.g., respiratory, GI, cardiac arrest, muscular, CNS)</td>
<td>Seizing or postictal, severe respiratory distress, recent cardiac arrest</td>
</tr>
<tr>
<td>Delayed (2)</td>
<td>Recovering from agent exposure or antidote</td>
<td>Diminished secretions, improving respiration.</td>
</tr>
<tr>
<td>Minor (3)</td>
<td>Walking and talking</td>
<td>Pinpoint pupils, runny nose, and mild to moderate difficulty breathing.</td>
</tr>
<tr>
<td>Non-Salvageable (4)</td>
<td>Unconscious</td>
<td>Cardiac/respiratory arrest of long duration.</td>
</tr>
</tbody>
</table>
Anthrax Poisoning
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus Anthracis. The serious forms of human anthrax are inhalation, cutaneous, and intestinal. Direct person-to-person spread of anthrax is extremely unlikely, if it occurs at all. There is no need to immunize or treat contacts of persons ill with anthrax.

- No treatment for household contacts
- No treatment for friends
- No treatment for coworkers, unless they also were exposed to the same source of infection

Provide supportive patient care and decontamination as needed.

Ricin Poisoning
Ricin is a very potent protein toxin made from mash left over after processing castor beans for oil. Ricin is considered a threat as a biological weapon primarily because it is widely available; it is a category B agent/disease with a high fatality. It is water-soluble, odorless, tasteless and not inactivated by heat. Ricin inhibits protein synthesis. It is very toxic to cells. The toxin may be inhaled, ingested, or in some instances directly introduced into the body by injection. It is not transmissible by person to person. Ricin should be particularly suspected when severe pulmonary distress occurs in previously healthy individuals. Signs, symptoms and pathology manifestations of ricin toxicity vary with dose and route of exposure. Symptoms may mimic pneumonia or food poisoning depending on the route of transmission:

- Fever
- Cough/congestion
- Wheezing/shortness of breath
- Nausea/vomiting/diarrhea
- Hypotension (severe cases)
- Pulmonary Edema/Failure (severe cases)

Provide supportive patient care and decontamination as needed.

Acute Radiation Syndrome
During victim prioritization, first responders can use available radiation detection equipment to determine the presence of significant amounts of contamination on an individual. The monitoring equipment may also be used to qualitatively compare the amount of contamination on one victim to the contamination on other victims. This may aid in prioritizing victims for decontamination.
At the post-decontamination monitoring point, first responders may use detection equipment to grossly assess the progress made in decontaminating victims. If operationally feasible, individuals who remain significantly contaminated following decontamination procedures should be subjected to additional decontamination. This will typically involve the victim returning to the contaminant removal/shower station for additional washing. Decontamination efforts should be reevaluated or suspended if contamination levels are not being significantly reduced.

The Environmental Protection Agency (EPA) recommends that no more than two additional decontamination attempts be performed for individuals with significant contamination remaining following the first decontamination attempt. An inability to reduce the measured radiation levels to near-background levels may suggest that the remaining contamination is internal.

Although lukewarm soapy water solution is considered ideal for most radiological decontamination scenarios, its use may not be practical or even recommended in certain cases. Unless soapy water is readily available or easy to make, it may not be practical to use it as a decontaminant. The incident commander should consider using alternative decontaminants or techniques in light of operational constraints.

Following decontamination, if practical, check each victim for remaining contamination, using appropriate meter. If considerable contamination remains on a victim, the victim should return to the shower station for additional washing; however, decontamination efforts for that individual should be reevaluated or suspended if contamination levels are not being significantly reduced. Multiple decontamination attempts are not generally recommended, since they are usually neither practical nor warranted. After decontamination, victims can be released to the clean area for drying with clean towels, redressing with clean replacement clothing or blankets, and medical evaluation. If possible, privacy and modesty should be preserved throughout the decontamination process – from undressing to redressing.

Provide supportive patient care as needed.
Pandemic Influenza

There is a continuous stream of information regarding the approaches to an outbreak of severe viral respiratory diseases, especially Pandemic Influenza. This disease outbreak would require significant operational changes in Fire and EMS operations, in conjunction with Public Health programs. There would be a variety of programs that would allow Fire and EMS providers to receive appropriate vaccination, prophylaxis, or treatment as the threat of the disease evolves. Discussion of this topic is beyond the scope of this handbook, and would be accomplished at the time of the event in conjunction with the District’s public health leaders, the Department’s leadership and medical control, and local infectious disease experts.
Clinical Indications:

- Continuous Quantitative Waveform Capnography (ETCO₂) should be used when available with all endotracheal and nasotracheal airways and those with respiratory distress or seizures.
- Continuous Quantitative Waveform Capnography (ETCO₂) should be considered for use on patients treated with CPAP, Epinephrine, Morphine and Midazolam.

Procedure:

1. Attach capnography sensor to a patient or endotracheal tube.
2. Note ETCO₂ level and waveform changes. These should be documented on each respiratory failure, cardiac arrest, or respiratory distress patient.
3. The capnometer should remain in place with the airway and be monitored throughout the pre-hospital care and transport.
4. Any loss of ETCO₂ detection or waveform indicates a potential airway problem and should be corrected.
5. The capnogram should be monitored as procedures are performed to verify or correct the airway problem.
6. In a perfusing patient, end-tidal ETCO₂ levels of 35-45 mmHg are considered normal.
7. The numerical value can aid in assessing hypoventilation (increased ETCO₂), or hyperventilation (decreased ETCO₂) in perfusing patients.
8. Hyperventilation shall be avoided in patients in cardiac arrest or those with head injuries without signs / symptoms of herniation.

Normal Capnogram:
<table>
<thead>
<tr>
<th>END-TIDAL CO₂ WAVEFORM / CHANGES</th>
<th>ETCO₂</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Normal ETCO₂" /></td>
<td>Normal perforation</td>
<td>- Normal perfusion</td>
</tr>
<tr>
<td><img src="image2" alt="Loss of previous waveform with ETCO₂ near zero" /></td>
<td>ETCO₂ with ETCO₂ near zero</td>
<td>- Endotracheal tube disconnected, dislodged, kinked or obstructed</td>
</tr>
<tr>
<td><img src="image3" alt="Sudden increase in ETCO₂" /></td>
<td>ETCO₂</td>
<td>- Loss of circulatory function</td>
</tr>
<tr>
<td><img src="image4" alt="Slow rate with increased ETCO₂" /></td>
<td>ETCO₂ with ETCO₂ increased in rate</td>
<td>- Return of spontaneous circulation</td>
</tr>
<tr>
<td><img src="image5" alt="Rapid rate with decreased ETCO₂" /></td>
<td>ETCO₂ with ETCO₂ decreased in rate</td>
<td>- Hypoventilation</td>
</tr>
<tr>
<td><img src="image6" alt="CPR Assessment" /></td>
<td>ETCO₂</td>
<td>- If elevated above normal levels, need for increased ventilation</td>
</tr>
<tr>
<td><img src="image7" alt="“Sharkfin” waveform" /></td>
<td>ETCO₂</td>
<td>- Partial airway obstruction</td>
</tr>
<tr>
<td><img src="image8" alt="Decreasing ETCO₂ with loss of plateau." /></td>
<td>ETCO₂ with loss of plateau.</td>
<td>- Hyperventilation</td>
</tr>
</tbody>
</table>

- Effects of hyperventilation
- Cardiac arrest
- Attempt to maintain minimum of 10 mmHg
- Asthma
- COPD
- ET tube cuff leak or deflated cuff
- ET tube in the hypopharynx
- Partial obstruction
Utilization of Carbon Monoxide Oximeter:

- This is a noninvasive instrument used for the detection of capillary carbon monoxyhemoglobin in a patient with a pulse.

Clinical Indications:

- Carbon Monoxide Oximeter should be used on patients with smoke inhalation or inhalation of other hydrocarbon exhaust. Consider use for firefighters during incident rehabilitation.

Procedure:

- Apply finger probe to patient’s finger (preferably the non-dominant ring finger, or another finger with a large clean nail).
  - A reading of >12% indicates mild carbon monoxide inhalation.
  - A reading of >25% indicates severe carbon monoxide inhalation.

Special Considerations:

- Pediatrics: Not intended for use on patients weighing less than 30 kg.
- Pregnancy: Fetal SpCO may be 10-15% higher than the maternal reading.
- Smokers: Heavy smokers may have a baseline SpCO level up to 10%.
- A misapplied or dislodged sensor will cause inaccurate readings.
- Never use tape to secure the sensor.
- Do not place the sensor on the thumb.
Clinical Indications:

- The CPAP device should be applied to patients when inadequate ventilation is suspected due to pulmonary edema (CHF), COPD, pneumonia or near drowning.
- Patient is ≥15 years of age.

Contraindications:

- Asthma.
- Respiratory Arrest / Apnea.
- Patient has a tracheotomy.
- Active vomiting or upper GI bleeding.
- Patient has a suspected pneumothorax or chest trauma.

Procedure:

1. Ensure adequate oxygen supply to ventilation device.
2. Explain the procedure to the patient.
3. Consider placement of a nasopharyngeal airway.
4. Place the delivery mask over the mouth and nose. Oxygen should be flowing at this point.
5. Secure the mask with provided straps starting with the lower straps until minimal air leak occurs.
6. Titrate device up to 10 cm H₂O in patient’s ≥15 years of age (Consider lower settings for COPD patients at 5 cm H₂O).
8. Encourage the patient to allow forced ventilation to occur. Observe closely for signs of complication. The patient must be breathing for optimal use of the CPAP device.
9. Administer appropriate medications as required (nebulized albuterol for COPD or nitroglycerin for CHF).
10. If the patient begins to deteriorate due to respiratory failure, remove the CPAP device, provide BVM ventilations and assess the need for advanced airway management.
Clinical Indications:

- Adult (4.0 mm) QuickTrach: Any patient >100 pounds (45 kg).
- Pediatric (2.0mm) QuickTrach: Any patient <100 pounds (45 kg) and >2 years (24 months) in age.
- Acute upper airway obstruction, which cannot be relieved using basic airway maneuvers, finger sweep, or endotracheal visualization and Magill forceps removal.
- Respiratory arrest with facial or neck injury, or abnormal anatomy, which make endotracheal intubation impossible.
- Inability to ventilate patient with a bag valve mask.

Procedure:

1. Expose the neck.
2. Identify the cricoid membrane/ligament located between the cricoid cartilage and the thyroid cartilage.
3. Prep the skin.
4. Puncture the cricothyroid membrane at a 90-degree angle with the catheter/syringe assembly.
5. Aspirate for air upon introducing the catheter/syringe.
6. Upon aspiration of air, redirect the catheter/syringe in a 45-degree angle (toward feet), and advance until the stopper meets the skin.
7. Remove the stopper.
8. Advance the catheter (not the needle) until the flange rests on the skin.
9. Remove the needle-syringe assembly.
10. Apply the strap.
11. Attach the connecting tube to the 15 mm adaptor.
12. Attach a bag valve mask (BVM) to the other end of the connecting tube.
13. Ventilate the patient using the BVM.
15. Document the procedure and results on the patient care report (PCR).
Clinical Indications:

- Apnea.
- Inability to maintain a patent airway by other means.
- Need to prevent aspiration.
- Impending compromise of airway.
- Closed head injury (GCS <9) requiring assisted ventilation.
- SPO\textsubscript{2} cannot be maintained above 90% with ventilatory assistance via BVM and supplemental oxygen.
- Inability to maintain adequate oxygenation by other means.
- Patient ≥15 years of age.

Contraindications:

- Patient is maintaining their own airway.
- High risk airways:
  - Extremely anterior, large neck
  - Limited neck extension or mobility
- Pediatric patients less than 15 years of age.

Procedure:

1. Determine the need for Medication Facilitated Intubation.
2. Pre-Oxygenate with 100% supplemental oxygen.
   - Nasal Cannula with high flow oxygen (passive oxygenation)
   - NRB – For patients with adequate respiratory rate/effort.
   - BVM – For patients requiring ventilatory support.
3. Monitor EKG, pulse oximetry, and vital signs.
4. BVM with capnography circuit in place, suitable size mask, oral/nasal airways, and appropriate size King Airway shall be immediately available.
5. Obtain IV access.
6. Administer Medications:
   - Pre mediate with **Lidocaine 1.5 mg/kg IV/IO**.
Administer **Etomidate 0.3 mg/kg IV/IO, maximum of 30 mg**. May repeat dose once if Trismus (reduced opening of the jaw caused by spasm) is present or further sedation is required. (Use with Hypertensive, stroke or TBI patients)

- If after the maximum amount of Etomidate is administered and the patient requires additional sedation, administer:
  - **Midazolam (Versed) 2-5 mg IV/IO, up to a maximum of 10 mg**.

7. Perform orotracheal intubation with passive oxygenation with nasal cannula and high flow oxygen in nares or mouth

8. Confirm tube placement with Continuous Quantitative Waveform Capnography (ETCO₂) (or with ETCO₂ detector if not available) and presence of lung sounds and symmetric chest rise.

9. Secure the endotracheal tube.

10. In the event this pathway is undertaken and the provider is unable to secure the airway with ET intubation, the default Rescue Airway will be the King Airway.

11. Administer additional sedatives as needed per protocol and/or Medical Control.

Clinical Indications:

- Following unsuccessful endotracheal intubation:
  - Endotracheal intubation provides a definitive airway. Every attempt should be made to secure an airway with an endotracheal tube. Following two (2) unsuccessful attempts to place an endotracheal tube, or if it appears additional endotracheal intubation attempts would be unsuccessful, use of the King Airway should be considered.
  - The King Airway may be considered the initial airway of choice in the cardiac arrest patient.

Contraindications:

- Patients who are conscious or who have an intact gag reflex.
- Patients under three (3) feet in height.
- Patients with known esophageal disease (varices, alcoholism, cirrhosis etc.) or ingestion of caustic substances.

Size Chart:

<table>
<thead>
<tr>
<th>Product</th>
<th>Patient Height</th>
<th>Size</th>
<th>Color</th>
<th>Cuff Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LT-D</td>
<td>35 to 45 inches</td>
<td>2</td>
<td>Green</td>
<td>25-35 ml</td>
</tr>
<tr>
<td>LT-D</td>
<td>41-51 inches</td>
<td>2.5</td>
<td>Orange</td>
<td>30-40 ml</td>
</tr>
<tr>
<td>LT-D</td>
<td>4 to 5 feet</td>
<td>3</td>
<td>Yellow</td>
<td>45-60 ml</td>
</tr>
<tr>
<td>LT-D</td>
<td>5 to 6 feet</td>
<td>4</td>
<td>Red</td>
<td>60-80 ml</td>
</tr>
<tr>
<td>LT-D</td>
<td>Over 6 feet</td>
<td>5</td>
<td>Purple</td>
<td>70-90 ml</td>
</tr>
</tbody>
</table>

Procedure:

1. Body Substance Isolation (BSI).
2. Attach pulse oximeter and/or EtCO\(_2\) to monitor oxygen saturation and/or CO\(_2\) readings.
3. Choose the correct KING LT-D size, based on patient height.
4. Test cuff inflation system by injecting the maximum volume of air into the cuffs. Remove all air from both cuffs prior to insertion.
5. Apply a water-based lubricant to the beveled distal tip and posterior aspect of the tube, taking care to avoid introduction of lubricant in or near the ventilatory openings.
6. Pre-oxygenate patient with 100% oxygen for at least 1 minute.

7. Position the head. The ideal head position for insertion of the KING LT-D is the "sniffing position". However, the angle and shortness of the tube also allows it to be inserted with the head in a neutral position.

8. Hold the KING LT-D at the connector with dominant hand. With non-dominant hand, hold mouth open and apply chin lift.

9. With the KING LT-D rotated laterally 45-90° such that the blue orientation line is touching the corner of the mouth, introduce tip into mouth and advance behind base of tongue. Never force the tube into position.

10. As tube tip passes under tongue, rotate tube back to midline (blue orientation line faces chin).

11. Without exerting excessive force, advance KING LT-D until proximal opening of gastric access lumen is aligned with teeth or gums.

12. With a syringe inflate the KING LT-D; inflate cuffs with the minimum volume necessary to seal the airway at the peak ventilatory pressure employed (just seal volume).

13. Attach the BVM to the 15 mm connector of the KING LT-D. While gently bagging the patient to assess ventilation, simultaneously withdraw the airway until ventilation is easy and free flowing (large tidal volume with minimal airway pressure).

14. Depth markings are provided at the proximal end of the KING LT-D which refers to the distance from the distal ventilatory openings. When properly placed with the distal tip and cuff in the upper esophagus and the ventilatory openings aligned with the opening to the larynx, the depth markings give an indication of the distance, in cm, from the vocal cords to the upper teeth.

15. Attach EtCO₂ monitoring device to adaptor and follow guidelines for its use.

16. Confirm proper position by auscultation, chest movement and verification of Continuous Quantitative Waveform Capnography (ETCO₂). **Note: Do not let go of the King Airway until secured.**

17. Secure the KING LT-D to patient using tape or an approved commercial device.

Clinical Indications:

➤ Non-vigorous Neonatal patients with thick meconium stained amniotic fluid.

NOTE: If the newborn is vigorous, suction with a bulb syringe, do not intubate. If thick meconium stained amniotic fluid is present, do not stimulate the infant to breathe. Use appropriate aspiration adapter.

Procedure:

1. Intubate immediately with appropriate size endotracheal tube.
2. Connect endotracheal tube to meconium aspiration adapter to suction.
3. Withdraw endotracheal tube while suctioning.
4. If the endotracheal tube is filled with meconium, re-intubate with a new endotracheal tube and suction again until clear.
5. Resume Neonatal Resuscitation protocol.
6. If intubating and suctioning takes longer than 90 seconds or heart rate <80, initiate BVM with oxygen therapy.
Clinical Indications:
- CNS trauma.
- Rigidity or hypoxia from seizures (e.g. "clenched teeth").
- Poisonings.
- Metabolic disturbance.
- Patients with severe respiratory distress.

Contraindications:
- Non-breathing or near apneic patient.
- Known or likely fracture/instability of mid-face secondary to trauma.
- Suspected basilar skull fracture.
- Children <15 years of age.
- Relative contraindications:
  - Blood clotting abnormalities.
  - Nasal Polyps.
  - Upper neck hematomas or infections.

Procedure:
1. Prepare, position and oxygenate the patient with 100% Oxygen.
2. Choose proper ET tube about 1 mm less than for oral intubation.
3. For patients with suspected intracranial pressure, administer Lidocaine 1.5 mg/kg IV/IO.
4. Lubricate ET tube generously with water-soluble lubricant such as Lidocaine Jelly.
5. Pass the tube in the largest nostril with the beveled edge against the nasal septum and perpendicular to the facial plate.
6. Use forward and lateral back and forth rotational motion to advance the tube. **Never force the tube.**
7. Continue to advance the tube noting air movement through it; use the BAAM whistle to assist you.
8. Apply firm, gentle cricoid pressure and advance the tube quickly past the vocal cords during inspiration.
9. Inflate the cuff with 5-10 ml of air and secure the tube to the patient’s face.
10. Auscultate for bilaterally equal breath sounds and absence of sounds over the epigastrum. If you are unsure of placement, remove tube and ventilate patient with bag valve mask.

11. Check placement by EtCO₂ monitor and record readings at the scene, enroute to the hospital, and at the hospital.

12. Reassess airway and breath sounds after transfer to the stretcher and during transport. These tubes are easily dislodged and require close monitoring and frequent reassessment.

Clinical Indications:

- Patients with hypotension, clinical signs of shock, and at least one or more of the following signs:
  - Jugular vein distention.
  - Tracheal deviation away from the side of the injury (often a late sign and difficult to see).
  - Absent or decreased breath sounds on the affected side.
  - Hyper-resonance to percussion on the affected side.
  - Increased resistance when ventilating a patient.
- Patients in traumatic arrest with chest trauma for whom resuscitation is indicated. These patients may require bilateral chest decompression even in the absence of the signs above.

Procedure:

1. Don personal protective equipment (gloves, eye protection, etc.).
2. Administer high flow oxygen.
3. Identify and prep the site:
   - Locate the fourth intercostal space in the anterior-axillary line on the same side as the pneumothorax.
4. Prepare the site with alcohol or betadine solution.
5. Insert the catheter into the skin over the fourth rib and direct it just over the top of the rib (superior border) into the pleura space.
6. Advance the catheter through the parietal pleura until a “pop” is felt and air or blood exits under pressure through the catheter, then advance catheter only to chest wall.
7. Remove the needle, leaving the plastic catheter in place.
8. Secure the catheter hub to the chest wall with dressings and tape.
9. Consider placing a finger cut from an exam glove over the catheter hub. Cut a small hole in the end of the finger to make a flutter valve. Secure the glove finger with tape or a rubber band. NOTE: do not waste time preparing the flutter valve; if necessary control the air flow through the catheter hub with your gloved thumb.
Clinical Indications:

- Cardiac arrest.
- Respiratory arrest.
- Hypoxic or obtunded patients.
- Patients with possible increasing ICP.

Contraindications:

- Presence of gag reflex.
- Clinched teeth.

Procedure:

1. Prepare, position and oxygenate the patient with 100% Oxygen.
2. Place nasal cannula with high flow oxygen on patient and such is to remain in-place during intubation attempts for passive oxygenation.
3. Select proper endotracheal tube (and stylette, if used), have suction ready.
   - Pediatric - Refer to Broselow™ tape.
4. Using laryngoscope, visualize vocal cords. (Use Sellick maneuver to assist you).
5. Limit each intubation attempt to 30 seconds with BVM between attempts.
6. Visualize tube passing through vocal cords.
7. Inflate the cuff with 5-10 ml of air and secure the tube to the patient’s face.
8. Auscultate for bilaterally equal breath sounds and absence of sounds over the epigastrium. If you are unsure of placement, remove tube and ventilate patient with bag valve mask.
9. Consider using an alternate airway device if endotracheal intubation efforts are unsuccessful.
10. Apply EtCO$_2$ monitor and record readings on scene, enroute to the hospital, and at the hospital.
11. Document endotracheal tube size, time, results, and placement location by the centimeter marks either at the patient’s teeth or lips on the patient care report (PCR). Document all devices used to confirm initial tube placement.
12. Consider placing an orogastric tube to clear stomach contents after the airway is secured with an ET tube.
Clinical Indications:

- Difficult intubation with a restricted view of the glottic opening. This may occur due to:
  - Short, thick (bull) neck.
  - Pregnancy.
  - Laryngeal edema (anaphylaxis, burns).
  - Normal anatomical variation.
  - Supra-glottic neoplasms (tumors above the glottic opening).
  - Inability to position patient appropriately (e.g. entrapment, confined space).

Contraindications:

- Pediatric patients under the age of 14.

Procedure:

- Hyperventilate the patient with 100% oxygen for at least one minute prior to each intubation attempt. Note, however, that this step should be omitted when ventilation (demonstrated by rise and fall of the chest) proves impossible.
- Prepare the ET tube and other intubation equipment (minimum 6.0 mm ET tube).
- Curve the bougie and ensure the distal tip is formed into a “J” shape;
- Perform a laryngoscopy, obtaining the best possible view of the glottic opening.
- Advance the bougie, continually observing its distal tip, with the concavity facing anteriorly;
- Visualize the tip of the bougie passing the vocal cords.
- Once the tip of the bougie has passed the epiglottis, continue to advance it in the mid-line so that it passes behind the epiglottis but in an anterior direction.
As the tip of the bougie enters the glottic opening you will either feel ‘clicks’ as it passes over the tracheal rings or the tip will arrest against the wall of the airways (‘hold-up’). This suggests correct insertion, although cannot be relied upon to indicate correct positioning with 100% accuracy. HOWEVER, FAILURE TO ELICIT CLICKS OR HOLD-UP IS INDICATIVE OF ESOPHAGEAL PLACEMENT. If hold-up is felt, the bougie should then be withdrawn approximately 5 cm to avoid the ET tube impacting against the carina.

Hold the bougie firmly in place and MAINTAIN LARYNGOSCOPY.

- Instruct your colleague to pass the endotracheal tube over the proximal end of the bougie.
- As the proximal tip of the bougie is re-exposed, the assistant should carefully grasp it, assuming control of the bougie and passing control of the ET tube to the intubator.
- The ET tube should then be carefully advanced (‘rail-roaded’) along the bougie and hence through the glottic opening, taking care to avoid movement of the bougie.
- SUCCESSFUL INTUBATION MAY BE CONSIDERABLY ENHANCED BY ROTATING THE ET TUBE 90°, SO THAT THE BEVEL FACES POSTERIORLY. In so doing the bougie may also rotate along the same plane but should not be allowed to move up or down the trachea.

Once the ET tube is fully in place hold it securely as your colleague withdraws the bougie.

Withdraw the laryngoscope.

Inflate the cuff. Then verify correct positioning of the ET tube using auscultation of the lung fields and epigastrium and observing for chest wall movement.

Secure the ET tube. The tip of the ET tube can move up to 6.0 cm once placed and this is certainly sufficient to dislodge it from the trachea.

Document the procedure and results on the patient care report (PCR).
Background:

Pulse Oximeters are noninvasive instruments used for the detection of arterial oxyhemoglobin. Each hemoglobin (Hgb) molecule can carry up to 4 oxygen molecules. Hgb molecules carrying 4 oxygen molecules is considered “fully saturated” and Hgb molecules carrying less than 4 oxygen molecules is considered “unsaturated”. Pulse oximetry measures the concentration of bound Hgb. It does not measure oxygen concentration.

Clinical Indications:

- Include SpO2 as a vital sign.
- All patients who require oxygen.
- All patients requiring EKG monitoring.
- All patients with respiratory, cardiovascular or neurological complaints.
- All patients with abnormal vital signs.
- All patients who receive respiratory depressants (Morphine, Diazepam, Midazolam).
- Critical trauma patients.

Procedure:

1. Apply probe to index finger or thumb.
2. A normal SpO2 on room air is 96-100%.
3. Moderate hypoxemia is characterized by values <90%.
4. Severe hypoxemia is characterized by values <80%.
5. Document the results on the patient care report (PCR).

Special Considerations:

The following circumstances may result in low/absent SpO2 readings:

- Motion at the sensor site.
- Hypoperfusion
- Cold temperature.
- Edema.
- Anemia.
- Carbon monoxide poisoning.
- Methemoglobinemia.
Background:

Tracheostomy patients with an In-Dwelling Tube or Stoma.

- Most patients with a permanent tracheostomy (with tube or stoma) can adequately breathe through the opening.
- Some of these patients have complete surgical reconstruction of the airway and breathe only through the tube or stoma, while other patients may have the opening to the mouth and can breathe through the tracheostomy tube, stoma, nose, or mouth.
- If air escaping is felt or heard at the nose or mouth when ventilating a partial neck breather, the nose and mouth must be sealed (pinching the nose closed and closing the mouth using a jaw lift) prior to ventilating the patient.
- Tracheostomy patients requiring ventilatory assistance require specialized techniques be employed in order to be properly ventilated.
  - EMS personnel must identify the tracheostomy site and tube (if present).
  - Check the tracheostomy tube or stoma for any blockage.
  - Look, listen, and feel for breathing at the tube or stoma site.
  - Assess for breathing and adequacy of respirations.

Clinical Indications:

- Respiratory arrest.
- Cardiac arrest.
- Hypoventilation.
- Severe respiratory distress due to an obstructed tracheostomy tube.

Procedures:

If a tracheostomy tube has the standard 15 mm adapter and the patient can be ventilated through the tube:

1. Attach a BVM to the adapter.
2. Ventilate with a bag-valve mask and 100% oxygen.
3. Assess for adequacy of ventilations and check for leaks.
4. If the tube is cuffed, inflate the cuff until there is no air leak.
If the patient cannot be ventilated through the tube:
1. Visually inspect the tube and tracheostomy for any obstructing material and remove if possible.
2. Attempt to ventilate with 2 breaths.
3. If successful, continue to ventilate as required.

If there is no obvious obstructing material and the patient cannot be ventilated:
1. Suction the airway and attempt to ventilate with 2 breaths.
2. If successful, continue to ventilate as required.

If the patient still cannot be ventilated:

**BLS Providers should:**
1. Remove the tube carefully.
2. Suction the stoma.
3. Place a pediatric sized mask over the stoma site.
4. Ventilate with a bag-valve mask and 100% oxygen.
5. Load and go should be initiated as soon as possible.
6. On scene times should be kept to a minimum.
7. Treat other life-threatening conditions en route.
8. Transport the patient to the nearest appropriate health care facility.
9. Notify the receiving health care facility of the patient's status as soon as possible.
10. Monitor and treat the patient en route.

**ALS Providers should:**
1. Remove the tube carefully.
2. Place a pediatric mask over the stoma site.
3. Ventilate with a bag-valve mask and 100% oxygen.
4. Choose the appropriate sized endotracheal tube.
5. Insert the tube into the stoma until the cuff is just inside the stoma (cuffed tubes only).
6. Inflate the cuff and check for air leaks.
7. Ventilate the patient checking for chest rise and fall.
8. Auscultate lung sounds for equal bilateral breath sounds and no sounds over the epigastrium.

If a tracheostomy tube is not present (i.e. a stoma):

1. Place a pediatric mask over the stoma site.
2. Ventilate with an appropriately sized bag-valve mask and 100% oxygen.
3. Suctioning can be done through the tracheostomy tube or stoma.
4. Care must be taken to insert the suction catheter no more than 5 cm (2 inches) beyond the lower edge of the opening.
Clinical Indications:

- Patients in cardiac arrest (pulseless, apneic).
- Age 1 to 8 years, use reduced energy Pediatric Pads.

Contraindications:

- Traumatic cardiac arrest.
- Patients with a fully obstructed airway.
- Hazardous environments.

Procedure:

1. If multiple rescuers available, one rescuer should provide uninterrupted chest compressions while the AED is being prepared for use.
2. Apply defibrillator pads per manufacturer recommendations. Use alternate placement when implanted devices (pacemakers, AICDs) occupy preferred pad positions.
3. Remove any medication patches on the chest and wipe off any residue.
4. Activate AED for analysis of rhythm.
5. Stop CPR and clear the patient for rhythm analysis. Keep interruption in CPR as brief as possible.
6. Defibrillate if appropriate by depressing the “shock” button. Assertively state “CLEAR” and visualize that no one, including yourself, is in contact with the patient prior to defibrillation. The sequence of defibrillation charges is preprogrammed for monophasic defibrillators. Biphasic defibrillators will determine the correct joules accordingly.
7. Begin CPR (chest compressions and ventilations) immediately after the delivery of the defibrillation.
8. After 2 minutes of CPR, analyze rhythm and defibrillate if indicated. Repeat this step every 2 minutes.
9. If “no shock advised” appears, perform CPR for 2 minutes and then re-analyze. Continue CPR during the charging process.
10. Transport and continue treatment as indicated.
11. Keep interruption of CPR compressions as brief as possible. Adequate CPR is a key to successful resuscitation. If a spontaneous pulse returns: See return of spontaneous circulation protocol (ROSC).
Clinical Indications:

- Cardiac arrest with ventricular fibrillation or pulseless ventricular tachycardia.

Procedure:

1. Ensure chest compressions are adequate and interrupted only when necessary.
2. Clinically confirm the diagnosis of cardiac arrest and identify the need for defibrillation.
3. Apply hands free pads to the patient’s chest in the proper position (Anterior-Lateral or Anterior-Posterior position).
4. Set the appropriate energy level.
5. Charge the defibrillator to the selected energy level. Continue chest compressions while the defibrillator is charging.
6. Hold compressions, assertively state, “CLEAR” and visualize that no one, including yourself, is in contact with the patient.
7. Deliver the desired energy by depressing the shock button for hands free operation.
8. Immediately resume chest compressions and ventilations for 2 minutes. After 2 minutes of CPR, analyze rhythm and check for pulse only if appropriate for rhythm.
9. Repeat the procedure every two minutes as indicated by patient response and EKG rhythm.
10. Keep interruption of CPR compressions as brief as possible. Adequate CPR is a key to successful resuscitation.
Clinical Indications:

- Cardiac arrest with persistent ventricular fibrillation or pulseless ventricular tachycardia refractory to multiple defibrillations. (four)

Procedure:

1. Ensure chest compressions are adequate and interrupted only when necessary.
2. Clinically confirm the diagnosis of cardiac arrest with persistent ventricular fibrillation or pulseless ventricular tachycardia. Obtain a second defibrillator or an automatic AED.
3. Apply hands free pads to the patient’s chest in the proper positions (Anterior – Lateral AND Anterior-Posterior position).
4. Set the energy level to 360 joules on each manual defibrillator or if using an AED as well as a defibrillator stop CPR and activate the AED for analysis of the rhythm.
5. Simultaneously charge the defibrillator(s) to 360 joules.
6. Hold compressions, assertively state, “CLEAR” and visualize that no one, including yourself, is in contact with the patient.
7. Defibrillate the patient with the desired energy by depressing the shock button on either both manual defibrillators or the manual defibrillator and the AED. The energy from both devices should be delivered nearly simultaneously allowing for ideal sequential administration of the electricity.
8. Immediately resume chest compressions and ventilations for 2 minutes. After 2 minutes of CPR, analyze the rhythm and check for a pulse only if appropriate for the rhythm.
9. Repeat the procedure every two minutes as indicated by patient response and EKG rhythm.
10. Keep interruption of CPR compressions as brief as possible. Adequate CPR is a key to successful resuscitation.
Clinical Indications:

- Cardiac or trauma related arrest.

Contraindications:

- Patients less than 12 years of age.
- Patient is too small. *The suction cup is not being completely compressed when lowered.*
- Patient is too large. *The support legs of the device cannot be locked into place without compressing the patient.*

Assembly and Application of the LUCAS 2 CPR Device:

1. Activate the device
   - Push ON/OFF for 1 second to start self-test and power Lucas device.

2. Back Plate
   - Pause manual CPR and carefully place back plate under the patient, below armpits and resume manual CPR.

3. Compressor
   - Pull release rings once to unlock the claw locks. Attach the back plate and listen for the “click”. Pull up on the device once to ensure attachment.

4. Position the Suction Cup
   - Center the suction cup over the chest. The lower edge of the suction cup should be immediately above the end of the sternum.

5. Push down on the Suction Cup
   - Push the adjust button and push the suction cup down with two fingers. The pressure pad should touch the patient’s chest. If the pad does not touch or fit properly, continue manual compressions. Push the pause button to lock in the start position.

6. Start compressions
   - Check for proper position and adjust if necessary. Push the active (30:2) or active (continuous) button to start the device.

7. Lucas Stabilization Strap
   - Attach the Lucas stabilization strap under the patient’s neck and around the shoulders. Ensure that the straps are snug. Continue to assess for proper placement through the use of the device.
Integrating the LUCAS 2 Device into Patient Care:

1. Perform your initial assessment as per protocol. Perform manual CPR until the LUCAS 2 device is attached.

2. After the first rhythm interpretation and/or defibrillation, your next priority if BLS airway interventions are successful, is to apply the LUCAS 2 device.

3. After applying the LUCAS 2 device, ensure that the device is in Active (30:2) mode until an advanced airway is placed. After an advanced airway is placed, switch the device to Active (Continuous) mode so the device can give continuous uninterrupted compressions.

4. After resuscitation, assess the patient for resuscitation-related injuries.

5. Consider the Use of Etomidate for sedation if patient regains consciousness or exhibits signs of pain while using Lucas Device for CPR

When Transporting the Patient:

1. Secure the patient’s arms with the straps on the support legs. Be sure not to apply the straps so tightly to occlude any IV(s).

2. Pause compressions any time you move the patient to the backboard/stretcher. Re-verify device placement before resuming compressions.

3. Do not perform compressions while the patient’s chest is not horizontal (e.g. going up or down stairs).

4. Assure that the patient is adequately restrained in the EMS transport unit.

Care after Use: Do not immerse the LUCAS 2 in liquid. The device can be damaged if liquid enters the hood.

1. Clean all outer surfaces of the device with a soft cloth and warm water with a mild cleaning or disinfecting agent.

2. Allow the device to dry before re-packing.
Clinical Indications:

- Suspected cardiac event.
- Suspected tricyclic overdose.
- Electrical injuries.
- Syncope.
- CHF.

Procedure:

1. Assess patient and monitor cardiac status.
2. If patient is unstable, definitive treatment is the priority. If patient is stable or stabilized after treatment, perform a 12 Lead EKG.
3. Prepare EKG monitor and connect patient cable with electrodes.
4. Expose chest and prep as necessary. Modesty of the patient should be respected.
5. Apply chest leads and extremity leads using the following landmarks:
   - RA - Right arm.
   - LA - Left arm.
   - RL - Right leg.
   - LL - Left leg.
   - V1 - 4th intercostal space at right sternal border.
   - V2 - 4th intercostal space at left sternal border.
   - V3 - Directly between V2 and V4.
   - V4 - 5th intercostal space at left mid-clavicular line.
   - V5 - Level with V4 at left anterior axillary line.
   - V6 - Level with V5 at left mid-axillary line.
6. When performing a right sided EKG in patients with a suspected inferior wall MI with possible right ventricular involvement (RVI):
   - V4R - 5th intercostal space at right mid-clavicular line.
7. Instruct patient to remain still.
8. Press the appropriate button to acquire the 12 Lead EKG.
9. ALS Providers shall interpret the EKG and if STEMI is suspected, transmit the EKG to an interventional cardiology facility if possible.
When making a radio report to a STEMI center, providers will report their own interpretation of the 12-lead, then read the machine interpretation verbatim to the hospital staff.


<table>
<thead>
<tr>
<th>Wall affected</th>
<th>Leads</th>
<th>Artery(s) involved</th>
<th>Reciprocal changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior</td>
<td>$V_2 - V_4$</td>
<td>Left coronary artery, Left anterior descending (LAD)</td>
<td>II, III, AVF</td>
</tr>
<tr>
<td>Anterolateral</td>
<td>I, AVL, $V_3 - V_6$</td>
<td>Left anterior descending (LAD) and diagonal branches, circumflex and marginal branches</td>
<td>II, III, AVF</td>
</tr>
<tr>
<td>Anteroseptal</td>
<td>$V_1 - V_4$</td>
<td>Left anterior descending (LAD)</td>
<td></td>
</tr>
<tr>
<td>Inferior</td>
<td>II, III, AVF</td>
<td>Right coronary artery (RCA)</td>
<td>I, AVL</td>
</tr>
<tr>
<td>Lateral</td>
<td>I, AVL, $V_5$, $V_6$</td>
<td>Circumflex branch or left coronary artery</td>
<td>II, III, AVF</td>
</tr>
<tr>
<td>Posterior</td>
<td>$V_8$, $V_9$</td>
<td>Right coronary artery (RCA) or circumflex artery</td>
<td>$V_1 - V_4$ ST segment depression ($R &gt; S$ in $V_1$ and $V_2$).</td>
</tr>
<tr>
<td>Right ventricular</td>
<td>$V_4R$</td>
<td>Right coronary artery (RCA)</td>
<td>-----</td>
</tr>
</tbody>
</table>
Clinical Indications:

- Unstable patient with a tachydysrhythmia (rapid atrial fibrillation, supraventricular tachycardia or ventricular tachycardia).
- Patient is not pulseless (the pulseless patient requires unsynchronized cardioversion, i.e. defibrillation).

Procedure:

1. Ensure the patient is attached properly to a monitor/defibrillator capable of synchronized cardioversion.

2. Have all equipment prepared for unsynchronized cardioversion/defibrillation if the patient fails synchronized cardioversion and the condition worsens.

3. Consider the use of pain or sedating medications.

4. Set energy selection to the appropriate setting.

5. Set monitor/defibrillator to synchronized cardioversion mode.

6. Make certain all personnel are clear of patient.

7. Press and hold the shock button to cardiovert. Stay clear of the patient until you are certain the energy has been delivered. **NOTE: It may take the monitor/defibrillator several cardiac cycles to “synchronize”, so there may be a delay between activating the cardioversion and the actual delivery of energy.**

8. Perform immediate unsynchronized defibrillation if the patient’s rhythm has deteriorated into pulseless ventricular tachycardia/ventricular fibrillation.

9. If the patient’s condition is unchanged, repeat steps 4 to 8 above, using escalating energy settings.

Clinical Indications:

- Monitored heart rate less than 60 per minute with signs and symptoms of inadequate cerebral or cardiac perfusion such as:
  - Chest pain.
  - Hypotension.
  - Pulmonary edema.
  - AMS, disorientation, confusion, etc.
  - Ventricular ectopy.
- Witnessed Asystole, pacing must be done early to be effective.

Procedure:

1. Attach standard four-lead monitor.
2. Apply defibrillation/pacing pads:
   - Anterior / Posterior: Anterior electrode on left precordium below the left nipple. Avoid placing on the nipple. Posterior electrode below left scapula, lateral to spine at heart level.
   - Anterior / Lateral: Lateral (apex) electrode lateral to left nipple with the center of the electrode on the midaxillary line. Anterior electrode below the right clavicle lateral to sternum.
3. Press pacer button and observe for sensor markers on each QRS complex.
4. Press rate or slowly rotate selector knob and adjust rate to 80 BPM for the adult patient and 100 BPM for the pediatric patient.
5. Press current or slowly rotate selector knob until capture is obtained.
6. Slowly increase output until capture of electrical rhythm on the monitor.
7. If unable to capture while at maximum current output, stop pacing immediately.
8. If capture observed on monitor, check for corresponding pulses and assess vital signs, skin color and capillary refill for improved perfusion.
9. Consider the use of sedation or analgesia if patient is uncomfortable.
10. Document the dysrhythmia and the response to external pacing with EKG strips on the patient care report (PCR).
Clinical Indications:

- Patient in cardiac arrest.

Precautions:

- Emphasize the need for:
  - Minimally interrupted compressions.
  - Appropriate depth and quality of compressions.
  - Compressor fatigue and change compressors as needed.
  - Team approach.
- Infants and small children may require modification of the procedure due to size.

Procedure (Based on a crew of four or more):

1. Established prior to arriving at the patients side, and includes the following:

   - **Position 1** (Patients left side)
     - Assesses responsiveness and checks pulses.
     - Initiates chest compressions immediately.
     - Alternates chest compressions with Position 2.
   - **Position 2** (Patients right side)
     - Removes clothing at chest.
     - Applies defibrillator pads immediately.
     - Attaches AED or Lifepak monitor/defibrillator.
     - Alternates chest compressions with Position 1.
     - Applies Lucas 2 if the device is available (If in use Position 1 or 2 monitors the units operation and placement. Pauses the unit at the discretion of the ALS provider in charge of patient care).
   - **Position 3** (Patients head)
     - Assembles and appropriately applies BLS airway measures.
       - Opens and clears the airway.
       - Inserts appropriately sized King Airway (per protocol) and continues ventilations
       - Provides BVM ventilations at appropriate rate and depth.
Position 4 (Paramedic)
- Makes all patient treatment decisions.
- Initiates IV/IO access (If IO, right humeral head is the preferred site).
- Administers medications and provides additional treatment as needed.

Position 5 or more (Extra)
- Assist in different positions when needed.
- Family Advocate
- Documents incident activity:
  - Time CPR started.
  - Times of medication administration.
  - Times of additional advanced procedures performed.
  - Obtains patient information from family and/or bystanders.
**Position 1** (Patient Left)
1. Assesses responsiveness and checks pulses
2. Initiates chest compressions immediately
3. Alternates chest compressions with Position 2

**Position 2** (Patient Right)
1. Removes clothing at chest
2. Attaches defibrillator pads
3. Attaches AED or ECG Monitor/defibrillator
4. Alternates chest compressions with Position 1
5. Applies Lucas 2 if available

**Position 3** (Patient Head)
1. Opens and clears airway
2. Insert King Airway per protocol
3. BVM ventilations at appropriate rate and depth

**Position 4** (Paramedic)
1. Makes all patient treatment decisions
2. Initiates IV/IO access (If IO, right humeral head is the preferred site)
3. Administers medications and provides additional treatment as needed

**Position 5 or more** (Extra)
1. Assist in different positions when needed
2. Document incident activity
3. Family Advocate
Clinical Indications:

- Patient in cardiac arrest 8 years and older.

Contraindications:

- Patients under the age of 8.
- Cardiac Arrest secondary to trauma.
- Remove device immediately with Return of Spontaneous Circulation (ROSC).

Precautions:

- Always place ETCO₂ detector between the ResQPOD and BVM.
- Do not interrupt CPR unless absolutely necessary.
- If a spontaneous return of circulation occurs, discontinue CPR and the ResQPOD. If the patient rearrests, resume CPR and reattach the ResQPOD.
- Do not delay compressions if the ResQPOD is not readily available.

Procedure:

Using the ResQPOD on a Facemask (preferred)

1. Connect the ResQPOD to the facemask.
2. Open the airway. Establish and maintain a tight face seal with the mask throughout chest compressions.
3. Connect the BVM source to the ResQPOD.
4. Perform High Quality CPR at the recommended compression-to-ventilation ratio.

Using the ResQPOD on an Endotracheal Tube (ET) (Preferred) or King Airway

1. Confirm ET tube or King Airway placement and secure with a commercial tube restraint.
2. Connect the ResQPOD to the ET tube or King Airway.
3. Place ETCO₂ detector (If available) between the ResQPOD and the BVM.
4. Perform High Quality CPR at the recommended compression-to-ventilation ratio.
5. Remove the clear tab and turn on the timing assist lights. Ventilate asynchronously at the rate of the timing light.
Clinical Indications:

- Patients with suspected hypoglycemia (diabetic emergencies, change in mental status, bizarre behavior, etc.).

Procedure:

1. Gather and prepare equipment.
2. Blood samples for performing glucose analysis should be obtained simultaneously with intravenous access when possible.
3. Place correct amount of blood on reagent strip or site on glucometer per the manufacturer’s instructions.
4. Time the analysis as instructed by the manufacturer.
5. Document the glucometer reading and treat the patient as indicated by the analysis and protocol.
6. Repeat glucose analysis as indicated for reassessment after treatment and as per protocol.
7. If after dextrose administration the glucose level is substantially low per a reading in a cool digit, utilize a more centrally located alternate site for testing.
Clinical Indications:
- Access of an existing venous catheter for medication or fluid administration in critical patient’s only

Providers MAY Access:
- Peripherally Inserted Central Catheters (PICC lines)
- Tunneling catheters such as Broviac, Hickman, and Groshong
- Non-tunneled, dual lumen catheters used for temporary dialysis access, i.e., Quinton catheters.

Providers MAY NOT Access:
- Dialysis catheters: Arteriovenous shunts (synthetic bridges between the arterial and venous circulation located under the skin in the forearm).
- Subcutaneous internal access devices that require access through the skin, for example, Port-a-Cat, Medi-Port

Procedure:
1. Clean the port of the catheter with an alcohol wipe.
2. Remove the cap to the port and attach the empty 10 ml syringe to the catheter port.
3. Unlock the clamp on the access line, if applicable, and aspirate blood from the port. Blood should aspirate freely. If it does not, replace the cap and DO NOT use the access port.
4. Lock the clamp, if applicable, and remove the syringe with the aspirated blood. Dispose of the syringe in a biohazard container.
5. Connect a syringe containing 10 ml of normal saline to the port, unlock the clamp, and flush the device. The line should flush easily. Re-clamp the line.
6. Remove the syringe and connect the primed IV to the port. Unclamp the line and adjust flow rate as needed.
7. Begin administration of medications or IV fluids slowly and observe for any signs of infiltration. If difficulties are encountered, stop the infusion and reassess.
8. Record procedure, any complications, and fluids / medications administered on the patient care report (PCR).
Clinical Indications:

- External jugular vein cannulation is indicated in a critically ill patient >8 years of age who requires intravenous access for fluid or medication administration and in whom an extremity vein is not obtainable.
- External jugular cannulation can be attempted initially in life threatening events where no obvious peripheral site is noted.

Procedure:

1. Place the patient in a supine head down position. This helps distend the vein and prevents air embolism.
2. Turn the patient’s head toward the opposite side if no risk of cervical injury exists.
3. Prep the site with alcohol.
4. Apply pressure to the vein lightly with one finger above the clavicle to allow the vein to engorge.
5. Align the catheter with the vein and aim toward the same side shoulder.
6. Puncture the vein midway between the angle of the jaw and the clavicle and consul the vein in the usual method.
7. Attach the IV tubing or saline lock and secure the catheter with taping and/or dressing.
8. Document the procedure, time, and result (success) on the patient care report (PCR).
Clinical Indications:

- Patients where peripheral IV access is unobtainable with any of the following:
  - Cardiac arrest. **The right proximal humeral head is the preferred site.**
  - Single or Multi-system trauma with severe hypovolemia.
  - Any unconscious or seriously ill patient requiring immediate medication therapy or fluid replenishment.

Contraindications:

- Fracture proximal to proposed intraosseous site.
- History of Osteogenesis Imperfecta.
- Current or prior infection at proposed intraosseous site.
- Previous intraosseous insertion or joint replacement at the selected site.

Procedure:

1. Locate landmarks.
   - Adult ≥40 kg (AD or LD Needle)
     - Proximal Tibia - The insertion point is two finger widths below the patella, 1-2 cm medial of the tibial tuberosity.
     - Distal Tibia - Identify the major structures of the lower leg, the distal tibia (anterior or most forward lower leg bone) and the medial malleolus (medial ankle bone or protrusion). The insertion point is two finger widths proximal to the medial malleolus and midline on the tibia.
     - Proximal Humeral - Palpate and identify the mid-shaft humerus and continue palpating toward the proximal aspect or humeral head. As you near the shoulder you will note a protrusion. This is the base of the greater tubercle insertion site.
   - Pediatric 3-39 kg (PD Needle)
     - Proximal Tibia - 1 cm distal to tibial tuberosity and then medial along the flat aspect. Gently guide the driver, do not push. If NO tuberosity is present, the insertion is located two finger widths below the patella and then medial along the flat aspect of the tibia. Carefully feel for the “give” indicating penetration into the medullary space.
2. Prepare the skin with alcohol.

3. Load the needle onto the driver.

4. Firmly stabilize the leg near (not under) the insertion site

5. Firmly press the needle against the site and operate the driver. Use firm, gentle pressure.

6. As the needle reaches the bone, stop and be sure that the 5 mm marking on the needle is visible; if it is, continue to operate the driver.

7. When a sudden decrease in resistance is felt and the flange of the needle rests against the skin, remove the driver and the stylette from the catheter. For adult humerus site drive the needle so hub touches skin surface.

8. Confirm placement by aspiration of bone marrow.

9. Place EZ-IO™ immobilization device over hub.

10. Attach primed extension set.

11. Flush the EZ-IO™ needle rapidly with 10 ml of saline. Infuse 4 ml of 1% Cardiac Lidocaine for conscious patients and allow dwell time of 2-4 minutes.

12. If no infiltration is seen, attach the IV line and infuse fluids and/or medications as normal.

13. Secure the needle by securing tape on immobilization device.

14. IV bag may need to be under pressure for infusion.

15. Document the procedure, time, and results on the patient care report (PCR).
Clinical Indications:

- Life threatening illness or injury in a child <8 years of age or <40 kg in weight.

Procedure:

1. Expose the lower leg.
2. Identify the tibial tuberosity (bony prominence below the knee cap) on the proximal tibia. The insertion location will be 1-2 cm (2 finger widths) below this and medially.
3. Prep the site with alcohol.
4. Hold the intraosseous needle perpendicular to the skin, twist the needle with a rotating grinding motion applying controlled downward force until a "pop" or "give" is felt indicating loss of resistance. Do not advance the needle any further.
5. Remove the stylette and attach a 10 ml syringe filled with 5 ml of Normal Saline.
6. Attempt to extract marrow into the syringe; then inject the saline while observing for infiltration.
7. Stabilize and secure the needle.
8. Document the procedure, time, and result (success) on the patient care report (PCR).
Background:

The Broselow™ Pediatric Emergency Tape is designed to be used as a quick reference to drug dosing and equipment sizing on pediatric patients. The Broselow™ tape is calibrated in different colors according to different lengths. The color that corresponds to the patient’s length is used. If the Broselow™ bag is also used, the color on the tape can be matched with the color on the pouch that contains the appropriately sized equipment and drugs.

Procedure:

1. Place the patient in a supine position.
2. Remove tape from package and unfold.
3. Place tape next to patient, ensuring that the multicolored side is facing up.
4. Place red end of tape even with the top of the patient’s head.
5. Place the edge on one hand on the red end of the tape.
6. Starting from the head, run the edge of your free hand down the tape.
7. Stop hand even with the heel of the patient’s foot (if patient is larger than tape, stop here and use appropriate adult technique).
8. Verbalize the color block (on edge of tape) and weight range where your free hand has stopped. If patient falls on the line, go to the next higher section.
9. Use color block (on edge of tape) to identify the weight range of the patient.
10. Use weight range to determine appropriate sized of equipment and approximate dosages for medications.
Background:
The purpose of spinal immobilization is to effectively splint the entire body to minimize movement of the spine for patients with suspected spinal cord injuries.

Indications for Immobilization:
- Altered mental status.
- Serious multi-system trauma.
- Neck pain secondary to significant MOI (i.e., spider-webbed windshield, dash deformity, rollover, passenger space intrusion greater than 12 inches, etc.).
- Any mechanism that produced a violent impact to the head, neck, chest, torso or pelvis (i.e., assault, entrapment in structural collapse, etc.).
- Incidents producing sudden acceleration, deceleration or lateral bending forces to the head, neck or torso (i.e., high speed MVC, pedestrian struck, involvement in explosion).
- Ejection or fall from any motorized or human powered transportation device (i.e., scooters, skateboards, motor vehicles, motorcycles or recreational vehicles).
- Major injury that may distract patient’s awareness to neck/back pain (i.e., pelvic fracture, femur fracture, extensive burns, extensive soft tissue injury, acute abdomen, significant chest injury, degloving or crush injury, etc.).
- Pain upon palpation to any part of cervical spine.
- Neck pain to patient’s range of motion.
- Inability to communicate (speech or hearing impaired, foreign language, small children).
- Any fall that is 3 times the patient’s height.
- Victim of shallow water diving incident.
- When in doubt – Immobilize!!
- See Selective Spinal Immobilization protocol.
Background:
The helmet removal procedure is a guideline designed in two parts. Part I is for those patients wearing a motorcycle, bicycle, or other non-football type head protective device. Part II is designed for those patients wearing a football helmet.

Non-Football Helmets
1. Perform a Primary Survey if possible. Also, if the situation permits, ascertain if the victim has the ability to move their extremities. If unable to perform a primary survey, go to step 2.
2. The in-charge rescuer should designate a trained rescuer (Rescuer II) to manually control the cervical spine. The in-charge rescuer should kneel beside the patient and remove the chin strap device. A third rescuer should prepare padding for use to keep the spine in a neutral position.
3. The in-charge rescuer should then take control of the cervical spine from a side position to the patient. Rescuer II should then relinquish control of the cervical spine to the in-charge rescuer.
4. Rescuer II should remove the helmet by spreading the sides of the helmet and removing the helmet using caution not to manipulate the cervical spine. The in-charge rescuer should be prepared to hold the head, as when the helmet is removed there will be an increase in weight.
5. A pad may need to be inserted under the patient's head to maintain position of the c-spine. Cervical spine control should then be maintained by rescuer II.
6. The in-charge rescuer should then resume the primary survey, further assessment and interventions.

Football Helmets
1. Perform a Primary Survey. Also, if the situation permits, ascertain if the victim has the ability to move all extremities.
2. If the football helmet fits and the airway is maintainable with the helmet in place, do not remove the helmet. Immobilize manually and complete the primary survey. If transportation is necessary, the cervical spine should be immobilized with the helmet and shoulder pads in place. A CID, towels, or blanket rolls may be used to immobilize the head on a back board. The face mask may be removed.
3. If the football helmet does not fit correctly or the airway is not maintainable with the helmet in place, then the helmet needs to be removed.
4. The in-charge rescuer should designate a trained rescuer (rescuer II) to manually control the cervical spine. The in-charge rescuer should kneel beside the patient and remove the chin strap, ear pads, and remove the face mask retainers. (If not already done) A third rescuer should prepare padding for use to keep the spine in a neutral position.

5. The in-charge rescuer should then take control of the cervical spine from a side position to the patient. Rescuer II should then relinquish control of the cervical spine to the in-charge rescuer.

6. Rescuer II should remove the helmet by spreading the sides of the helmet and removing it from the head without moving the cervical spine. The in-charge rescuer should be prepared to hold the head, as when the helmet is removed there will be an increase in weight. Padding may need to be inserted under the patient's head to maintain neutral position. Cervical spine control should then be maintained by rescuer II.

7. If shoulder pads need to be removed, the helmet should be removed prior to the shoulder pads. When removing shoulder pads remove the straps and lift on side of the pads prior to log-rolling. Then after rolling the patient on their side, finish removing the shoulder pads. A cervical immobilization device (CID) pad or a 1” pad may be sufficient to maintain neutral alignment of the cervical spine.

8. Immobilize on a long backboard using a cervical collar, straps, and a cervical immobilization device. Continue the assessment.
Combative Patient Restraint - Adult & Pediatric:

There are many reasons why a patient may be combative – mental illness, drug/alcohol ingestion, post-ictal state, hypoxia, traumatic head injuries or from an unknown etiology. The priority when caring for medical patients who present with combative behavior is to identify and treat the underlying cause. 

Note: Prior to restraining a patient, the EMS provider must assess the patient’s mental status and determine whether the patient presents a potential or definite life threat to themselves or others.

Patient Management:

If patient has an altered mental status:

- Ensure adequate assistance is available to restrain the patient.
- All personnel should be instructed as to how the patient will be restrained. This will ensure the safety of the patient as well as emergency personnel.
- Restrain the patient.
- Document.
- Assess the patient continuously to prevent complications until turned over to ED personnel.

Restraint procedure:

1. Soft medical restraints only are secured to each extremity.
2. Place patient supine on a long backboard (LBB).
3. Both lower extremities are secured to the LBB.
4. Left arm is secured to the LBB beside the patient’s body.
5. Right arm is flexed above the patient’s head and secured to the LBB by the wrist.
6. Patient’s body is secured to the LBB using straps.
7. Perform a complete assessment on the patient and reassess every 5 minutes.
8. Notify the receiving facility of transport.
9. Consider the use of chemical restraint (See Behavioral / Psychological Emergencies Protocol).
10. The use of medication mandates continuous observation by the paramedic, to prevent respiratory arrest, insufficiency, or aspiration.
Suicidal patient who is alert and oriented as normal and refusing transport:

1. Attempt to convince the patient to allow transport, use family and/or friends to assist. However, family/friends may agitate the patient and need to be distanced.
2. Request the assistance of the Metropolitan Police Department (MPD).
3. All personnel should be instructed as to how the patient will be restrained. This will ensure the safety of the patient as well as emergency personnel.
4. Restrain the patient.
5. Perform a complete assessment on the patient and reassess every 5 minutes.
6. Notify the receiving facility of transport and ask for security personnel to be available upon arrival, if needed.

Documenting a Restraint Procedure:

1. Reason(s) why restraint was necessary.
2. Any assessment findings obtained through observation (injuries, behavior, mental status, etc.) prior to restraining.
3. Describe the position in which the patient was restrained.
4. Time the patient was restrained.
5. Assessment findings after the patient was restrained and during transport.
6. Once the patient is restrained, one EMS provider must remain with the patient at all times.

Note: Do not place or allow any restraint to impair circulation or respirations. The dignity of the patient must be considered during and after the restraining process.
Clinical Indications:

- A tourniquet may be used to control potentially fatal hemorrhage and shall be the first action along with appropriate airway ventilation and circulation when indicated.

Precautions:

- A tourniquet applied incorrectly can increase blood loss.
- Injury due to tourniquet is unlikely if the tourniquet is removed within 1 hour. In cases of life threatening bleeding benefit outweighs theoretical risk.
- A commercially made tourniquet is the preferred tourniquet. If none is available, a blood pressure cuff inflated to a pressure sufficient to stop bleeding is an acceptable alternative.
- Other improvised tourniquets are not allowed.

Procedure:

- First attempt to control hemorrhage by using direct pressure over bleeding area while applying tourniquet proximally
- If arterial bleeding is significant or unable to control hemorrhage using direct pressure, apply tourniquet according to manufacturer specifications and using the steps below:
  - Cut away any clothing so that the tourniquet will be clearly visible. NEVER obscure a tourniquet with clothing or bandages.
  - Apply tourniquet proximal to the wound and not across any joints.
  - Tighten tourniquet until bleeding stops. Applying tourniquet too loosely will only increase blood loss by inhibiting venous return.
  - Mark the time and date of tourniquet application.
  - Keep tourniquet on throughout hospital transport – a correctly applied tourniquet should only be removed by the receiving hospital.
  - Consider use of Pain control with a Narcotic or Ketamine if narcotic is unavailable.
Clinical Indications:
- Continuous lavage to the cornea, conjunctiva, and cul-de-sac due to injuries secondary to solvents, gasoline, detergents, alkali burns, non-embedded foreign bodies, foreign body sensation without visible debris, and severe infection

Contraindications:
- Penetrating eye injuries
- Suspected or actual rupture of the globe
- To place known allergens into ocular space

Insertion Procedure:
- Instill topical ocular anesthetic (e.g. 2 drops of Tetracaine.)
- Attach Morgan Lens to sterile IV tubing and prime with solution (saline bag.)
- Have patient look down, retract upper lid and insert Morgan Lens under lid.
- Have patient look up, retract lower lid and gently place lens.
- Release lower lid over lens and ensure steady, copious flow.
- Secure tubing to prevent accidental lens removal. Absorb outflow with extra towels and sheets.
- Irrigate with at least 1 Liter of fluid and DO NOT RUN DRY.

Removal Procedure:
- Ensure flow of solution is continuing.
- Have patient look up and retract lower lid and upper lid if necessary.
- Gently slide Morgan Lens out.
- Stop flow of solution only after removing lens completely from eye.

Document procedure completely, including solution and volume used to irrigate.
Clinical Indications:

- Cardiac arrest when an endotracheal tube has been placed and venous or IO access is unobtainable. IV/IN/IO are the preferred routes of administration of life saving medication.

Medications that can be administered by endotracheal route:

- Narcan
- Atropine
- Epinephrine
- Lidocaine
- Midazolam (Versed)

Procedure:

1. Ensure that the correct medication, patient, dosage, time is identified.
2. Hyperventilate the patient with 4-5 breaths and remove BVM.
3. If the BVM has a supplied medication port, administer medication through the medication port and ventilate the patient.
4. If the BVM does not have a supplied medication port:
   - Hyperventilate the patient.
   - Disconnect the BVM.
   - Administer medication via the endotracheal tube.
   - Re-attach the BVM and ventilate the patient to allow the medication to reach the bronchial tree so it can be absorbed into the bloodstream.
5. Medications administered via endotracheal route, should be administered at twice the IV dose and should be diluted with sterile normal saline to a volume of at least 10 ml for adults and 1-5 ml for pediatric patients.
Clinical Indications:

- Patient without IV access requiring urgent medication administration (e.g., active seizure, respiratory arrest secondary to opiate overdose, hypoglycemia or pain management).

Medications that can be administered by intranasal route:

- Narcan
- Glucagon
- Midazolam (Versed)
- Fentanyl

Procedure:

1. Determine appropriate medication dose per applicable protocol.
2. Draw medication into syringe and carefully dispose of sharps if the medication is drawn from a vial. If medication is needle-less, attach mucosal atomizer device directly to syringe.
3. Gently insert the atomizer into the nare and stop once resistance is met.
4. Rapidly administer the medication.
5. If the medication is ≥1 ml, administer half of the medication in one nare and the other half in the other nare.
Clinical Indications:

- Patient’s condition warrants medication to improve or stabilize condition.

Precautions:

- Observe universal precautions and ensure body substance isolation (BSI).
- Be certain that the route you choose to use is appropriate for the drug; see specific protocols or medication formulary.
- Be certain the drug you want to administer is the one you use.
- Check expiration dates, dosages and routes before administration.
- Use sterile technique for drawing up medications and filling syringes.
- Rapid administration of drugs can cause untoward effects, avoid them by administering the drugs according to protocol.
- Always check for extravasation, especially when administering dextrose and dopamine.

Procedures:

**IV Administration (ALS - AEMT)**

1. Use appropriate needless cannula or luer lock syringe for solution.
2. Cleanse injection port with alcohol.
3. Insert needless cannula or syringe onto injection port.
4. Clamp Pinch IV tubing between port and IV bag; inject medication slow or rapid as required.
5. Release tubing and follow medication with a 10-20 ml fluid bolus.
6. Record medication given, concentration of dose, amount given and time.

**IO Administration (ALS - AEMT)**

1. Establish intraosseous line per protocol.
2. Prepare medication.
3. Cleanse injection port with alcohol, inject medication and flush with saline.
4. Record medication given, concentration of dose, amount given and time.

- **Note:** Any medication that can be administered via IV access may be administered via IO access in the same manner and at the same dose as indicated by the protocol for IV administration.
**IM Administration (ALS - AEMT)**

1. Use 1.0 to 1.5 inch, 21-23 gauge needle.
2. Select site, usually deltoid or gluteal muscles.
3. Cleanse site with alcohol.
4. Eject air from syringe.
5. Insert needle at 90 degree angle.
6. Aspirate, if no blood return, inject medication.
7. Apply pressure to site, cover with sterile dressing.
8. Record medication given, concentration of dose, amount given and time.

**SQ Administration (ALS - AEMT)**

1. Use ¾ inch to 1 inch, 23-25 gauge needle.
2. Select site, usually lateral mid 1/3 arm.
3. Cleanse site with alcohol.
4. Eject air from syringe.
5. Insert needle at 45 degree angle, bevel up.
6. Aspirate, if no blood return, inject medication.
7. Cover with sterile dressing.
8. Record medication given, concentration of dose, amount given and time.

**Nebulized Administration (ALS - BLS)**

1. Medication is measured and introduced into nebulizer.
2. Attach oxygen tubing to the nebulizer and adjust flow rate to 10 lpm or as prescribed by the manufacturer’s recommendations.
3. Patient is instructed to breathe deeply and to hold a deep inspiration every 4-5 breaths.
4. Patient is monitored throughout procedure per protocol.
5. Treatment is continued until all medication is administer or is discontinued due to complication in patient condition.
6. Record medication given, concentration of dose, amount given and time.
The following medications have been approved by the Medical Director and the District of Columbia Department of Health (DOH) to be utilized by EMS providers within the District of Columbia Fire and EMS Department:

- Acetylsalicylic Acid (Aspirin) ................................. ALS - BLS
- Adenosine (Adenocard) ...................................... ALS
- Albuterol Sulfate (Proventil) ............................... ALS - BLS
- Amiodarone (Cardorone) .................................... ALS
- Atropine Sulfate ................................................ ALS
- Calcium Chloride 10% ........................................ ALS
- Dextrose 50%, 25%, 10% ........................................ ALS - AEMT
- Diazepam (Valium) (ChemPack) ......................... ALS
- Diltaize (Cardizem) ............................................ ALS
- Diphenhydramine HCL (Benadryl) ....................... ALS - AEMT
- Dopamine (Intropin) .......................................... ALS
- Enalaprat (Vasotec) ............................................ ALS
- Epinephrine HCL 1:1.000 / 1:10,000 (Adrenalin) ...... ALS - BLS
- Etomidate (Amidate) .......................................... ALS
- Fentanyl (Sublimaze) (Controlled Medication) ....... ALS
- Furosemide (Lasix) ............................................ ALS
- Glucagon HCL .................................................. ALS - AEMT
- Glucose (Oral) .................................................. ALS - BLS
- Haloperidol (Haldol) ......................................... ALS
- Hydrocortisone (Solu-cortef) ............................... ALS - AEMT
- Hydroxocobalamin (Cyanokit) ............................. ALS
- Ipratropium Bromide (Atrovent) ......................... ALS - BLS
- Ketamine (Ketalar) (Controlled Medication) ......... ALS
- Labetalol (Normodyne) ..................................... ALS
- Lidocaine HCL (Xylocaine) ................................. ALS
- Magnesium Sulfate .......................................... ALS
- Methylprednisolone Sodium Succinate (Solu-Medrol) ALS
- Midazolam HCL (Versed) (Controlled Medication) .. ALS
- Morphine Sulfate (Controlled Medication) ............. ALS
- Naloxone HCL (Narcan) .................................... ALS - BLS
- Nitroglycerin (Nitrostat) .................................... ALS - BLS
- Ondansetron (Zofran) ....................................... ALS
- Oxygen ........................................................... ALS - BLS
- Prednisone ....................................................... ALS
- Pralidoxime Chloride / 2-pam CL (WMD) ............... ALS - BLS
- Prochlorperazine (Compazine) ............................ ALS
- Racemic Epinephrine ......................................... ALS
- Sodium Bicarbonate ......................................... ALS
- Sodium Chloride 0.9% ....................................... ALS - BLS
- Tetracaine Hydrochloride .................................. ALS - BLS
- Tranexamic Acid (TXA, Cyklokapron) .................. ALS
Class:
- Analgesic, anti-inflammatory, antipyretic, anti-platelet aggregator.

Actions:
- Irreversibly inactivates cyclooxygenase and blocks platelet aggregation, thus reducing propagation of clot in coronary vessels during MI. Blocks pain impulses in the CNS as a NSAID.

Indications:
- Chest pain or discomfort suggestive of MI or cardiac ischemia.

Contraindications:
- Hypersensitivity.
- Sign or symptoms of acute CVA (may be a intracerebral bleed)

Precautions:
- Any significant active bleeding.

Adverse Reactions:
- Gastritis, nausea and vomiting.

Adult Dosage / Route:
- 324 mg / 4-81 mg baby aspirin PO if not taken during the previous 24 hours.

Pediatric Dosage / Route:
- Not indicated.
Class:

- Antiarrhythmic.

Actions:

- Adenosine is a naturally occurring substance present in all cells that slows conduction through the AV node of the heart. Because of its rapid onset of action and short half-life, the administration of Adenosine is sometimes referred to as "chemical cardioversion".

Indications:

- Paroxysmal Supraventricular Tachycardia (PSVT) refractory to common vagal maneuvers.
- Stable Monomorphic Wide Complex Tachycardia.

Contraindications:

- 2nd and 3rd degree heart blocks.
- Sick sinus syndrome.
- Hypersensitivity.
- History of WPW or in the presence of "Delta waves".

Precautions:

- May cause transient dysrhythmias.
- Effects antagonized by theophylline.
- May cause bronchospasm in asthma patients.

Adverse Reactions:

- Dyspnea.
- Nausea.
- Headache.
- Dizziness.

Adult Dosage / Route:

- 6 mg rapid IV followed by a rapid 10-20 ml flush.
- If no response after initial dose in 2 minutes, administer 12 mg rapid IV push followed by a rapid 10-20 ml flush.

Pediatric Dosage / Route:

- **Initial dose**: 0.1 mg/kg rapid IV/IO. If required **second dose**: 0.2 mg/kg rapid IV/IO. **Medical Control Required**.
Class:
- Sympathetic agonist.

Actions:
- A synthetic sympathomimetic that causes bronchodilation with reduced Beta 1 cardiac effects. Beta 2 adrenergic.

Indications:
- Bronchial asthma.
- Bronchospasm associated with chronic bronchitis, emphysema, allergic reaction, toxic inhalation, pulmonary edema and congestive heart failure.
- Crush injuries with prolonged extrication.

Contraindications:
- Hypersensitivity.
- Uncontrolled cardiac dysrhythmias.

Precautions:
- Caution should be exercised in patients with a cardiac history.

Adverse Reactions:
- Palpitations.
- Anxiety.
- Dizziness.
- Headache.
- Nervousness.
- Arrhythmias.
- Nausea / vomiting.

Adult Dosage / Route:
- 2.5 mg administered by nebulizer.
- BLS Providers may administer 5.0 mg without medical control.
- ALS Providers may administer 7.5 mg without medical control.
- ALS Providers may administer continuous Albuterol without medical control if patient is in moderate to severe distress or respiratory failure is impending (Asthma / COPD).
Pediatric Dosage / Route:

- 2.5 mg administered by nebulizer.
- BLS Providers may administer 5 mg without order.
- ALS Providers may administer 7.5 mg without order.
Class:

- Class III Antiarrhythmic.

Actions:

- Prolongs phase 3 of the action potential, duration, and refractory period in myocardial cells; acts as noncompetitive inhibitor of alpha- and beta-adrenergic receptors. It also has sodium and potassium channel blocker actions.

Indications:

- Ventricular Tachycardia with a Pulse.
- Pulseless Ventricular Tachycardia.
- Ventricular Fibrillation.

Contraindications:

- Known hypersensitivity to the drug.
- Marked sinus bradycardia.
- Second- and third-degree AV block.
- Cardiogenic shock.
- Hypokalemia, Hypomagnesemia (need to be corrected prior to Amiodarone use).

Precautions:

- May cause burning at site of administration.

Adverse Reactions:

- Cardiac: Hypotension, bradycardia, AV block, arrhythmias.
- Respiratory: Interstitial pneumonitis, ARDS.
- CNS: Malaise, muscle fatigue, ataxia, dizziness, and paresthesias.

Adult Dosage / Route:

Ventricular Tachycardia with a Pulse

- 150 mg mixed in 100 ml Normal Saline infused over 10 minutes. May be repeated one time in 10 minutes.

Pulseless Ventricular Tachycardia and Ventricular Fibrillation

- Initial dose: 300 mg IV/IO.
- Second dose: 150 mg IV/IO.
- Third dose: 150 mg IV/IO.
Return of Spontaneous Circulation (ROSC)

- 150 mg mixed in 100 ml Normal Saline and infused over 10 minutes.

Pediatric Dosage / Route:

Ventricular Tachycardia with a Pulse

- Contact Medical Control.

Pulseless Ventricular Tachycardia and Ventricular Fibrillation

- Initial dose: 5 mg/kg IV/IO.
- Repeat doses: 5 mg/kg IV/IO.
- Maximum total dose: 15 mg/kg IV/IO.

Return of Spontaneous Circulation (ROSC)

- 5 mg/kg slow infusion. Mix dose in 100 ml NS. Utilize a 10 gtts set and infuse at 100 gtts/minute over 10 minutes.
ATROPINE SULFATE

Class:
- Anticholinergic / Parasympatholytic agent.

Actions:
- Blocks acetylcholine receptors in organophosphate poisonings.
- Reverses suspected vagal tone in bradycardia, asystole, and PEA.

Indications:
- Symptomatic bradycardia
- Organophosphate poisoning.
- WMD Nerve Agent poisoning.

Contraindications:
- Use with caution in high degree blocks (2\textsuperscript{nd} degree Type II and 3\textsuperscript{rd} degree).

Precautions:
- If given too slowly, can cause transient bradycardias.
- Use caution when administering to patients with glaucoma.

Adverse Reactions:
- Palpitations.
- Tachycardia.
- Dilated pupils.
- Dry mouth.
- Blurred vision.

Adult Dosage / Route:

Bradycardia (ALS Only)
- 0.5 mg IV. Repeat once in 5 minutes if the patient remains symptomatic.

Organophosphate Poisoning / WMD (ALL PROVIDER LEVELS)

Auto-Injectors: DuoDote\textsuperscript{TM}
- 2 mg IM via DuoDote\textsuperscript{TM} auto-injector every 10-15 minutes to a maximum total dose of three DuoDote\textsuperscript{TM} auto-injectors.

Auto-Injectors: Mark 1 NAAK
- 2 mg via auto-injector every 10 minutes.
Otherwise
• 1-2 mg IV/IO after exhausting auto-injector series repeat every 10 minutes as needed.

Pediatric Dosage / Route:

Bradycardia (ALS Only)
• 0.02 mg/kg IV/IO, minimum dose of 0.1 mg and a maximum of 0.5 mg.

Organophosphate Poisoning / WMD – ALL PROVIDER LEVELS

Auto-Injectors DuoDote™
• Patients weighing 12 kg or greater administer 2 mg atropine via DuoDote™ auto-injector every 20 minutes to a maximum total dose of three DuoDote™ auto-injectors.

Auto-Injectors Mark 1 NAAK
• Ages 8 or greater: 2 mg IM via AtroPen, repeat every 20 minutes as needed.

Auto-Injectors AtroPen (CHEMPACK)
• Ages 3 or less: 0.5 mg IM via AtroPen, repeat every 20 minutes as needed.
• Ages 3-7: 1 mg IM via AtroPen, repeat every 20 minutes as needed.

Otherwise
• 0.05 mg/kg IV/IO after exhausting auto-injector series (maximum single dose of 2 mg), repeat every 20 minutes as needed.

Special Pediatric Instructions

If a WDM MCI event occurs and pediatric AtroPen auto-injectors are not readily available from the CHEMPACK cache then providers shall administer either one (1) DuoDote™ auto-injector or one (1) complete Mark 1 kit to any pediatric patient who is displaying moderate/severe signs of nerve agent or organophosphate poisoning. Repeat dose every 20 minutes.
CLASS: Electrolyte, calcium supplement.

Actions:
- Increases myocardial contractile force and ventricular automaticity.
- Balances hyperkalemia.
- Aids in the re-entry of calcium into muscle when given for calcium channel blocker or magnesium sulfate toxicity.

Indications:
- Known or suspected hyperkalemic cardiac arrest (renal patient).
- Magnesium sulfate toxicity.
- Calcium channel blocker toxicity (toxicity may be caused by overdose of calcium channel blocker medications such as Nifedipine, Verapamil, etc.

Contraindications:
- Digitalis toxicity (Calcium chloride worsens arrhythmias secondary to digitalis toxicity).

Precautions:
- Sodium bicarbonate precipitates with Calcium chloride. Therefore, flush the IV line with 10 ml of Normal Saline between administrations of these two medications.

Adverse Reactions:
- Tissue necrosis if the IV infiltrates.
- Bradycardia, hypotension or asystole can occur with rapid injection.

Adult Dosage / Route:
- 1 gm IV. Slow administration for patients with a palpable pulse when treating crush syndrome or patients with profound hypotension after the administration of diltiazem.
- 1 gm IVP when treating patients in cardiac arrest.

Pediatric Dosage / Route:
- 20 mg/kg IV. Slow administration for patients with a palpable pulse.
Class:

- Carbohydrate.

Actions:

- Increases blood glucose levels.

Indications:

- Hypoglycemia.

Contraindications:

- Suspected intracranial hemorrhage.
- Known or suspected CVA in the absence of hypoglycemia.

Precautions:

- Blood glucose measurement is preferred prior to the administration of glucose.

Adverse Reactions:

- Dextrose can cause local venous irritation and tissue necrosis if infiltration occurs.

Adult Dosage / Route (AEMT - ALS):

- >12 years, administer 25 gm slow IV. May repeat once if BGL remains <70 mg/dl.

Pediatric Dosage / Route (ALS Only):

- 1 month to 12 years, dilute 1:1 and administer 2 ml/kg of D25.
- Newborn to 1 month, dilute 1:4 and administer 5 ml/kg of D10.
Class:

- Benzodiazepine.

Actions:

- Increases the inhibitory processes in the cerebral cortex.

Indications:

- Sustained or recurrent seizure activity following nerve agent or organophosphate exposure.

Contraindications:

- Known hypersensitivity to the drug.

Precautions:

- Should be used with caution in patients with AMS, hypotension, or acute angle glaucoma.
- May cause respiratory depression.
- May cause CNS depression in patients that have consumed alcohol or other sedatives.

Adverse Reactions:

- Neuro: Motor impairment, ataxia, confusion, slurred speech, and lightheadedness.
- Cardio: Hypotension

Adult Dosage / Route:

- Auto-Injector: 10 mg IM repeated every 10 minutes until cessation of seizure activity.
- IV: 2-10 mg IV max 20 mg without medical Control (Secondary replacement medication for Midazolam).

Pediatric Dosage / Route:

- Auto-Injector: If greater than 33 kg (72 pounds): 10 mg IM.
- From medication vial: If less than 33 kg: 0.3 mg/kg IV/IO/IM over 2-3 minutes to a maximum single dose of 10 mg.
Class:
- Calcium ion influx inhibitor (Slow Calcium Channel Blocker).
- Antiarrhythmic.

Actions:
- Inhibits the influx of calcium (Ca2+) ions during membrane depolarization of cardiac and vascular smooth muscle. The therapeutic benefits of diltiazem in supraventricular tachycardias are related to its ability to slow AV nodal conduction time and prolong AV nodal refractoriness.
- Decreases sinoatrial and atrioventricular conduction and has a negative inotropo effect.

Indications:
- Symptomatic Atrial Fibrillation or Atrial Flutter with Rapid Ventricular Response.
- Symptomatic Paroxysmal Supraventricular Tachycardia (PSVT).

Contraindications:
- Known hypersensitivity to the drug.
- Hypotension with systolic pressure less than 90 mmHg.
- Congestive Heart Failure.
- Acute MI.
- Sick sinus syndrome.
- Second- or third-degree AV block, except with functioning pacemaker.
- Presence of Wolfe Parkinson White (WPW).

Precautions:
- Interactions: additive effects if used with βeta Blockers.
- The elimination half-life of midazolam increases during co-administration with diltiazem. This can result in prolonged sedation when co-administered with midazolam.

Adverse Reactions:
- Cardiac: Hypotension, bradycardia, AV block.

Adult Dosage / Route:
- Initial Dose: 0.25 mg/kg slow IV over 2 minutes.
- Second Dose administered 15 minutes after initial dose: 0.35 mg/kg slow IV over 2 minutes.
Pediatric Dosage / Route:

- Not Indicated.
Class:

- Potent antihistamine.

Actions:

- Block histamine receptor sites in allergic reactions.
- Reverses side effects of dystonic reactions caused by phenothiazines.

Indications:

- Anaphylaxis.
- Allergic reactions.
- Dystonic reactions.
- Nausea when administered in combination with Prochlorperazine

Contraindication:

- Hypersensitivity.

Precautions:

- Use with caution in patients that are pregnant, history of asthma, or experiencing severe intoxication.

Adverse Reactions:

- Hypotension.
- Headache.
- Palpitations.
- Tachycardia.
- Sedation.
- Drowsiness.

Adult Dosage / Route (AEMT - ALS):

- 25-75 mg, slow IV/IM.

Pediatric Dosage / Route (ALS Only):

- 1 mg/kg, slow IV/IM up to a maximum dose 50 mg.
Class:
  - Sympathomimetic.

Actions:
  - At low doses (2-5 mcg/kg/min), increases perfusion to kidneys and abdominal organs.
  - At moderate doses (5-10 mcg/kg/min), increases force and rate of ventricular contractions (Beta 1 effects).
  - At high doses (10-20 mcg/kg/min), peripheral vasoconstrictor (Alpha 1 effects).

Indications:
  - Hypovolemic shock with sufficient fluid resuscitation.
  - Cardiogenic shock.
  - Septic shock.
  - Anaphylactic shock.

Contraindications:
  - Should not be used in the management of hypovolemia until sufficient volume replacement is achieved.
  - Pre-existing tachydysrhythmias.

Precautions:
  - Do not mix with Sodium Bicarbonate.
  - Continue to monitor EKG, blood pressure and heart rate.

Adverse Reactions:
  - Nervousness.
  - Headache.
  - Dysrhythmias.
  - Hypertension.
  - Nausea / vomiting.

Adult Dosage / Route:
  - 5-20 mcg/kg/min via infusion.

Pediatric Dosage / Route:
  - 5-20 mcg/kg/min via infusion.
Class:
- Angiotensin Converting Enzyme (ACE) Inhibitor

Actions:
- Inhibits conversion of angiotensin I to angiotensin II. Resulting in decrease afterload and decreased aldosterone secretion.

Indications:
- CHF
- Hypertension with pulmonary edema

Contraindications:
- Hypotension (SBP 110 mmHg).
- Pregnancy.
- Known sensitivity to ACE inhibitors.

Precautions:
- Interactions: additive effects if used with βeta Blockers.
- The elimination half-life of midazolam increases during co-administration with Diltiazem. This can result in prolonged sedation when co-administered with midazolam.

Adverse Reactions:
- Cardiac: Hypotension, Dizziness due to orthostatic hypotension.

Adult Dosage / Route:
- 1.25 mg IV.

Pediatric Dosage / Route:
- Medical Control Required.
**EPINEPHRINE HCL**

1:1,000 and 1:10,000

Medication Formulary

**Class:**
- Sympathomimetic.

**Actions:**
- A potent alpha and beta stimulant that increases heart rate, cardiac contractile force, myocardial electrical activity, systemic vascular resistance, blood pressure and automaticity. Increases myocardial oxygen demand.

**Indications:**
- Cardiac arrest.
- Severe anaphylaxis.
- Bronchial asthma.

**Contraindications:**
- Hypertension.
- Pre-existing tachydysrhythmias with a pulse.

**Precautions:**
- Use with caution in patients with a history of coronary artery disease because Epinephrine may precipitate acute MI.
- Use with caution in pregnant patients.
- Do not mix with Sodium Bicarbonate.

**Adverse Reactions:**
- Palpitations.
- Anxiety.
- Tremors.
- Headache.
- Dizziness.
- Nausea / vomiting.

**Adult Dosage / Route:**

**Cardiac Arrest**
- 1:10,000 1 mg IV/IO every 3-5 minutes for the duration of the arrest.
- 1:1,000 2 mg ET diluted in 5 ml saline every 3-5 minutes.

**Severe Anaphylaxis**
- 1:1,000 0.3-0.5 mg IM, repeat as necessary (ALS).
- 0.3 mg IM via Auvi-Q (BLS or ALS).
Severe Asthma

- 1:1,000 0.3 mg IM (ALS).
- 0.3 mg IM via Auvi-Q (BLS or ALS).

Pediatric Dosage / Route:

Cardiac Arrest

- 1:10,000 0.01 mg/kg IV/IO every 3-5 minutes for the duration of the arrest.
- 1:1,000 0.1 mg/kg ET diluted in 1-5 cc saline every 3-5 minutes.

Bradycardia

- 1:10,000 0.01 mg/kg IV/IO.
- 1:1,000 0.1 mg/kg ET.
- 0.1-1 mcg/kg/min infusion. If <10 kg mix 0.4 mg 1:1,000 in a 100 ml NS for a concentration of 4 mcg/ml. Infuse with a 60 gtts set for the desired dose. If >10 kg mix 0.8 mg 1:1,000 in a 100 ml NS for a concentration of 8 mcg/ml. Infuse with a 60 gtts set for the desired dose.

Severe Anaphylaxis

- 1:1,000 0.01 mg/kg IM, up to a maximum single dose of 0.5 mg. May repeat once in 5 minutes (ALS).
- Auvi-Q 0.15 mg IM for patient’s ≤3 years of age. May repeat once in 5 minutes (BLS or ALS).
- 0.1-1 mcg/kg/min infusion. If <10 kg mix 0.4 mg 1:1,000 in a 100 ml NS for a concentration of 4 mcg/ml. Infuse with a 60 gtts set for the desired dose. If >10 kg mix 0.8 mg 1:1,000 in a 100 ml NS for a concentration of 8 mcg/ml. Infuse with a 60 gtts set for the desired dose.
Class:
- Hypnotic medication without analgesic activity.

Actions:
- Believed to have GABA like effects. The exact mechanism is unknown.

Indications:
- Respiratory Failure/Respiratory Arrest.
- Medication Facilitated Intubation.
- Sedation during CPR

Contraindications:
- Hypotension.
- Adrenal insufficiency.
- Laryngospasm.
- Active labor.
- Known hypersensitivity to Etomidate.

Precautions:
- Rapid onset when used as anesthetic.

Adverse Reactions:
- Respiratory: Apnea.
- Musc.-Skeletal: Transient skeletal muscle movements.
- GI: Nausea.

Adult Dosage / Route:
- 0.3 mg/kg IV/IO over 1 minute, maximum of 30 mg. May repeat dose once if Trismus (reduced opening of the jaw caused by spasm) is present or further sedation is required.

Pediatric Dosage / Route:
- Less than 10 years of age: Not indicated.
- Patients that are age 10 years or greater: Medical Control Required.
Class:
  - Synthetic Narcotic Analgesic.

Actions:
  - Binds to opioid receptors.

Indications:
  - Acute Coronary Syndrome/Chest Pain.
  - Pain Management.
  - Burns Thermal/Chemical.

Contraindications:
  - Hypotension.
  - Respiratory depression.
  - Traumatic brain injury.

Precautions:
  - May cause respiratory depression.
  - Onset is almost immediate when administered via IV.

Adult Dosage / Route:
  - If the patient exhibits signs / symptoms of hypoperfusion Contact Medical Control for Fentanyl
  - In patients 65 years old and greater consider an initial dose of half your normal adult dose when administering opiates (Morphine / Fentanyl).

Pain Management
  - 25-50 mcg IV per dose every 5 minutes to a maximum of 200 mcg. Use 25 mcg for the elderly or a weight under 70 kg.

Burn Management
  - 50-100 mcg IV per dose every 5 minutes to a maximum of 200 mcg. Use 25 mcg for the elderly or a weight under 70 kg.

Pediatric Dosage / Route:
  - 1 mcg/kg IV/IO/IN up to a maximum single dose of 50 mcg. Medical Control Required for additional doses.
Class:
- Loop diuretic.

Actions:
- A potent diuretic that inhibits sodium re-absorption by the kidneys.
- Vasodilatation of the pulmonary veins.

Indications:
- Acute pulmonary edema.
- Congestive heart failure.
- Hypertension.

Contraindications:
- Hypersensitivity.
- Known allergy to sulfonamides.
- Dehydrated patients.
- Pregnancy.
- Hypotension.

Precautions:
- Severe dehydration and electrolyte depletion may occur from excess doses of Furosemide.

Adverse Reactions:
- Dehydration.
- Decreased circulatory blood volume.
- Decreased cardiac output.
- Loss of electrolytes.

Adult Dosage / Route:
- 20-40 mg slow IV. Medical Control Required

Pediatric Dosage / Route:
- 0.5 mg/kg IV. Medical Control Required
Class:
- Pancreatic hormone.
- Anti-hypoglycemic.

Actions:
- Converts stored glycogen to glucose, increasing blood glucose levels.
- Improves cardiac contractility and increases heart rate.

Indications:
- Hypoglycemia when IV access is unobtainable (should not be a first line treatment for hypoglycemia when IV access is available).
- Beta blocker and calcium channel blocker overdose with bradycardia.
- Allergic Reaction / Anaphylaxis.

Contraindications:
- Hypersensitivity to proteins.

Precautions:
- Administer cautiously to patients with kidney and liver dysfunctions.
- Effective only if sufficient stores of glycogen in the liver.

Adverse Reactions:
- Nausea and vomiting.
- Tachycardia.

Adult Dosage / Route:
Hypoglycemia (AEMT - ALS)
- 1 mg IN/IM.

Calcium Channel / Beta Blocker Overdose (ALS Only)
- 1 mg IV every 5 minutes, up to a maximum of 3 mg.

Allergic Reaction / Anaphylaxis not responding to Epinephrine on Beta Blockers (ALS Only)
- 2 mg IVP.
Pediatric Dosage / Route (ALS Only):

Hypoglycemia

- 1 mg IN/IM ≥25 kg. 0.5 mg <25 kg.

Calcium Channel / Beta Blocker Overdose

- 1 mg IV every 5 minutes, up to maximum of 3 mg.

Allergic Reaction / Anaphylaxis

- Medical Control Required.
Class:
- Carbohydrate.

Actions:
- Increases blood glucose level.

Indications:
- Altered mental status secondary to hypoglycemia.
- Beta Blocker overdose

Contraindications:
- Patients unable to protect their own airway.
- Patients unable to swallow.

Precautions:
- Assure that the patient has a gag reflex.

Adverse Reactions:
- Aspiration.
- Nausea and vomiting.

Adult Dosage / Route:
- 25-50 gm PO or one single dose tube. May repeat once.

Pediatric Dosage / Route:
- 0.5 gm/kg PO if the child is < 8 years of age (ALS).
Class:

- Tranquilizer.
- Anti-psychotic.

Actions:

- Strong anti-emetic effect and impairs central thermoregulation. Produces weak central anticholinergic effects and transient orthostatic hypotension due to blockade of dopamine activity.

Indications:

- Management of manifestations of psychotic disorders and for treatment of agitated states in acute and chronic psychoses.

Contraindications:

- Patients with known hypersensitivity.
- Coma.
- Parkinson's disease.
- Alcoholism.
- CNS depression.
- Cocaine overdose.

Precautions:

- Severe cardiovascular disorders (may cause transient hypotension or precipitate angina pectoris).
- Receiving anticonvulsant medication (may lower convulsive threshold).

Adverse Reactions:

- Extra-pyramidal Syndrome (EPS).
- Headache.
- Lethargy.
- Headache.
- Tachycardia.
- Hypotension.

Adult Dosage / Route:

- 5 mg IM. Patients over the age of 65 years, 2.5 mg IM.

Pediatric Dosage / Route:

- Children >12 years of age: 5 mg IM. Medical Control Required
- Children 6-12 years of age: 2 mg IM. Medical Control Required.
HYDROCORTISONE
Solu-Cortef

Class:
- Glucocorticoid steroid.

Actions:
- Acts as an anti-inflammatory glucocorticoid. The exact mechanism is undetermined.

Indications:
- Numerous emergencies in patients with adrenal insufficiency.

Contraindications:
- None in the patients with adrenal insufficiency.

Precautions:
- None.

Adverse Reactions:
- Cardiac: Transient hypertension.

Adult Dosage / Route (AEMT - ALS):
- 100 mg IV/IO/IM.

Pediatric Dosage / Route:
- 2 mg/kg IV/IO/IM to a maximum of 100 mg.
**Class:**
- Antidote.
- Precursor of vitamin B12.

**Actions:**
- Binds with cyanide ions to form cyanocobalamin, which is excreted in the urine.

**Indications:**
- Treatment of cyanide poisoning with altered mental status or symptoms of circulatory compromise.

**Contraindications:**
- Patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin.

**Precautions:**
- Administer slowly over 15 minutes.
- Transient hypertension.

**Adverse Reactions:**
- Hypertension.
- Headache.
- Red-colored urine.
- Headache.
- Nausea.

**Adult Dosage / Route:**
- Initial dose is 5 grams infused over 15 minutes slow IV. (Each 2.5 g vial of hydroxocobalamin for injection is to be reconstituted with 100 ml of Normal Saline and administered at 10-15 ml/minute.) An additional 5 gram dose may be administered with Medical Control order.

**Pediatric Dosage / Route:**
- 70 mg/kg (reconstitute concentration is 25 mg/ml). Each 2.5 g vial of hydroxocobalamin for injection is to be reconstituted with 100 ml of Normal Saline and infused at 10-15 ml/minute. Maximum single dose 5 grams.
Class:
- Anticholinergic.
- Bronchodilator.

Actions:
- Bronchodilatation.
- Dries respiratory tract secretions.
- Most effective in combination with a beta-adrenergic bronchodilator.

Indications:
- Bronchospasm related to asthma, chronic bronchitis, and emphysema.

Contraindications:
- Sensitivity to Atropine.
- Tachydysrhythmias.
- ****The aerosol solution and all new inhalers **DO NOT** contain Soy Lecithin and as such **CAN** be used with patients **with sensitivity to soybeans or peanuts.****

Precautions:
- Administer cautiously to patients with narrow-angle glaucoma.

Adverse Reactions:
- Tachycardia.
- Palpitations.
- Dizziness.
- Headache.
- Dry mouth.

Adult Dosage / Route:
- 2.5 ml (500 mcg) mixed with 2.5 mg Albuterol via nebulizer.

Pediatric Dosage / Route:
- 2.5 ml (500 mcg) mixed with 2.5 mg Albuterol via nebulizer.
Class:
- General Anesthetic.

Actions:
- N-Methyl d-aspartate (NMDA) receptor antagonist.

Indications:
- Crush injuries with prolonged extrication and potential compartment syndrome for pain and sedation.
- Analgesia if Narcotic pain medication not available.

Contraindications:
- AMI.
- Uncontrolled severe Hypertension.

Precautions:
- May have additive and/or synergistic effects when other sedatives are present.

Adverse Reactions:
- Cardiac: Hypertension, Flushing, Palpitations.
- GI: Increased oral secretions, Nausea & Vomiting.
- Respiratory: Increased secretions, bronchorrhea

Adult Dosage / Route:

Pain Management
- 0.2 mg/kg IV/IO/IM administered over 1 minute. May repeat once in 5 minutes as needed.

Crush Injuries
- 0.2 mg/kg IV/IO/IM administered over 1 minute. May repeat every 5 minutes for a total of three (3) doses to ensure provider safety during extrication.

Pediatric Dosage / Route:
- Contact Medical Control. Anticipate orders for 0.1-0.2 mg/kg IV/IM/IO.
Class:
- Alpha and βeta Blocker.

Actions:
- Direct acting alpha antagonist and non-selective beta antagonist.

Indications:
- Hypertensive crisis.
- CVA / Brain attack.

Contraindications:
- Asthma.
- Hypotension.
- Brady Dysrhythmias.
- CHF.
- Cardiogenic shock.
- Heart blocks of any degree.

Precautions:
- Interactions: additive effects if used with βeta Blockers.
- Must obtain Medical Control order to administer with signs and symptoms of CVA from receiving Stroke Center.

Adverse Reactions:
- Cardiac: Hypotension.
- GI: Nausea and vomiting.
- Resp.: Bronchospasm.

Adult Dosage / Route:
- 10-20 mg slow IV over 1-2 minutes repeated in 5 minutes to a total of three doses as long as SBP is greater >180 mm/Hg.

Pediatric Dosage / Route:
- Medical Control Required
Class:

- Antiarrhythmic.
- Local anesthetic.

Actions:

- Suppresses ventricular ectopy.
- Blocks conduction of pain impulses.

Indications:

- Ventricular fibrillation.
- Ventricular tachycardia.
- Multifocal or frequent PVC’s (>6 per minute).
- Medication Facilitated Intubation with suspected head injury.
- ROSC following the use of Lidocaine as the primary antiarrhythmic medication.
- Intraosseous line anesthesia.

Contraindications:

- Ventricular escape rhythms with bradycardia.
- 2° type II and 3° heart blocks.
- Bradycardia.

Precautions:

- Use caution in patients over the age 65.
- History of liver disease or dysfunction.

Adverse Reactions:

- Muscle twitching.
- Slurred speech.
- Coma.
- Hypotension.
- Altered mental status.

Adult Dosage / Route:

**Ventricular Fibrillation / Pulseless Ventricular Tachycardia**

- 1 mg/kg IV/IO may be repeated every 5 minutes up to a maximum of 3 mg/kg.
Ventricular Tachycardia with a pulse

- 1 mg/kg IV/IO may be followed by 0.5 mg/kg every 5 minutes, up to a maximum of 3 mg/kg.

Return of Spontaneous Circulation (ROSC)

- 0.5 mg/kg IV/IO repeated every 5 minutes to a maximum dose of 3 mg/kg.

Medication Facilitated Intubation

- 1.5 mg/kg IV/IO.

Intraosseous Line Anesthesia

- 20-40 mg IO (2-4 ml 1% Cardiac Lidocaine) and allow 1-2 minute settle time.

Pediatric Dosage / Route:

Ventricular Fibrillation / Pulseless Ventricular Tachycardia

- 1 mg/kg IV/IO may be repeated every 5 minutes up to a maximum of 3 mg/kg.

Ventricular Tachycardia with a pulse

- 1 mg/kg IV/IO may be followed by 0.5 mg/kg every 5 minutes, up to a maximum of 3 mg/kg.

Return of Spontaneous Circulation (ROSC)

- 0.5 mg/kg IV/IO repeated every 5 minutes.
Class:
- Electrolyte.
- Anticonvulsant.

Actions:
- Reverses magnesium deficiency.
- Calcium channel blocker.
- Increases intracellular potassium.
- Relaxes smooth muscle.

Indications:
- Torsades de pointes.
- Seizures due to eclampsia.
- Bronchospasm in asthma or COPD that does not respond to other therapy.

Contraindications:
- Hypotension.
- Heart block.
- Chronic kidney disease/dialysis.

Precautions:
- Continuously monitor blood pressure, respiratory effort, level of consciousness, and muscle strength before and after medication administration.

Adverse Reactions:
- Hypotension.
- Respiratory depression.
- Circulatory collapse.
- Muscle weakness/paralysis.
- Bradycardia.
- CNS depression.

Adult Dosage / Route:

Torsades de pointes (Pulseless)
- 2 gm slow IV/IO. Mix 2 gm in 10 ml of Normal Saline and administer over 2 minutes.
Torsades de pointes (With a pulse)
- 2 gm slow infusion. Mix 2 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 50 gtts/min.

Eclampsia
- 4 gm slow infusion. Mix 4 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 50 gtts/min. May be repeated one time until cessation of visible seizure activity.

Asthma
- 2 gm slow infusion. Mix 2 gm in 100 ml of Normal Saline. Utilize a 10 gtts set and infuse at 50 gtts/min.

Pediatric Dosage / Route:
Torsades de pointes (Pulseless)
- 25-50 mg/kg slow IV/IO. Mix required dosage in 10 ml Normal Saline and administer over 2 minutes. Maximum dose of 2 gm.

Torsades de pointes (With a pulse)
- 25-50 mg/kg IV over 20 minutes, up to a maximum single dose of 2 gm.

Asthma
- 25-50 mg/kg IV over 20 minutes, up to a maximum single dose of 2 gm.
Class:
- Anti-inflammatory.
- Steroid.

Actions:
- A synthetic steroid that is effective as an anti-inflammatory. Also controls severe or incapacitating allergic reactions.

Indications:
- Asthma (When unable to take oral Prednisone).
- Severe anaphylaxis.
- Exacerbation of COPD (When unable to take oral Prednisone).

Contraindications:
- Known hypersensitivity.

Precautions:
- Cardiac arrhythmias or circulatory collapse can occur with large rapidly administer dosages.

Adverse Reactions:
- Cardiac arrhythmias.
- Hypertension.
- Vertigo.
- Headache.

Adult Dosage / Route:
- 125 mg IV/IM.

Pediatric Dosage / Route:
- 2 mg/kg IV/IM, up to a maximum single dose of 125 mg.
Class:
- Benzodiazepine.

Actions:
- A short acting central nervous system depressant that causes amnesia, sedation, and muscle relaxation.

Indications:
- Active seizures / status epilepticus.
- Sedation prior to cardioversion or transcutaneous pacing in conscious patients.
- Chest pain or tachycardia due to overdose on ingestion of cocaine, amphetamine, ecstasy, LSD, PCP or ketamine.
- Medication Facilitated Intubation
- Chemical sedation for combative patients with mental disturbances or overdose.
- Seizures secondary to Organophosphate and Carbamate Poisoning.
- Seizures secondary to WMD Nerve Agent poisoning.

Contraindications:
- Known hypersensitivity.
- Hypotension.

Precautions:
- Monitor respirations.
- Avoid mixing with other medications, flush IV line after administration.
- Titrate in small doses.

Adverse Reactions:
- Respiratory depression.
- Apnea.
- Hypotension.
- Amnesia.
- Nausea.
Adult Dosage / Route:

Seizures / Eclampsia / Excited Delirium / Nerve Agents, Organophosphate poisoning, or Carbamate Poisoning

- **Intranasal dose:** 10 mg IN, 5 mg each nostril. Repeat every 5 minutes with one 5 mg dose to a maximum dose of 10 mg. **Contact Medical Control** for additional doses.
- **Intramuscular:** 5 or 10 mg IM.
- **Intravenous dose:** 2-5 mg IV/IO every 2 minutes to a maximum of 10 mg until cessation of visible seizure activity.

Cardioversion / Pacing / Envenomations / Bites and Stings / Medication Facilitated Intubation Additional Sedation

- 2-5 mg IV/IO/IN, up to a maximum dose of 10 mg.

Stimulant Induced Chest Pain / Acute Pulmonary Edema (CHF)

- 2-5 mg IV/IN, up to a maximum dose of 10 mg. **Medical Control Required**

Pediatric Dosage / Route:

Seizures

- **Intranasal dose:** 0.2 mg/kg IN to a maximum dose of 5 mg. Repeat once in 5 minutes until cessation of visible seizure activity. **Medical Control Required** for additional doses.
- **Intravenous dose:** 0.1 mg/kg IV/IO, up to a maximum single dose of 2 mg. Repeat once in 5 minutes until cessation of visible seizure activity.

Cardioversion / Pacing

- 0.1 mg/kg IV/IN, up to a maximum single dose of 5 mg.

Stimulant Induced Chest Pain / CHF

- 0.1 mg/kg IV/IN, up to a maximum single dose of 5 mg. **Medical Control Required**

Nerve Agents, Organophosphate poisoning, or Carbamate Poisoning

- 0.2 mg/kg IV/IO/IM/IN, up to a maximum single dose of 5 mg.
Class:
- Narcotic.
- Analgesic.

Actions:
- Potent analgesic.
- Decreases peripheral vascular resistance causing vasodilatation.
- Decreases cardiac workload and oxygen demand on the heart.

Indications:
- Chest pain not relieved by nitroglycerin (second line agent for Fentanyl).
- Pain management. (Second line agent for Fentanyl).

Contraindications:
- Known hypersensitivity.
- Head injury.
- Hypotension.
- Respiratory depression.

Precautions:
- Monitor respiratory status and blood pressure. Have Naloxone readily available.

Adverse Reactions:
- Hypotension.
- Respiratory depression.
- Syncope.
- Bronchospasm.

Adult Dosage / Route:
- If the patient exhibits signs / symptoms of hypoperfusion Contact Medical Control for Morphine
- In patients 65 years old and greater consider an initial dose of half your normal adult dose when administering opiates (Morphine / Fentanyl).
Pain Management / Burns
- 2 mg IV. Repeat as needed until pain is relieved or a maximum of 10 mg is reached. An additional dose of 2 mg up to a maximum single dose of 10 mg may be repeated one time after 10 minutes.

Cardiac Chest Pain
- 2 mg IV, up to a maximum of 10 mg.

Pediatric Dosage / Route:
Pain Management
- 0.1 mg/kg IV until pain is relieved or a maximum single dose of 10 mg is reached. An additional dose of 0.5 mg/kg up to a maximum single dose of 10 mg may be repeated one time after 10 minutes.
Class:
- Narcotic Antagonist.

Actions:
- Reverses narcotic effects.

Indications:
- Suspected narcotic / opiate overdose.
- Altered Mental Status of unknown origin.

Contraindications:
- Known hypersensitivity.

Precautions:
- Half-life is shorter than most narcotics and may allow the patient to re-develop a decreased level of consciousness and/or respiratory depression.
- May induce opiate withdrawal in patients that have a physical dependency to narcotics / opiates.

Adverse Reactions:
- Nausea / vomiting.
- Headache.
- Tachycardia.
- Acute withdrawal syndrome (violent behavior).

Adult Dosage / Route (BLS Only):
- 2 mg IN. May repeat twice at the same dose.

Adult Dosage / Route (AEMT-ALS):
- 2 mg IV/IN or IM. If no response from the initial dose within 5 minutes repeat 4 mg IV/IN and titrate to effect thereafter if indicated.

Pediatric Dosage / Route (ALS Only):
- 0.1 mg/kg IV/IM/IN, up to a maximum single dose of 2 mg.
Class:

- Nitrate.
- Vasodilator.

Actions:

- Coronary and systemic vasodilator that decrease peripheral vascular resistance and preload.
- Decreases cardiac workload and oxygen demand on the heart.

Indications:

- Chest pain of cardiac origin.
- Pulmonary edema associated with congestive heart failure.
- Hypertension.

Contraindications:

- Hypotension.
- Suspected intracranial pressure.
- Taken Viagra or similar medications (Sildenafil, Cialis, Tadalafil, Levitra, Vardenafil) in the previous 24 hours.

Precautions:

- Use extreme caution when right ventricular involvement (RVI) is suspected. Contact Medical Control prior to administration.
- Ensure that an IV is established prior to nitroglycerin in patients with a suspected inferior wall MI.

Adverse Reactions:

- Hypotension.
- Headache.
- Reflex tachycardia.
- Nausea / vomiting.

Adult Dosage / Route:

Cardiac Chest Pain

- 0.4 mg SL every 5 minutes, up to a maximum of 3 doses. Nitro paste 1” after 2nd NTG dose.
- BLS providers may assist the patient with his/her own prescribed Nitroglycerin only after a thorough patient assessment.
Congestive Heart Failure

- 0.4 mg SL every 5 minutes, **no maximum dose**. Nitro paste 1”.

Pediatric Dosage / Route:

- Not indicated.
Class:
- Anti-emetic.

Actions:
- Potent anti-emetic.

Indications:
- Persistent vomiting due to gastrointestinal problems.

Contraindications:
- History of allergic reaction.

Precautions:
- Avoid intra-arterial or subcutaneous administration.

Adverse Reactions:
- Allergic reaction.

Adult Dosage / Route:
- 4 mg IV over 30 seconds.

Pediatric Dosage / Route:
- 0.15 mg/kg IV over 30 seconds. Maximum single dose 4 mg.
Class:
- Gas.

Actions:
- Odorless, colorless, tasteless gas that is essential for life.

Indications:
- Cardiopulmonary arrest.
- Trauma.
- Dyspnea.
- Suspected hypoxemia.
- Cardiac related chest pain.

Contraindications:
- None.

Precautions:
- Utilize the prescribed dose of a COPD patient unless the patient is in severe respiratory distress then 100% is required.

Adverse Reactions:
- May induce respiratory drive in some COPD patients.

Adult Dosage / Route:
- ≥15 lpm for BVM, 12-15 lpm via NRB mask or 2-6 lpm via nasal cannula.
- Routine oxygen administration is **NOT REQUIRED** if pulse ox is greater than 94%

Pediatric Dosage / Route:
- ≥15 lpm for BVM, 12-15 lpm via NRB mask or blow-by, 2-6 lpm via nasal cannula. Routine oxygen administration is **NOT REQUIRED** if pulse ox is greater than 94%
Class:
- Cholinesterase reactivator.

Actions:
- Reactivates cholinesterase which has been deactivated by chemical nerve agents and organophosphate poisons.
- Relieves paralysis of the respiratory muscles following chemical nerve agent or organophosphate exposure.

Indications:
- Second drug given for the treatment of poisoning due to organophosphate pesticides and chemical nerve agents (First drug of choice is Atropine).
- Primary indication for Pralidoxime administration is muscle weakness or respiratory depression in these patients.

Contraindications:
- Known hypersensitivity.

Precautions:
- Not indicated for poisonings with carbonate pesticides.
- Effects during pregnancy are unknown.
- Safety and efficacy in children is unknown.
- Do not administer more than 3 auto-injectors due to its hypertensive effects.

Adverse Reactions:
- Tachycardia, laryngospasm, muscle rigidity if IV and infused too quickly.
- Mild to moderate pain at injection site.
- Blurred or double vision, dizziness, loss of coordination, headache drowsiness, hypertension, tachycardia.

Adult Dosage / Route:
- 600 mg IM, up to 1800 mg or 3 auto-injectors.

Pediatric Dosage / Route:
- Not indicated.
Class:
  ➢ Corticosteroids.

Actions:
  ➢ Reduces inflammation.

Indications:
  ➢ Bronchospasm with mild - moderate respiratory distress.
  ➢ Bronchospasm with moderate-severe respiratory distress if IV access is not available.

Contraindications:
  ➢ Known sensitivity.
  ➢ Liver disease.
  ➢ Pregnancy.

Precautions:
  ➢ None in the short term emergency setting.

Adult Dosage / Route:
  ➢ 60 mg P.O.

Pediatric Dosage / Route:
  ➢ 1-2 mg/kg, up to a maximum of 10 mg. Patient has to be >20 kg and able to swallow.
Class:
- Phenothiazine.

Actions:
- Common neuroleptic actions that result in a decrease in nerve stimulation.

Indications:
- Nausea and Vomiting. (second line agent for Ondansetron (Zofran)).

Contraindications:
- CNS depression.
- Severe liver or cardiac disease.
- Narrow glaucoma, pediatric surgery.
- Bone marrow disorders.

Precautions:
- May cause hypotension when administered via IV.
- May cause dyskinesia or the extrapyramidal effects.
- May cause seizures and seizure-like activity.
- May cause anxiety.

Adult Dosage / Route:
- 10 mg by slow IV. **Do not administer more than 5 mg per minute.**
- 5-10 mg IM.

Pediatric Dosage / Route:
- Medical Control Required.
Class:
- Direct acting βeta agonist and anti-inflammatory.

Actions:
- Stimulates both alpha and beta receptors reducing edema and producing bronchodilation.

Indications:
- Croup with audible stridor.
- Bronchospasm with moderate-severe respiratory distress.

Contraindications:
- Hypertension.
- Tachydysrhythmias.

Precautions:
- Concurrent use with other adrenergic agents will have additive adrenergic side effects.
- Use with MAO inhibitors may lead to hypertensive crisis.
- Beta blockers may negate therapeutic effect.

Adult Dosage / Route:
- 0.5 ml (11.25 mg) mixed with 3 ml of Normal Saline via nebulizer.

Pediatric Dosage / Route:
- <5 kg, 0.25 ml (5.62 mg) mixed with 3 ml of Normal Saline via nebulizer.
- ≥5 kg, 0.5 ml (11.25 mg) mixed with 3 ml of Normal Saline via nebulizer.
Class:
- Electrolyte.
- Alkalizing agent.

Actions:
- Drives serum potassium back into the cell.
- Enhances urinary excretion of tricyclic antidepressants.
- Neutralizes acidosis.

Indications:
- Hyperkalemia.
- Metabolic acidosis.
- Tricyclic antidepressant (TCA) overdose or ingestion.

Contraindications:
- Pre-existing alkalosis.

Precautions:
- Inactivates simultaneously administered catecholamine’s (epinephrine or dopamine).
- Flush IV line between medication administrations.

Adverse Reactions:
- Alkalosis.
- Hypokalemia.
- Seizures.
- Tissue sloughing at injection site.

Adult Dosage / Route:
- 1 mEq/kg IV/IO.

Pediatric Dosage / Route:
- 1 mEq/kg IV/IO.
Class:
- Isotonic Crystalloid Solution.

Actions:
- Fluid and sodium replacement.

Indications:
- Anytime IV access and/or medication administration is obtained.

Contraindications:
- High doses in the presence of congestive heart failure can cause circulatory overload.

Precautions:
- Electrolyte depletion can occur following large amounts of normal saline.

Adverse Reactions:
- Thirst.

Adult Dosage / Route:
- IV/IO or saline lock.

Pediatric Dosage / Route:
- IV/IO or saline lock.
Class:
   Local anesthetic for the eye.

Actions:
   Blocks the initiation and conduction of nerve impulses.

Indications:
   Topically applied local anesthetic for eye examination.

Contraindications:
   hypersensitivity to ester anesthetics.
   Not to be applied in large amounts or to infants less than 1 year of age.
   Do not use in the presence of penetrating trauma.

Precautions:
   Advise patient that the drops may burn for a few seconds.

Adverse Reactions:
   Stinging in affected eye.

Adult Dosage / Route:
   1-2 drops per eye.

Pediatric Dosage / Route:
   1-2 drops per eye
Class:

- Anti-Fibrinolytic.

Actions:

- Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding. Onset of action within 4 hours after IV administration. Exact time of onset unclear and variable.

Indications:

**Must meet all criteria below:**

- Adults (Age 15 or greater) with hemorrhagic shock from trauma.
- Must have obvious bleeding external wounds neck to mid-thigh or suspected severe internal injuries from blunt or penetrating trauma.
- Trauma occurred within last 3 hours.
- Must have sustained tachycardia 110 beats per minute and/or sustained hypotension with systolic blood pressure 90 mmHg or less.

Contraindications:

- Non-hemorrhagic shock.
- Non-traumatic hemorrhagic shock.
- Hemorrhagic shock stabilized with other hemostatic agents/measures.

Precautions:

- Delayed effects up to 48 hours consistent with anti-inflammatory actions.

Adverse Reactions:

- While a theoretical concern, TXA has not been shown to cause significant increase in deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke in published trials to date.

Adult Dosage / Route:

- 1 gram mixed in 100 ml Normal Saline infused over 10 minutes.

Pediatric Dosage / Route:

- Not Indicated.
There are many causes of abdominal pain of which some can be life threatening. When evaluating a patient experiencing abdominal pain attempt to determine the cause of the complaint utilizing the following differential.

<table>
<thead>
<tr>
<th>Upper GI Bleed</th>
<th>Lower GI Bleed</th>
<th>Gynecological</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hx of peptic ulcer disease; Can cause massive hemorrhage.</td>
<td>May be occult or bright red; A common cause of orthostatic hypotension and undetected anemia.</td>
<td>Think ectopic!! Pain plus vaginal bleeding and sometimes syncope.</td>
</tr>
<tr>
<td>Esophageal varices (Hx of cirrhosis, hepatitis).</td>
<td>Diverticulitis</td>
<td>Ectopic Pregnancy</td>
</tr>
<tr>
<td>Peptic Ulcer Disease</td>
<td>Hemorrhoids</td>
<td>Pelvic Inflammatory Disease/STD's.</td>
</tr>
<tr>
<td>Aspirin, NSAID's</td>
<td>Cancer</td>
<td>Ovarian Cyst (No Bleeding)</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Inflammatory Bowel Disease</td>
<td>Kidney / Urinary Tract Infection (Blood in Urine).</td>
</tr>
<tr>
<td>Ingestion of caustic substances.</td>
<td>Chronic Diarrhea, overuse of laxatives.</td>
<td>Endometriosis (Severe pain before and during menstrual cycles).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Colicky Pain</th>
<th>Peritoneal Pain</th>
<th>Vomiting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spasmotic – usually results from smooth muscle contracting against obstruction of hollow organ.</td>
<td>Rigid board-like abdomen, resulting from infection or long standing rupture.</td>
<td>Non-specific symptom, caused by a wide variety of underlying problems some of which are serious.</td>
</tr>
<tr>
<td>Bowel Obstruction</td>
<td>Ruptured Appendix</td>
<td>Infection of GI Tract</td>
</tr>
<tr>
<td>Renal Obstruction “Kidney Stones”.</td>
<td>Ruptured Ovarian Cyst</td>
<td>Ulcers</td>
</tr>
<tr>
<td>Gallbladder Obstruction</td>
<td>Pelvic Inflammatory Disease (PID).</td>
<td>Toxic Ingestions</td>
</tr>
<tr>
<td>Ulcerative Colitis</td>
<td>Perforated Ulcer</td>
<td>Bowel Obstruction</td>
</tr>
<tr>
<td>Crohn's Disease</td>
<td>Peritonitis Advanced</td>
<td>Stones of the Gallbladder or Kidney.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Back Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Every pain presenting with new onset back pain (&gt;60 yrs.) should have an abdominal exam R/O AAA.</td>
</tr>
<tr>
<td>Abdominal Aortic Aneurysm</td>
</tr>
<tr>
<td>Cholelithiasis</td>
</tr>
<tr>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Perforated Ulcer</td>
</tr>
</tbody>
</table>
There are many presentations that represent an acute coronary syndrome, especially in females, the elderly, in patients with diabetes, and those with underlying histories of heart disease. Consider acute coronary syndromes in patients with pain or discomfort from the jaw to the lower abdomen.

<table>
<thead>
<tr>
<th></th>
<th>Myocardial Infarction</th>
<th>Angina Pectoris</th>
<th>Dissecting Aneurysm</th>
<th>Pericarditis</th>
<th>Peptic Ulcer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location</strong></td>
<td>Substernal may vary</td>
<td>Substernal</td>
<td>Substernal</td>
<td>Substernal more left sided</td>
<td>Epigastric Substernal</td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>Usually sudden</td>
<td>Exertional</td>
<td>Acute</td>
<td>Sub-acute</td>
<td>Acute or Sub-acute</td>
</tr>
<tr>
<td><strong>Provocation</strong></td>
<td>Usually none. See comments.</td>
<td>Exercise excitement stress, cold, meals</td>
<td>None</td>
<td>Worsened: lying down breathing, swallowing, coughing, twisting</td>
<td>Alcohol, lack of foods, acid foods</td>
</tr>
<tr>
<td><strong>Quality</strong></td>
<td>Crushing, Heaviness, dull Pressure Band-like Constricting Squeezing</td>
<td>Discomfort Choking Pressure Squeezing, Strangling, Constricting</td>
<td>Deep tearing Shearing &quot;Knife-like&quot;</td>
<td>Sharp</td>
<td>Burning</td>
</tr>
<tr>
<td><strong>Radiation</strong></td>
<td>Across, mid-thorax anterior, arms shoulder, neck jaw, teeth, fingers</td>
<td>Same as MI</td>
<td>Back lumbar region</td>
<td>Usually none occasionally shoulder, neck, flank</td>
<td>Occasionally back</td>
</tr>
<tr>
<td><strong>Alleviation</strong></td>
<td>None</td>
<td>Rest, NTG</td>
<td>None</td>
<td>Tripod position shallow respirations</td>
<td>Antacids, food</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Usually under 30 minutes. Can be longer.</td>
<td>5-15 min.</td>
<td>Hours</td>
<td>Hours</td>
<td></td>
</tr>
<tr>
<td><strong>Comments</strong></td>
<td>SOB, N&amp;V, pallor, diaphoresis impending doom</td>
<td>May be nocturnal</td>
<td>Sudden onset may subside spontaneously or be associated with paralysis</td>
<td>May be associated with URI, flu pronestyl hydralazine lupus; MAY BE FEBRILE</td>
<td>ASA, NSAID’s e.g. Motrin Advil, may trigger.</td>
</tr>
<tr>
<td>Location</td>
<td>Pancreatitis</td>
<td>Esophageal Rupture</td>
<td>Pulmonary Embolism</td>
<td>Esophageal Spasm</td>
<td>Costo-Chondritis</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
<td>--------------------</td>
<td>--------------------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Location</td>
<td>Epigastric</td>
<td>Retrosternal</td>
<td>Multiple</td>
<td>Substernal, Epigastric</td>
<td>Anterior / Lateral</td>
</tr>
<tr>
<td>Onset</td>
<td>Acute / Sub-acute</td>
<td>Acute</td>
<td>Sudden or Gradual</td>
<td>Sub-acute</td>
<td>Sudden or Gradual</td>
</tr>
<tr>
<td>Provocation</td>
<td>Alcohol, trauma, gall bladder disease</td>
<td>Swallowing</td>
<td>Respirations, cough</td>
<td>Spontaneous, cold liquids, recumbency</td>
<td>Movement, palpation, cough, respiration</td>
</tr>
<tr>
<td>Quality</td>
<td>Severe or dull</td>
<td>Severe</td>
<td>Sharp or dull</td>
<td>Dull, pressure, colicky</td>
<td>Sharp superficial</td>
</tr>
<tr>
<td>Radiation</td>
<td>Back</td>
<td>Lateral</td>
<td>None</td>
<td>Jaw, either arm</td>
<td>None</td>
</tr>
<tr>
<td>Alleviation</td>
<td>Time</td>
<td>None</td>
<td>None</td>
<td>Antacids, occasionally NTG</td>
<td>Time, heat, analgesia</td>
</tr>
<tr>
<td>Duration</td>
<td>Hours</td>
<td>Hours</td>
<td>Variable</td>
<td>5-60 minutes</td>
<td>Variable</td>
</tr>
<tr>
<td>Comments</td>
<td>May be viral e.g. Mumps</td>
<td>Alcohols with forceful vomiting; associated with pleural effusion, shock and hydro-pneumothorax</td>
<td>Sudden onset may subside spontaneously or be associated with paralysis</td>
<td>May be associated with URI, flu pronestyl hydralazine lupus; MAY BE FEBRILE</td>
<td>ASA, NSAID’s e.g. Motrin Advil, may trigger.</td>
</tr>
</tbody>
</table>
Eye Opening

Spontaneously 4
To Voice 3
To Pain 2
No Response 1

Motor Response

To Verbal Command - Obeys 6
To Painful Stimulus - Localizes Pain 5
Flexion - Withdraw 4
Flexion - Abnormal 3
Extension 2
No Response 1

Verbal Response

<table>
<thead>
<tr>
<th>Less than 2 years old</th>
<th>2-5 years old</th>
<th>Greater than 5 years old</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smiles/Coos/Cries</td>
<td>Appropriate Words</td>
<td>Oriented and Conversations</td>
<td>5</td>
</tr>
<tr>
<td>Cries</td>
<td>Inappropriate Words</td>
<td>Disoriented and Conversations</td>
<td>4</td>
</tr>
<tr>
<td>Inappropriate/Cries/Screams</td>
<td>Cries/Screams</td>
<td>Inappropriate Words</td>
<td>3</td>
</tr>
<tr>
<td>Grunts</td>
<td>Grunts</td>
<td>Incomprehensible Sounds</td>
<td>2</td>
</tr>
<tr>
<td>No Response</td>
<td>No Response</td>
<td>No Response</td>
<td>1</td>
</tr>
</tbody>
</table>

Glasgow Coma Score Total (3-15)
This reference applies to 400 mg of Dopamine in 250 ml solution (concentration of 1600 mcg/ml), infuse via 60 drop tubing at the following rates.

For patients <40 kg, refer to the Broselow™ tape for drip/min calculation.

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>5 mcg gtts/min</th>
<th>10 mcg gtts/min</th>
<th>15 mcg gtts/min</th>
<th>20 mcg gtts/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>8</td>
<td>16</td>
<td>24</td>
<td>30</td>
</tr>
<tr>
<td>50</td>
<td>10</td>
<td>20</td>
<td>30</td>
<td>40</td>
</tr>
<tr>
<td>60</td>
<td>12</td>
<td>24</td>
<td>34</td>
<td>45</td>
</tr>
<tr>
<td>70</td>
<td>14</td>
<td>26</td>
<td>40</td>
<td>54</td>
</tr>
<tr>
<td>80</td>
<td>15</td>
<td>30</td>
<td>45</td>
<td>60</td>
</tr>
<tr>
<td>90</td>
<td>18</td>
<td>34</td>
<td>52</td>
<td>68</td>
</tr>
<tr>
<td>100</td>
<td>20</td>
<td>40</td>
<td>56</td>
<td>75</td>
</tr>
<tr>
<td>110</td>
<td>22</td>
<td>42</td>
<td>62</td>
<td>84</td>
</tr>
<tr>
<td>120</td>
<td>24</td>
<td>45</td>
<td>68</td>
<td>90</td>
</tr>
<tr>
<td>130</td>
<td>24</td>
<td>50</td>
<td>74</td>
<td>98</td>
</tr>
<tr>
<td>140</td>
<td>26</td>
<td>53</td>
<td>80</td>
<td>105</td>
</tr>
<tr>
<td>150</td>
<td>28</td>
<td>56</td>
<td>85</td>
<td>112</td>
</tr>
<tr>
<td>160</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td>120</td>
</tr>
<tr>
<td>170</td>
<td>32</td>
<td>64</td>
<td>96</td>
<td>128</td>
</tr>
<tr>
<td>180</td>
<td>34</td>
<td>68</td>
<td>102</td>
<td>135</td>
</tr>
<tr>
<td>190</td>
<td>36</td>
<td>72</td>
<td>106</td>
<td>142</td>
</tr>
<tr>
<td>200</td>
<td>38</td>
<td>75</td>
<td>112</td>
<td>150</td>
</tr>
</tbody>
</table>

**Quick Calculation**

Take patient’s weight in pounds, drop the last number and then subtract 2. This will give you the starting drip rate at 5 mcg/kg/min. For every change in micrograms, add or subtract 3 drops.

Example: Patient weighs 175 lb.
175 drop 5 = 17, 17 - 2 = 15
5 mcg/kg/min = 15 gtts/min, 6 mcg/kg/min = 15 + 3 = 18 gtts/min
(Note that this quick calculation is a very close approximate dose)
This reference applies to mixing 1 milligram of Epinephrine 1:1,000 in a 100 ml solution (concentration of 10 mcg/ml), infuse via 60 drop tubing at the following rates. Example: \( \frac{2 \text{ mcg/min}}{1000 \text{ mcg} / 100 \text{ cc}} \times 60 \text{ gtts/cc} = 12 \text{ gtts/min} \).

For patients <40 kg, refer to the Broselow™ tape for drip/min calculation.

<table>
<thead>
<tr>
<th>1 mcg/min</th>
<th>2 mcg/min</th>
<th>3 mcg/min</th>
<th>4 mcg/min</th>
<th>5 mcg/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 gtts/min</td>
<td>12 gtts/min</td>
<td>18 gtts/min</td>
<td>24 gtts/min</td>
<td>30 gtts/min</td>
</tr>
<tr>
<td>6 mcg/min</td>
<td>7 mcg/min</td>
<td>8 mcg/min</td>
<td>9 mcg/min</td>
<td>10 mcg/min</td>
</tr>
<tr>
<td>36 gtts/min</td>
<td>42 gtts/min</td>
<td>48 gtts/min</td>
<td>54 gtts/min</td>
<td>60 gtts/min</td>
</tr>
</tbody>
</table>

This reference applies to mixing 1 milligram of Epinephrine 1:1,000 in a 250 ml solution (concentration of 4 mcg/ml), infuse via 60 drop tubing at the following rates. Example: \( \frac{2 \text{ mcg/min}}{1000 \text{ mcg} / 250 \text{ cc}} \times 60 \text{ gtts/cc} = 30 \text{ gtts/min} \).

<table>
<thead>
<tr>
<th>1 mcg/min</th>
<th>2 mcg/min</th>
<th>3 mcg/min</th>
<th>4 mcg/min</th>
<th>5 mcg/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 gtts/min</td>
<td>30 gtts/min</td>
<td>45 gtts/min</td>
<td>60 gtts/min</td>
<td>75 gtts/min</td>
</tr>
<tr>
<td>6 mcg/min</td>
<td>7 mcg/min</td>
<td>8 mcg/min</td>
<td>9 mcg/min</td>
<td>10 mcg/min</td>
</tr>
<tr>
<td>90 gtts/min</td>
<td>105 gtts/min</td>
<td>120 gtts/min</td>
<td>135 gtts/min</td>
<td>150 gtts/min</td>
</tr>
</tbody>
</table>
### Normal Vital Signs

<table>
<thead>
<tr>
<th></th>
<th>Respirations</th>
<th>Pulse</th>
<th>Systolic BP*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td>12 - 20</td>
<td>60 -100</td>
<td>90 - 140</td>
</tr>
<tr>
<td>Adolescent</td>
<td>12 - 24</td>
<td>60 -100</td>
<td>&gt;90</td>
</tr>
<tr>
<td>Children (1 to 10 years)</td>
<td>22 - 34</td>
<td>80 -140</td>
<td>&gt;75</td>
</tr>
<tr>
<td>Infants (1 month to 1 year)</td>
<td>24 - 40</td>
<td>90 -150</td>
<td>&gt;70</td>
</tr>
<tr>
<td>Neonate (0 to 28 days)</td>
<td>30 - 60</td>
<td>100 -160</td>
<td>&gt;60</td>
</tr>
</tbody>
</table>

* For children 1 to 10 years of age, you can determine the lower limit of an acceptable blood pressure using the following formula:

\[
\text{Minimal systolic blood pressure} = 70 + (2 \times \text{age in years})
\]
Determine the APGAR score at the first minute postpartum. Repeat at the 5 minute interval.

<table>
<thead>
<tr>
<th>Test</th>
<th>0 Points</th>
<th>1 Point</th>
<th>2 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity (Muscle Tone)</td>
<td>Absent</td>
<td>Arms &amp; legs extended</td>
<td>Active movement with flexed arms &amp; legs</td>
</tr>
<tr>
<td>Pulse (Heart Rate)</td>
<td>Absent</td>
<td>Below 100 bpm</td>
<td>Above 100 bpm</td>
</tr>
<tr>
<td>Grimace (Response Stimulation or Reflex Irritability)</td>
<td>No Response</td>
<td>Facial grimace</td>
<td>Sneeze, cough, pulls away</td>
</tr>
<tr>
<td>Appearance (Skin Color)</td>
<td>Blue-gray, pale all over</td>
<td>Pink body and blue extremities</td>
<td>Normal over entire body – Completely pink</td>
</tr>
<tr>
<td>Respiration (Breathing)</td>
<td>Absent</td>
<td>Slow, irregular</td>
<td>Good, crying</td>
</tr>
</tbody>
</table>

Score of 7-10 is usually associated with coughing and crying within seconds of delivery. Newborns with this score typically do not require and further resuscitation.

Score of 4-6 the newborn is moderately depressed. Will typically appear pale or cyanotic and have respiratory complications and flaccid muscle tone. These newborns will require some type of resuscitative efforts.
The following chart shows the average ET, suction and orogastric tube size that is compatible to the age of the patient.

<table>
<thead>
<tr>
<th>Age</th>
<th>ET Size</th>
<th>Suction Catheter</th>
<th>Orogastric Tube</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-term</td>
<td>2.5 - 3.0 uncuffed</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>Term</td>
<td>3.0 - 3.5 uncuffed</td>
<td>6 - 8</td>
<td>8</td>
</tr>
<tr>
<td>6 Months</td>
<td>3.5 uncuffed</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>12 - 18 Months</td>
<td>4.0 uncuffed</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>3 Years</td>
<td>4.5 uncuffed</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>5 Years</td>
<td>5.0 uncuffed</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>6 Years</td>
<td>5.5 uncuffed</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>8 Years</td>
<td>6.0 uncuffed</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>12 Years</td>
<td>6.5 cuffed</td>
<td>10</td>
<td>16</td>
</tr>
<tr>
<td>16 Years</td>
<td>7.0 - 8.0 cuffed</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>Adult Female</td>
<td>7.5 - 8.0 cuffed</td>
<td>12</td>
<td>18</td>
</tr>
<tr>
<td>Adult Male</td>
<td>8.0 - 8.5 cuffed</td>
<td>14</td>
<td>18</td>
</tr>
</tbody>
</table>

1. This chart is meant as a guide only.
2. The size and weight of the child must be taken into consideration for sizing.
3. A quick formula to use when determining endotracheal tube size in pediatric patients is Size = (Age in Years) / 4 + 4.
4. The use of a Broselow™ tape or similar device is encouraged for pediatric patients.
Rule of Nines

Detailed calculation reference for pediatrics > 1 year of age:
For every year over one, add 0.5% to each leg and subtract 1% for the head

<table>
<thead>
<tr>
<th>Age</th>
<th>Head</th>
<th>Each leg</th>
<th>Age</th>
<th>Head</th>
<th>Each leg</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>17%</td>
<td>14.5%</td>
<td>6</td>
<td>13%</td>
<td>16.5%</td>
</tr>
<tr>
<td>3</td>
<td>16%</td>
<td>15%</td>
<td>7</td>
<td>12%</td>
<td>17%</td>
</tr>
<tr>
<td>4</td>
<td>15%</td>
<td>15.5%</td>
<td>8</td>
<td>11%</td>
<td>17.5%</td>
</tr>
<tr>
<td>5</td>
<td>14%</td>
<td>16%</td>
<td>9</td>
<td>10%</td>
<td>18%</td>
</tr>
</tbody>
</table>
**Airborne Transmission**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Transmission</th>
<th>Prevention</th>
<th>Post-Exposure</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuberculosis (TB)</td>
<td>Droplets; Coughing, sneezing, intubation, suctioning</td>
<td>Initial 2-step test, annual PPD. Wear HEPA masks.</td>
<td>Source = PPD Employee = PPD, unless PPD tested within prior 12 weeks or previously PPD reactive</td>
<td>PPD at week 12 post-exposure. If new positive; chest x-ray and Rx with isoniazid for 6 months.</td>
</tr>
<tr>
<td>Meningitis (Bacterial / Viral)</td>
<td>Droplets; Coughing, sneezing, intubation, suctioning</td>
<td>HEPA Mask</td>
<td>Antibiotic; Cipro, Rocephin, Rifampin</td>
<td>Seek medical care if symptoms of meningitis develop; fever, stiff neck, severe headache.</td>
</tr>
<tr>
<td>Influenza (FLU)</td>
<td>Close contact droplets; coughing, sneezing, intubation, suctioning, Also direct contact with vesicle fluid.</td>
<td>Flu shot (Vaccination)</td>
<td>Treatments; analgesics, Rimantadine, Tamiflu, Relenza.</td>
<td>As determined by medical professional.</td>
</tr>
<tr>
<td>Varicella Zoster (Chicken Pox)</td>
<td>Close contact droplets; coughing, sneezing, intubation, suctioning. Also direct contact with vesicle fluid.</td>
<td>Vaccine = 1 shot (Varivax). HEPA mask.</td>
<td>Treatment; Varicella Zoster Immune Globulin (VZIG) within 96 hrs. of exposure.</td>
<td>As determined by medical professional.</td>
</tr>
</tbody>
</table>

**Blood-Borne Transmission**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Transmission</th>
<th>Prevention</th>
<th>Post-Exposure</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>Blood to blood, to non-intact skin and mucous membranes.</td>
<td>No Vaccine</td>
<td>See post-exposure control protocol.</td>
<td>Periodic screening; 6, 12, 26 weeks after exposure.</td>
</tr>
<tr>
<td>Syphilis</td>
<td>Blood and/or open sores / lesions</td>
<td>No Vaccine</td>
<td>Source = RPR Employee = RPR Penicillin.</td>
<td>Repeat test at 3 and 6 months. If positive refer to medical professional.</td>
</tr>
<tr>
<td>Hepatitis-B (HBV)</td>
<td>Blood to blood, to non-intact skin and mucous membranes.</td>
<td>Vaccine = 3 shot series. Titer and re-immunize if necessary.</td>
<td>Source = Acute Hep. Panel Employee = Acute Hep. Panel. If source positive, employee not immune; administer immune globulin and consider HAV vaccine series.</td>
<td>Periodic screening; 6, 12, 26 weeks after exposure.</td>
</tr>
<tr>
<td>Hepatitis-C (HCV)</td>
<td>Blood to blood, to non-intact skin and mucous membranes.</td>
<td>No Vaccine</td>
<td>Source = Acute Hep. Panel Employee = Acute Hep. Panel. If source positive, consider employee qualitative HCV RNA &amp; ALT testing 6 weeks after exposure.</td>
<td>Periodic screening; 6, 12, 26 weeks after exposure. If employee becomes HCV RNA positive, treat with Interferon / Ribavirin for 6 months.</td>
</tr>
<tr>
<td>Other</td>
<td>Transmission</td>
<td>Prevention</td>
<td>Post-Exposure</td>
<td>Follow-up</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------</td>
<td>---------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Hepatitis-A(HAV)</td>
<td>Fecal/oral</td>
<td>Vaccine = 2 shot series</td>
<td>Source = Acute Hep. Panel Employee = Acute Hep. Panel. If source positive, employee not immune; administer immune globulin and consider HAV vaccine series.</td>
<td>Periodic screening; 12 weeks after exposure or if symptoms occur.</td>
</tr>
<tr>
<td>Tetanus</td>
<td>Soiled object causing open wound.</td>
<td>Vaccine good for 10 years.</td>
<td>If no vaccine, administer at this time. If over 7 years from last vaccination and sustained open wound, booster dose.</td>
<td>Seek medical care if symptoms of tetanus develop; lockjaw, rigid muscles.</td>
</tr>
<tr>
<td>Lyme Disease</td>
<td>Tick-borne; tick attached 24 hours.</td>
<td>Avoid tick infested areas. Vaccine = 3 shot series for prone areas.</td>
<td>Antibiotics; Amoxicillin, Doxycycline.</td>
<td>As determine by medical professional.</td>
</tr>
<tr>
<td>Scabies</td>
<td>Direct contact; mite infested areas, bedding / clothing, nursing homes.</td>
<td>Avoid infested areas.</td>
<td>Lindane and Kwell applied to the entire body for 24 hours.</td>
<td>Close supervision of treatment including bathing.</td>
</tr>
<tr>
<td>Rabies</td>
<td>Virus-laden salvia of infected animal; animal bites.</td>
<td>Avoid animal bites.</td>
<td>Wash infected areas. Administer rabies anti-serum injection and first dose of rabies vaccine. Contact animal control, monitor for presence of infection.</td>
<td>If animal is positive, continue to treat employee with vaccine.</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1°</td>
<td>1st degree, primary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2°</td>
<td>2nd degree, secondary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3°</td>
<td>3rd degree</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>=</td>
<td>about, approximately</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p</td>
<td>after</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a</td>
<td>before</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abd.</td>
<td>abdomen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ab</td>
<td>abortion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APAP</td>
<td>acetaminophen/Tylenol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACS</td>
<td>acute coronary syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMI</td>
<td>acute myocardial infarction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AALS</td>
<td>advanced cardiac life support</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMA</td>
<td>against medical advice</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABC</td>
<td>airway, breathing, circulation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETOH</td>
<td>alcohol (ethanol)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A&amp;O</td>
<td>alert and oriented</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amb</td>
<td>ambulate, ambulatory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AC</td>
<td>antecubital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ant.</td>
<td>anterior</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AOSTF</td>
<td>arrived on scene to find</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA</td>
<td>aspirin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASHD</td>
<td>atherosclerotic heart disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AFib</td>
<td>atrial fibrillation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aflutter</td>
<td>atrial flutter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AICD</td>
<td>automatic internal cardiac defibrillator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AED</td>
<td>automated external defibrillator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AAO</td>
<td>awake, alert, oriented</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVM</td>
<td>bag-valve-mask</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BPM</td>
<td>beats per minute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BBS</td>
<td>bilateral breath sounds</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BGA</td>
<td>blood glucose analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BS</td>
<td>blood sugar, breath sounds</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BM</td>
<td>bowel movement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CaCl</td>
<td>calcium chloride</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ca</td>
<td>carcinoma, cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPR</td>
<td>cardiopulmonary resuscitation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C°</td>
<td>centigrade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVA</td>
<td>cerebrovascular accident</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Δ</td>
<td>change</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CP</td>
<td>chest pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>chief complaint</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMS</td>
<td>circulation, motor, sensation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTA</td>
<td>clear to auscultation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c/o</td>
<td>complains of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>coronary artery bypass graft</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cc</td>
<td>cubic centimeter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOA</td>
<td>dead on arrival at hospital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOS</td>
<td>dead on scene</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↓</td>
<td>decreased, depressed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DT's</td>
<td>delirium tremens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D25</td>
<td>dextrose 25%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D5W</td>
<td>dextrose 5% in water</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D50</td>
<td>dextrose 50%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dx</td>
<td>diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBP</td>
<td>diastolic blood pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D/C</td>
<td>discontinue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gtt.</td>
<td>drop</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gtt's</td>
<td>drops</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENT</td>
<td>ear, nose, and throat</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG, EKG</td>
<td>electrocardiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ED</td>
<td>emergency department</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epi</td>
<td>Epinephrine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>=</td>
<td>equals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Term</td>
<td>Abbreviation</td>
<td>Definition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>erectile dysfunction medications</td>
<td>EDF</td>
<td>last menstrual period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>estimated date of confinement</td>
<td>EDC</td>
<td>left, liter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>endotracheal tube</td>
<td>ETT</td>
<td>left</td>
<td></td>
<td></td>
</tr>
<tr>
<td>every</td>
<td>q or Q</td>
<td>left lower quadrant of abdomen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>external jugular</td>
<td>EJ</td>
<td>left upper quadrant of abdomen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fahrenheit</td>
<td>F°</td>
<td>less than</td>
<td></td>
<td></td>
</tr>
<tr>
<td>female</td>
<td>f. or ♀</td>
<td>less than or equal to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>format for capnography measurements</td>
<td>EtCO2=XX</td>
<td>level of consciousness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gastrointestinal gauge</td>
<td>GI</td>
<td>loss of consciousness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mm Hg</td>
<td></td>
<td>medical intensive care unit (hospital)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gravida</td>
<td>G</td>
<td>milliequivalent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>greater than</td>
<td>&gt;</td>
<td>microgram</td>
<td></td>
<td></td>
</tr>
<tr>
<td>greater than or equal to</td>
<td>≥</td>
<td>milligram</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ground level fall</td>
<td>GLF</td>
<td>milligrams per deciliter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gunshot wound</td>
<td>GSW</td>
<td>milliliter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>headache</td>
<td>HA</td>
<td>millimeters of Mercury</td>
<td></td>
<td></td>
</tr>
<tr>
<td>head, eyes, ears, nose, throat</td>
<td>HEENT</td>
<td>minute</td>
<td></td>
<td></td>
</tr>
<tr>
<td>heart rate</td>
<td>HR</td>
<td>mobile intensive care unit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>history</td>
<td>Hx</td>
<td>motor vehicle collision</td>
<td></td>
<td></td>
</tr>
<tr>
<td>increased, elevated</td>
<td>↑</td>
<td>moves all extremities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>inferior</td>
<td>inf.</td>
<td>moves all extremities well</td>
<td></td>
<td></td>
</tr>
<tr>
<td>insulin dependent diabetes mellitus</td>
<td>IDDM</td>
<td>multiple sclerosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>intensive care unit</td>
<td>ICU</td>
<td>myocardial infarction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>intramuscular</td>
<td>IM</td>
<td>nasal cannula</td>
<td></td>
<td></td>
</tr>
<tr>
<td>intranasal</td>
<td>IN</td>
<td>nasogastric tube</td>
<td></td>
<td></td>
</tr>
<tr>
<td>intravenous</td>
<td>IV</td>
<td>nausea/vomiting/diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>jugular venous distention</td>
<td>JVD</td>
<td>negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>keep vein open</td>
<td>KVO</td>
<td>Nitroglycerin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>kilogram</td>
<td>kg</td>
<td>no complaint</td>
<td></td>
<td></td>
</tr>
<tr>
<td>laceration</td>
<td>LAC</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lactated Ringer's</td>
<td>LR</td>
<td>non-insulin dependent diabetes mellitus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>estimated date of confinement</td>
<td>EDC</td>
<td>left</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ABBREVIATIONS**

**Approved for use**
### District of Columbia
Fire and EMS Protocols
Appendix

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKDA</td>
<td>no known drug allergies</td>
<td>SL</td>
<td>sublingual</td>
</tr>
<tr>
<td>NRB</td>
<td>Non-rebreather</td>
<td>SVT</td>
<td>supraventricular tachycardia</td>
</tr>
<tr>
<td>NS</td>
<td>normal saline</td>
<td>SBP</td>
<td>systolic blood pressure</td>
</tr>
<tr>
<td>NSR</td>
<td>normal sinus rhythm</td>
<td>x2</td>
<td>times 2, or times 3, or times …</td>
</tr>
<tr>
<td>OD</td>
<td>overdose</td>
<td>TKO</td>
<td>to keep open</td>
</tr>
<tr>
<td>O₂ or O₂</td>
<td>oxygen</td>
<td>TCP</td>
<td>transcutaneous pacing</td>
</tr>
<tr>
<td>P</td>
<td>para</td>
<td>Rx or Tx</td>
<td>treatment</td>
</tr>
<tr>
<td>pt.</td>
<td>patient</td>
<td>VF</td>
<td>ventricular fibrillation</td>
</tr>
<tr>
<td>PCR</td>
<td>patient care report</td>
<td>VT</td>
<td>ventricular tachycardia</td>
</tr>
<tr>
<td>/</td>
<td>per</td>
<td>V.S.</td>
<td>vital signs</td>
</tr>
<tr>
<td>PPTE</td>
<td>person, place, time, event</td>
<td>w/c</td>
<td>wheelchair</td>
</tr>
<tr>
<td>P.E.</td>
<td>physical exam</td>
<td>wt.</td>
<td>weight</td>
</tr>
<tr>
<td>+</td>
<td>positive</td>
<td>c or w/</td>
<td>with</td>
</tr>
<tr>
<td>post.</td>
<td>posterior</td>
<td>s or w/out</td>
<td>without</td>
</tr>
<tr>
<td>POV</td>
<td>privately owned vehicle</td>
<td>y.o.</td>
<td>year(s) old</td>
</tr>
<tr>
<td>PEA</td>
<td>pulseless electrical activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMS</td>
<td>pulse, motor, sensation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SpO₂</td>
<td>pulse oximetry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PERL</td>
<td>pupils equal and reactive to light</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROM</td>
<td>range of motion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTS</td>
<td>Revised Trauma Score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R or R.</td>
<td>right</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBBB</td>
<td>right bundle branch block</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RLQ</td>
<td>right lower quadrant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RUQ</td>
<td>right upper quadrant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RL</td>
<td>Ringer’s lactate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.O.B.</td>
<td>shortness of breath</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S/S</td>
<td>signs/symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NaHCO₃</td>
<td>sodium bicarbonate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NaCl</td>
<td>sodium chloride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEMI</td>
<td>ST elevation myocardial infarction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAMPLE</td>
<td>signs/symptoms, allergies, medications, past</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>history, last oral, events leading to</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Effective Date: April 15, 2015
Revision Date: March 31, 2015
Version: 2.1
Page 297
# CYANOKIT—PEDIATRIC DOSING

**Dose:** 70 mg/kg (maximum dose is 5g)  
**Drip Rate:** 10-15 mL/min (about 5 gtt/sec when using 20gtt set)  
(Adjust IV tubing roller clamp wheel between midway and wide open—NOT wide open!!!)

<table>
<thead>
<tr>
<th>BROSLow Color/Weight</th>
<th>Initial Dose</th>
<th>Volume to Give</th>
<th>Infusion Instructions (after reconstituting 1 vial with 200 mL saline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gray 3-4.5 kg</td>
<td>280 mg</td>
<td>11 mL</td>
<td>Withdraw 11 mL from vial. Administer 11 mL via syringe SLOWLY over 1 minute.</td>
</tr>
<tr>
<td>Pink 6-7 kg</td>
<td>420 mg</td>
<td>17 mL</td>
<td>Withdraw 17 mL from vial. Administer 17 mL via syringe SLOWLY over 1.5 minutes.</td>
</tr>
<tr>
<td>Red 8-9 kg</td>
<td>560 mg</td>
<td>23 mL</td>
<td>Withdraw 23 mL from vial. Administer 23 mL via syringe SLOWLY over 2 minutes.</td>
</tr>
<tr>
<td>Purple 10-11 kg</td>
<td>700 mg</td>
<td>28 mL</td>
<td>Withdraw 28 mL from vial. Administer 28 mL via syringe SLOWLY over 2 minutes.</td>
</tr>
<tr>
<td>Yellow 12-14 kg</td>
<td>910 mg</td>
<td>36 mL</td>
<td>Withdraw 36 mL from vial. Administer 36 mL via syringe SLOWLY over 2.5 minutes.</td>
</tr>
<tr>
<td>White 15-18 kg</td>
<td>1120 mg</td>
<td>45 mL</td>
<td>Withdraw 45 mL from vial. Administer 45 mL via syringe SLOWLY over 3 minutes.</td>
</tr>
<tr>
<td>Blue 19-23 kg</td>
<td>1470 mg</td>
<td>60 mL</td>
<td>Withdraw and waste 140 mL from vial. Infuse remainder (60 mL).</td>
</tr>
<tr>
<td>Orange 24-29 kg</td>
<td>1890 mg</td>
<td>76 mL</td>
<td>Withdraw and waste 124 mL from vial. Infuse remainder (76 mL).</td>
</tr>
<tr>
<td>Green 30-36 kg</td>
<td>2310 mg</td>
<td>92 mL</td>
<td>Withdraw and waste 108 mL from vial. Infuse remainder (92 mL).</td>
</tr>
<tr>
<td>40 kg / 88 lbs</td>
<td>2800 mg</td>
<td>112 mL</td>
<td>Withdraw and waste 88 mL from vial. Infuse remainder (112 mL).</td>
</tr>
<tr>
<td>45 kg / 99 lbs</td>
<td>3150 mg</td>
<td>126 mL</td>
<td>Withdraw and waste 74 mL from vial. Infuse remainder (126 mL).</td>
</tr>
<tr>
<td>50 kg / 110 lbs</td>
<td>3500 mg</td>
<td>140 mL</td>
<td>Withdraw and waste 60 mL from vial. Infuse remainder (140 mL).</td>
</tr>
<tr>
<td>55 kg / 121 lbs</td>
<td>3850 mg</td>
<td>154 mL</td>
<td>Withdraw and waste 46 mL from vial. Infuse remainder (154 mL).</td>
</tr>
<tr>
<td>60 kg / 132 lbs</td>
<td>4200 mg</td>
<td>168 mL</td>
<td>Withdraw and waste 32 mL from vial. Infuse remainder (168 mL).</td>
</tr>
<tr>
<td>65 kg / 143 lbs</td>
<td>4550 mg</td>
<td>182 mL</td>
<td>Withdraw and waste 18 mL from vial. Infuse remainder (182 mL).</td>
</tr>
<tr>
<td>70 kg / 154 lbs (and above)</td>
<td>4900 mg</td>
<td>200 mL</td>
<td>Infuse entire vial.</td>
</tr>
</tbody>
</table>